

From: Biol. Abstr. 36, Abstr. No. 677 (1901).
DT Journal
LA Unavailable

=> d his

(FILE 'HOME' ENTERED AT 15:16:16 ON 02 DEC 2002)

FILE 'REGISTRY' ENTERED AT 15:16:24 ON 02 DEC 2002

L1 122 S ACETAMINOPHEN
L2 0 S ASPIRIN
L3 50 S ASPIRIN
 E STATIN
L4 1577 S E3
L5 29 S VITAMIN C
L6 77 S VITAMIN E
L7 8 S ATORVASTATIN
 E STANOL
L8 12 S E3
L9 3 S TIROFIBAN

FILE 'CPLUS' ENTERED AT 15:25:14 ON 02 DEC 2002

 E ATHEROSCLEROSIS

L10 33111 S E3
L11 10111 S L1
L12 12 S L11 AND L10
L13 15536 S L3
L14 196 S L13 AND L10
L15 50997 S L4
L16 327 S L15 AND L10
L17 49222 S L5
L18 420 S L17 AND L10
L19 26899 S L6
L20 800 S L19 AND L10

=> s 17

L21 697 L7

=> s 121 and 110

L22 130 L21 AND L10

=> d 122 100-130

L22 ANSWER 100 OF 130 CPLUS COPYRIGHT 2002 ACS
AN 1999:613662 CPLUS
DN 131:248237
TI Statin-matrix metalloproteinase inhibitor combinations
IN Newton, Roger Schofield; Roth, Bruce David
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 153 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	-----	-----	-----	-----	-----
PI	WO 9947138	A1	19990923	WO 1998-US24681	19981120
	W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2309588 AA 19990923 CA 1998-2309588 19981120
AU 9915916 A1 19991011 AU 1999-15916 19981120
BR 9815745 A 20001114 BR 1998-15745 19981120
EP 1063991 A1 20010103 EP 1998-960279 19981120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
JP 2002506818 T2 20020305 JP 2000-536378 19981120
ZA 9902106 A 19990930 ZA 1999-2106 19990316
US 2002049237 A1 20020425 US 2001-977162 20011012
PRAI US 1998-78265P P 19980317
WO 1998-US24681 W 19981120
US 1999-297592 B1 19990503
OS MARPAT 131:248237

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 101 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:609873 CAPLUS
DN 131:223312
TI Efficacy and safety of atorvastatin and pravastatin in patients with hypercholesterolemia
AU Assmann, G.; Huwel, D.; Schussman, K.-M.; Smilde, J. G.; Kosling, M.; Withagen, A. J. A. M.; Wunderlich, J.; Stoel, I.; Van Dormaal, J. J.; Neuss, J.; Oldenbroek, C.; Cuppers, M. C.; Von Eckardstein, A.; Schulte, H.; Wagner, B.; McLain, R.; Black, D. M.
CS Institut fur Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Munster, 48149, Germany
SO European Journal of Internal Medicine (1999), 10(1), 33-39
CODEN: EJIMEJ; ISSN: 0953-6205
PB Elsevier Science Ireland Ltd.
DT Journal
LA English-
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 102 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:538570 CAPLUS
DN 131:295415
TI Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig. Atorvastatin versus simvastatin
AU Conde, K.; Pineda, G.; Newton, R. S.; Fernandez, M. L.
CS Department of Nutritional Sciences, Lipid Metabolism Laboratory, University of Connecticut, Storrs, CT, USA
SO Biochemical Pharmacology (1999), 58(7), 1209-1219
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier Science Inc.
DT Journal
LA English-
RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 103 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:501721 CAPLUS
DN 131:153629
TI Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders
AU Murdock, David K.; Murdock, Anthony K.; Murdock, Robert W.; Olson, Karen J.; Frane, Arlyne M.; Kersten, Mary E.; Joyce, Diane M.; Gantner, Sue E.

CS The Lipid Clinic of Cardiovascular Associates of Northern Wisconsin and
The CARE Foundation, Wausau, WI, USA
SO American Heart Journal (1999), 138(1, Pt. 1), 151-155
CODEN: AHJOA2; ISSN: 0002-8703
PB Mosby, Inc.
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 104 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:489710 CAPLUS
DN 131:331943
TI Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin
AU Alfon, Jose; Royo, Teresa; Garcia-Moll, Xavier; Badimon, Lina
CS Cardiovascular Research Center, CSIC-HSCSP-UAB, Barcelona, Spain
SO Arteriosclerosis, Thrombosis, and Vascular Biology (1999), 19(7), 1812-1817
CODEN: ATVBFA; ISSN: 1079-5642
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 105 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:464665 CAPLUS
DN 131:295408
TI Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors
AU Alfon, Jose; Guasch, Joan F.; Berrozpe, Maria; Badimon, Lina
CS CSIC-HSCSP-UAB, Cardiovascular Research Center, Barcelona, 08034, Spain
SO Atherosclerosis (Shannon, Ireland) (1999), 145(2), 325-331
CODEN: ATHSBL; ISSN: 0021-9150
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 106 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:442143 CAPLUS
DN 131:306908
TI Lipophilic statins induce apoptosis of human vascular smooth muscle cells
AU Guijarro, Carlos; Blanco-Colio, Luis Miguel; Massy, Ziad A.; O'Donnell, Michael P.; Kasiske, Bertram L.; Keane, William F.; Egido, Jesus
CS Research Laboratories, Instituto de Investigacion Medica, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain
SO Kidney International, Supplement (1999), 71, S88-S91
CODEN: KISUDF; ISSN: 0098-6577
PB Blackwell Science, Inc.
DT Journal
LA English
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 107 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:282039 CAPLUS
DN 130:306593
TI Combination therapy using a HMG-CoA reductase inhibitor and a

Welcome to STN International! Enter x:x

LOGINID: sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * * * * * Welcome to STN International * * * * * * * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28 Oct 21 EVENTLINE has been reloaded
NEWS 29 Oct 24 BEILSTEIN adds new search fields
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 32 Nov 18 DKILIT has been renamed APOLLIT
NEWS 33 Nov 25 More calculated properties added to REGISTRY

NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:16:16 ON 02 DEC 2002

FILE 'REGISTRY' ENTERED AT 15:16:24 ON 02 DEC 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 DEC 2002 HIGHEST RN 474745-06-7
DICTIONARY FILE UPDATES: 1 DEC 2002 HIGHEST RN 474745-06-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s acetaminophen
L1 122 ACETAMINOPHEN

=> s aspirin
L2 0 ASPIRIN

=> s aspirin
L3 . 50 ASPIRIN

=> e statin

| | | |
|-----|------|---------------|
| E1 | 4 | STATILINUS/BI |
| E2 | 1 | STATIMO/BI |
| E3 | 1577 | --> STATIN/BI |
| E4 | 2 | STATINATE/BI |
| E5 | 25 | STATINE/BI |
| E6 | 16 | STATION/BI |
| E7 | 53 | STATIONARY/BI |
| E8 | 11 | STATIONIIS/BI |
| E9 | 20 | STATO/BI |
| E10 | 1 | STATO21/BI |
| E11 | 1 | STATOC/BI |
| E12 | 1 | STATOCAL/BI |

=> s e3

L4 1577 STATIN/BI

=> d 14 1577

L4 ANSWER 1577 OF 1577 REGISTRY COPYRIGHT 2002 ACS
RN 51-43-4 REGISTRY
CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]-, (R)-
CN Benzyl alcohol, 3,4-dihydroxy-.alpha.-[(methylamino)methyl]-, (-)- (8CI)

OTHER NAMES:

CN (-)-(R)-Epinephrine

CN (-)-3,4-Dihydroxy-.alpha.-[2-(methylamino)ethyl]benzyl alcohol

CN (-)-Adrenaline

CN (-)-Epinephrine

CN (R)-Adrenaline

CN (R)-Epinephrine

CN Adnephrene

CN Adrenal

CN Adrenalin

CN Adrenaline

CN Adrenine

CN Adrin

CN Ana-Kit

CN Bosmin

CN Chelafrin

CN Epifrin

CN Epinefrina

CN Epinephran

CN Epinephrine

CN Epipen

CN Epirenan

CN Exadrin

CN Hemisine

CN Hemostasin

CN **Hemostatin**

CN Hypernephrin

CN Isoptoepinal

CN l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol

CN l-Adrenaline

CN L-Adrenaline

CN l-Epinephrine

CN l-Epirenamine

CN Levoepinephrine

CN Levorenin

CN Levorenine

CN Levoreninum

CN Lyodrin

CN Methylarterenol

CN Mucidrina

CN Nephridine

CN Nieraline

CN Paraneprin

CN Primatene Mist

CN R-(-)-Epinephrine

CN Renaglandin

CN Renaleptine


CN Renalina

CN Renoform

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for

DISPLAY
 FS STEREOSEARCH
 DR 51028-73-0
 MF C9 H13 N 03
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
 BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,
 CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU,
 EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
 MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PHARMASEARCH, PIRA,
 PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

29110 REFERENCES IN FILE CA (1962 TO DATE)
 209 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 29125 REFERENCES IN FILE CAPLUS (1962 TO DATE)
 356 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s vitamin c
 1396 VITAMIN
 1686156 C
 L5 29 VITAMIN C
 (VITAMIN(W) C)

=> s vitamin e
 1396 VITAMIN
 588588 E
 L6 77 VITAMIN E
 (VITAMIN(W) E)


=> s atorvastatin
 L7 8 ATORVASTATIN

=> d 17 8

L7 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2002 ACS
 RN 125995-03-1 REGISTRY
 CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-(9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-,(2R-trans)-
 OTHER NAMES:

CN Atorvastatin .delta.-lactone
 CN Atorvastatin lactone
 FS STEREOSEARCH
 DR 142062-65-5
 MF C33 H33 F N2 O4
 SR CA
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, MRCK*, TOXCENTER, USPAT2,
 USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

28 REFERENCES IN FILE CA (1962 TO DATE)
 28 REFERENCES IN FILE CAPLUS (1962 TO DATE)

```
=> e stanol
E1      1      STANOHL/BI
E2      1      STANOJELL/BI
E3      12 --> STANOL/BI
E4      1      STANOLAN/BI
E5      1      STANOLAX/BI
E6      1      STANOLINE/BI
E7      4      STANOLONE/BI
E8      1      STANOMYCETIN/BI
E9      2      STANOSTAT/BI
E10     1      STANOV/BI
E11     1      STANOVAL/BI
E12     1      STANOX/BI
```

```
=> s e3
L8      12 STANOL/BI
```

=> d 18 12

L8 ANSWER 12 OF 12 REGISTRY COPYRIGHT 2002 ACS
 RN 83-45-4 REGISTRY
 CN Stigmastan-3-ol, (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:

CN 5.alpha.-Stigmastan-3.beta.-ol (6CI, 7CI, 8CI)

OTHER NAMES:

CN .beta.-Sitostanol

CN .beta.-Sitosterol, dihydro-

CN 24.alpha.-Ethylcholestanol

CN 5,6-Dihydro-.beta.-sitosterol

CN Dihydro-.beta.-sitosterol

CN Dihydrositosterin

CN Dihydrositosterol

CN **Fucostanol**

CN Sitostanol

CN Spinastanol

FS STEREOSEARCH

MF C29 H52 O


CI COM

LC STN Files: AGRICOLA, BEILSTEIN*, BIOPHARMA, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, DDFU, DRUGU, EMBASE, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

650 REFERENCES IN FILE CA (1962 TO DATE)

36 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

650 REFERENCES IN FILE CAPLUS (1962 TO DATE)

21 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s tirofiban

L9 3 TIROFIBAN

=> d 19 3

L9 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2002 ACS


RN 142373-60-2 REGISTRY

CN L-Tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Aggrastat
 CN L 700462
 CN MK 383
 CN N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine hydrochloride
 CN **Tirofiban hydrochloride**
 FS STEREOSEARCH
 MF C22 H36 N2 O5 S . Cl H
 SR CA
 LC STN Files: ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS,
 CASREACT, CEN, CIN, DIOGENES, DRUGPAT, DRUGUPDATES, EMBASE, IPA, MRCK*,
 PHAR, PROMT, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 CRN (144494-65-5)

Absolute stereochemistry.



● HCl

58 REFERENCES IN FILE CA (1962 TO DATE)
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 58 REFERENCES IN FILE CAPLUS (1962 TO DATE)

| | | |
|----------------------|------------|---------|
| => file caplus | SINCE FILE | TOTAL |
| COST IN U.S. DOLLARS | ENTRY | SESSION |
| FULL ESTIMATED COST | 56.02 | 56.23 |

FILE 'CAPLUS' ENTERED AT 15:25:14 ON 02 DEC 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Dec 2002 VOL 137 ISS 23
 FILE LAST UPDATED: 1 Dec 2002 (20021201/ED)

This file contains CAS Registry Numbers for easy and accurate

substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> e atherosclerosis

E1 1 ATHEROSCLEROSIA/BI
E2 4 ATHEROSCLEROSIC/BI
E3 33111 --> ATHEROSCLEROSIS/BI
E4 1 ATHEROSCLEROSIS8/BI
E5 1 ATHEROSCLEROSISARE/BI
E6 1 ATHEROSCLEROSISATHEROSCLEROSIS/BI
E7 1 ATHEROSCLEROSISHATHEROSCLEROSIS/BI
E8 1 ATHEROSCLEROSOIS/BI
E9 2 ATHEROSCLEROSOS/BI
E10 1 ATHEROSCLEROSS/BI
E11 1 ATHEROSCLEROSTIC/BI
E12 1 ATHEROSCLEROT/BI

=> s e3

L10 33111 ATHEROSCLEROSIS/BI

=> d his

(FILE 'HOME' ENTERED AT 15:16:16 ON 02 DEC 2002)

FILE 'REGISTRY' ENTERED AT 15:16:24 ON 02 DEC 2002

L1 122 S ACETAMINOPHEN
L2 0 S ASPRIN
L3 50 S ASPIRIN
E STATIN
L4 1577 S E3
L5 29 S VITAMIN C
L6 77 S VITAMIN E
L7 8 S ATORVASTATIN
E STANOL
L8 12 S E3
L9 3 S TIROFIBAN

FILE 'CAPLUS' ENTERED AT 15:25:14 ON 02 DEC 2002

E ATHEROSCLEROSIS

L10 33111 S E3

=> s l1

L11 10111 L1

=> s l11 and l10

L12 12 L11 AND L10

=> d l12 1-12

L12 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 2002:777648 CAPLUS

DN 137:257659

TI Therapeutic combinations for cardiovascular and inflammatory indications

IN Seibert, Karen; Keller, Bradley T.; Isakson, Peter C.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2002078625 | A2 | 20021010 | WO 2002-US9185 | 20020327 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| PRAI | US 2001-279239P | P | 20010328 | | |

L12 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 2002:736715 CAPLUS

DN 137:253031

TI Pharmaceutical preparations of glutathione and methods of administration thereof

IN Demopoulos, Harry B.; Seligman, Myron L.

PA USA

SO U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. 6,350,467.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | US 2002136763 | A1 | 20020926 | US 2002-83327 | 20020225 |
| | WO 9829101 | A1 | 19980709 | WO 1997-US23879 | 19971231 |
| | W: | AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, LZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | |
| | US 6350467 | B1 | 20020226 | US 1999-331947 | 19990628 |
| PRAI | US 1996-34101P | P | 19961231 | | |
| | WO 1997-US23879 | W | 19971231 | | |
| | US 1999-331947 | A2 | 19990628 | | |

L12 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 2002:717065 CAPLUS

DN 137:226613

TI Use of acetaminophen to prevent and treat arteriosclerosis

IN Nelson, Edward B.; Smith, Charles V.; Taylor, Addison A.

PA USA

SO U.S. Pat. Appl. Publ., 8 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 2002132855 | A1 | 20020919 | US 2001-887465 | 20010622 |
| PRAI | US 2000-222781P | P | 20000803 | | |

L12 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 2002:588980 CAPLUS
DN 137:135080
TI Modification of NSAIDs by sulfur-containing functional groups
IN Lai, Ching-San; Wang, Tingmin
PA Medinox, Inc., USA
SO U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 602,688.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | ----- | ----- | ----- | ----- | ----- |
| PI | US 6429223 | B1 | 20020806 | US 2000-715767 | 20001117 |
| | US 6355666 | B1 | 20020312 | US 2000-602688 | 20000623 |
| | WO 2002000167 | A2 | 20020103 | WO 2001-US19750 | 20010619 |
| | WO 2002000167 | A3 | 20020404 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2001070010 | A5 | 20020108 | AU 2001-70010 | 20010619 |
| PRAI | US 2000-602688 | A2 | 20000623 | | |
| | US 2000-715767 | A1 | 20001117 | | |
| | WO 2001-US19750 | W | 20010619 | | |

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2002 ACS
AN 2002:406402 CAPLUS
DN 137:320273
TI Effect of acetaminophen on the myeloperoxidase-hydrogen peroxide-nitrite mediated oxidation of LDL
AU Chou, Tien-min; Greenspan, Phillip
CS Department of Pharmaceutical and Biomedical Sciences, University of Georgia, College of Pharmacy, Athens, GA, 30602-2356, USA
SO Biochimica et Biophysica Acta (2002), 1581(1-2), 57-63
CODEN: BBACAO; ISSN: 0006-3002
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2002 ACS
AN 2002:90556 CAPLUS
DN 136:131255
TI Methods for early diagnosis of kidney disease and treatment by drug intervention using lysosome activating compounds
IN Comper, Wayne D.
PA Austria
SO U.S. Pat. Appl. Publ., 30 pp., Cont.-in-part of U.S. Ser. No. 415,217.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------------|-------|-------|-----------------|-------|
| | ----- | ----- | ----- | ----- | ----- |

PI: US 2002012906 A1 20020131 US 2001-893346 20010628
 US 2002110799 A1 20020815 US 1999-415217 19991012
 US 6447989 B1 20020910
 WO 2000037944 A1 20000629 WO 1999-IB2029 19991220
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
 MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
 SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI AU 1998-7843 A 19981221
 US 1999-415217 A2 19991012
 WO 1999-IB2029 W 19991220

L12 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 2001:905774 CAPLUS

DN 137:72333

TI Effect of acetaminophen on **atherosclerosis**

AU Chong, Pang H.; Kezele, Bob; Pontikes, Pamala J.

CS Department of Pharmacy Practice, University of Illinois at Chicago,
Chicago, IL, 60612-3736, USA

SO Annals of Pharmacotherapy (2001), 35(11), 1476-1479

CODEN: APHRER; ISSN: 1060-0280

PB Harvey Whitney Books Co.

DT Journal; General Review

LA English

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 2001:380616 CAPLUS

DN 135:10004

TI Compositions and methods for counteracting effects of reactive oxygen species and free radicals

IN Shashoua, Victor E.

PA Ceremedix, Inc., USA

SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

| | | | | |
|-------|-------|-------|-------|-------|
| ----- | ----- | ----- | ----- | ----- |
|-------|-------|-------|-------|-------|

PI WO 2001036454 A1 20010525 WO 2000-US31764 20001117

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1232174 A1 20020821 EP 2000-978811 20001117

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRAI US 1999-166381P P 19991118

WO 2000-US31764 W 20001117

OS MARPAT 135:10004

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2002 ACS
AN 1999:783925 CAPLUS
DN 132:22753
TI Preparation of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives for the elevation of pyruvate dehydrogenase (PDH) activity
IN Butlin, Roger John; Nowak, Thorsten; Burrows, Jeremy Nicholas; Block, Michael Howard
PA Zeneca Limited, UK
SO PCT Int. Appl., 211 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|-----------|----------|-----------------|----------|
| PI | WO 9962506 | A1 | 19991209 | WO 1999-GB1669 | 19990526 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2331685 | AA | 19991209 | CA 1999-2331685 | 19990526 |
| | AU 9940524 | A1 | 19991220 | AU 1999-40524 | 19990526 |
| | AU 740909 | B2 | 20011115 | | |
| | BR 9910821 | A | 20010213 | BR 1999-10821 | 19990526 |
| | EP 1082110 | A1 | 20010314 | EP 1999-923767 | 19990526 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | JP 2002516854 | T2 | 20020611 | JP 2000-551762 | 19990526 |
| | NO 2000006010 | A | 20010126 | NO 2000-6010 | 20001128 |
| PRAI | GB 1998-11427 | A | 19980529 | | |
| | WO 1999-GB1669 | W | 19990526 | | |
| OS | MARPAT | 132:22753 | | | |

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2002 ACS
AN 1999:593675 CAPLUS
DN 132:121896
TI Effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidation
AU McAuley, Daniel F.; Hanratty, Colm G.; McGurk, Colm; Nugent, Ailish G.; Johnston, G. Dennis
CS The Queen's University of Belfast, Belfast, BT9 7BL, UK
SO Journal of Toxicology, Clinical Toxicology (1999), 37(4), 435-440
CODEN: JTCTDW; ISSN: 0731-3810
PB Marcel Dekker, Inc.
DT Journal
LA English

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2002 ACS
AN 1998:484927 CAPLUS

DN 129:127177
 TI Pharmaceutical preparations of glutathione and methods of administration
 IN Demopoulos, Harry B.; Seligman, Myron L.
 PA Antioxidant Pharmaceuticals Corp., USA
 SO PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 9829101 | A1 | 19980709 | WO 1997-US23879 | 19971231 |
| | W: | AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | |
| | AU 9856205 | A1 | 19980731 | AU 1998-56205 | 19971231 |
| | EP 957901 | A1 | 19991124 | EP 1997-952640 | 19971231 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | |
| | JP 2001507696 | T2 | 20010612 | JP 1998-530206 | 19971231 |
| | US 6350467 | B1 | 20020226 | US 1999-331947 | 19990628 |
| | US 2002136763 | A1 | 20020926 | US 2002-83327 | 20020225 |
| PRAI | US 1996-34101P | P | 19961231 | | |
| | WO 1997-US23879 | W | 19971231 | | |
| | US 1999-331947 | A2 | 19990628 | | |

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2002 ACS
 AN 1994:163728 CAPLUS
 DN 120:163728
 TI Amines (phenoxyalkylamines) as inhibitors of squalene synthase and their preparation and pharmaceutical compositions
 IN Brown, George Robert; Eakin, Murdoch Allan; Mallion, Keith Blakeney; Harrison, Peter John
 PA Harrison, Alison, UK; Zeneca Ltd.
 SO PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|--|----------|-----------------|----------|
| PI | WO 9320807 | A1 | 19931028 | WO 1993-GB742 | 19930408 |
| | W: | AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US | | | |
| | RW: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | |
| | CA 2093777 | AA | 19931010 | CA 1993-2093777 | 19930408 |
| | AU 9339005 | A1 | 19931118 | AU 1993-39005 | 19930408 |
| | EP 589018 | A1 | 19940330 | EP 1993-908009 | 19930408 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | |
| | JP 06511259 | T2 | 19941215 | JP 1993-518098 | 19930408 |
| | US 5866611 | A | 19990202 | US 1994-157204 | 19940519 |
| PRAI | GB 1992-7855 | | 19920409 | | |
| | WO 1993-GB742 | | 19930408 | | |

DT Journal; General Review
LA Serbo-Croatian

L20 ANSWER 765 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1983:3813 CAPLUS
DN 98:3813
TI Effect of vitamin E on platelet aggregation and lipid pattern
AU Musca, Antonio; Cordova, Corrado; Violi, Francesco; Perrone, Alessandro;
Alessandri, Cesare; Salvadori, Flavio
CS IV Clin. Med., Univ. Roma, Rome, Italy
SO Clinica Terapeutica (Rome) (1982), 102(3), 273-6
CODEN: CLTEA4; ISSN: 0009-9074
DT Journal
LA Italian

L20 ANSWER 766 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1982:597317 CAPLUS
DN 97:197317
TI **Atherosclerosis** in cholesterol-fed Japanese quail: evidence for
amelioration by dietary vitamin E
AU Donaldson, W. E.
CS Nutr. Prog., North Carolina State Univ., Raleigh, NC, 27650, USA
SO Poultry Science (1982), 61(10), 2097-102
CODEN: POSCAL; ISSN: 0032-5791
DT Journal
LA English

L20 ANSWER 767 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1982:561428 CAPLUS
DN 97:161428
TI Vitamins E and A in vascular diseases
AU Butturini, U.
CS Ist. Clin. Med. Gen. Terapia Med., Univ. Studi Parma, Parma, 43100, Italy
SO Acta Vitaminologica et Enzymologica (1982), 4(1-2), 15-19
CODEN: AVEZA6; ISSN: 0300-8924
DT Journal
LA English

L20 ANSWER 768 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1982:83583 CAPLUS
DN 96:83583
TI Studies on .alpha.-tocopherol (vitamin E) in **atherosclerosis**
AU Tochihara, Toshihiko
CS Sch. Med., Nihon Univ., Tokyo, Japan
SO Nichidai Igaku Zasshi (1981), 40(12), 1287-96
CODEN: NICHAS; ISSN: 0029-0424
DT Journal
LA Japanese

L20 ANSWER 769 OF 800 CAPIUS COPYRIGHT 2002 ACS
AN 1982:67593 CAPIUS
DN 96:67593
TI Vitamin E in a rabbit model of endogenous hypercholesterolemia and
atherosclerosis
AU Westrope, Kenneth L.; Miller, Rodney A.; Wilson, Robert B.
CS Dep. Vet. Microbiol. Pathol., Washington State Univ., Pullman, WA, 99164,
USA
SO Nutrition Reports International (1982), 25(1), 83-8
CODEN: NURIBL; ISSN: 0029-6635
DT Journal
LA English

L20 ANSWER 770 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1981:138210 CAPLUS
DN 94:138210
TI Effect of vitamin E deficiency and qualitatively different dietary fats on the structure of the aorta and cardiac and renal arteries
AU Pozdnyakov, A. L.; Spirichev, V. B.; Levachev, M. M.; Blazhevich, N. V.; Lvovich, N. A.; Ponomareva, L. G.
CS Inst. Pitaniya, Moscow, USSR
SO Voprosy Pitaniya (1981), (1), 45-50
CODEN: VPITAR; ISSN: 0042-8833
DT Journal
LA Russian

L20 ANSWER 771 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1981:41490 CAPLUS
DN 94:41490
TI Replacement of intramuscular oily injections of aevita by vitamin A and E suppositories for the treatment of **atherosclerosis**
AU Yakimets, V. M.; Yakimets, O. M.; Vasilenko, Yu. K.; Tokarenko, L. F.; Kechatova, N. A.
CS Pyatigorsk. Farm. Inst., Pyatigorsk, USSR
SO Farmatsiya (Moscow, Russian Federation) (1980), 29(6), 9-12
CODEN: FRMTAL; ISSN: 0367-3014
DT Journal
LA Russian

L20 ANSWER 772 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1979:455062 CAPLUS
DN 91:55062
TI Vascular wall lipid metabolism in tocopherol-deficient rats
AU Saito, Yasushi; Matsuoka, Nobuo; Shirai, Kohji; Shinomiya, Masashige; Morisaki, Nobuhiro; Murano, Toshikazu; Sasaki, Norihiro; Yamamoto, Masamitsu; Kamagaya, Akira
CS Fac. Med., Chiba Univ., Chiba, Japan
SO Nippon Rinsho Taisha Gakkai Kiroku (1978), 15, 17-19
CODEN: NRTKDI
DT Journal
LA Japanese

L20 ANSWER 773 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1979:449551 CAPLUS
DN 91:49551
TI Effect of "Aevita" administered in suppository form on the blood lipid composition in experimental hypercholesterolemia in rabbits
AU Yakimets, O. M.; Yakimets, V. M.
CS Pyatigorsk. Farm. Inst., Pyatigorsk, USSR
SO Biol. Nauki (Moscow) (1979), (4), 63-5
CODEN: BINKBT; ISSN: 0303-4119
DT Journal
LA Russian

L20 ANSWER 774 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1979:202626 CAPLUS
DN 90:202626
TI Polyunsaturated fatty acids, vitamin E, and the proliferation of aortic smooth muscle cells
AU Cornwell, David G.; Huttner, James J.; Milo, George E.; Panganamala, R. V.; Sharma, H. M.; Geer, Jack C.
CS Dep. Physiol. Chem., Ohio State Univ., Columbus, Ohio, USA
SO Lipids (1979), 14(2), 194-207
CODEN: LPDSAP; ISSN: 0024-4201
DT Journal

LA English

L20 ANSWER 775 OF 800 CAPIUS COPYRIGHT 2002 ACS
AN 1979:150606 CAPIUS
DN 90:150606
TI Cholesterolemia in Japanese quail: response to a mixture of vitamins C and E and choline chloride
AU Morrissey, R. B.; Donaldson, W. E.
CS Dep. Poult. Sci., North Carolina State Univ., Raleigh, N. C., USA
SO Artery (Fulton, Mich.) (1979), 5(2), 182-92
CODEN: ARTEDR; ISSN: 0098-6127
DT Journal
LA English

L20 ANSWER 776 OF 800 CAPIUS COPYRIGHT 2002 ACS
AN 1979:37884 CAPIUS
DN 90:37884
TI Vitamin E, antioxidants and lipid peroxidation in experimental atherosclerosis of rabbits
AU Wilson, Robert B.; Middleton, Charles C.; Sun, Grace Y.
CS Dep. Vet. Microbiol. Pathol., Washington State Univ., Pullman, Wash., USA
SO J. Nutr. (1978), 108(11), 1858-67
CODEN: JONUAI; ISSN: 0022-3166
DT Journal
LA English

L20 ANSWER 777 OF 800 CAPIUS COPYRIGHT 2002 ACS
AN 1977:119706 CAPIUS
DN 86:119706
TI Effect of cholesterol feeding on tissue lipid peroxidation, glutathione peroxidase activity and liver microsomal functions in rats and guinea pigs
AU Tsai, Alan C.; Thie, Geesje M.; Lin, C. R.-S.
CS Sch. Public Health, Univ. Michigan, Ann Arbor, Mich., USA
SO J. Nutr. (1977), 107(2), 310-19
CODEN: JONUAI
DT Journal
LA English

L20 ANSWER 778 OF 800 CAPIUS COPYRIGHT 2002 ACS
AN 1976:461802 CAPIUS
DN 85:61802
TI Vitamin E, cholesterol, and lipids during atherogenesis in rabbits
AU Bitman, Joel; Weyant, Joan; Wood, D. L.; Wrenn, T. R.
CS Anim. Physiol. Genet. Inst., ARS, Beltsville, Md., USA
SO Lipids (1976), 11(6), 449-61
CODEN: LPDSAP
DT Journal
LA English

L20 ANSWER 779 OF 800 CAPIUS COPYRIGHT 2002 ACS
AN 1976:169685 CAPIUS
DN 84:169685
TI Hypolipemic tocopherol acetate compositions
IN Giudicelli, Pierre R. L.; Najer, Henry
PA Synthelabo S. A., Fr.
SO Fr. Demande, 5 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|-------|-------|-----------------|-------|
| ----- | ----- | ----- | ----- | ----- |

PI FR 2270862 A1 19751212 FR 1974-16994 19740516

- L20 ANSWER 780 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1975:562495 CAPLUS
DN 83:162495
TI Vitamin E deficiency in atherosclerotic rabbits
AU Awad, Atif B.; Gilbreath, Rex L.
CS Cook Coll., Rutgers State Univ., New Brunswick, N. J., USA
SO Nutr. Rep. Int. (1975), 11(4), 277-86
CODEN: NURIBL
DT Journal
LA English
- L20 ANSWER 781 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1975:512735 CAPLUS
DN 83:112735
TI Actions of vitamins A and E and some nicotinic acid derivatives on plasma lipids and on lipid infiltration of aorta in cholesterol-fed rabbits
AU Brattsand, Ralph
CS Res. Dep., AB Bofors Nobel-Pharma, Molndal, Swed.
SO Atherosclerosis (1975), 22(1), 47-61
CODEN: ATHSBL
DT Journal
LA English
- L20 ANSWER 782 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1975:441895 CAPLUS
DN 83:41895
TI Hypervitaminosis E in atherosclerotic rabbits
AU Awad, Atif B.; Gilbreath, Rex L.
CS Cook Coll., Rutgers State Univ., New Brunswick, N. J., USA
SO Nutr. Rep. Int. (1975), 11(5), 409-17
CODEN: NURIBL
DT Journal
LA English
- L20 ANSWER 783 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1973:123031 CAPLUS
DN 78:123031
TI Role of tocopherol (antioxidant) deficiency in the origin of atherosclerosis
AU Voskresenskii, O. N.
CS Dep. Pharmacol., N. I. Pirogov State Med. Sch., Odessa, USSR
SO Vop. Med. Khim. (1973), 19(1), 87-90
CODEN: VMDKAM
DT Journal
LA Russian
- L20 ANSWER 784 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1972:417296 CAPLUS
DN 77:17296
TI Problems of stabilization of thrombocytes and erythrocytes by flavanoids, ascorbic acid, and tocopherol
AU Zuern, H.
CS Bezirksinst. Blutspende-Transfusionswes., Dresden, E. Ger.
SO Bibl. Haematol. (Basel) (1971), No. 38(Pt. 2), 221-3
CODEN: BIHAA2
DT Journal
LA English
- L20 ANSWER 785 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1969:36405 CAPLUS

DN 70:36405
TI Plasma and muscle tocopherol contents during vitamin E therapy in arterial disease
AU Larsson, Hans; Haeger, Knut
CS Dep. Biochem., AB Ferrosan, Malmo, Swed.
SO Pharmacol. Clin. (1968), 1(2), 72-6
CODEN: PHCLAL
DT Journal
LA English

L20 ANSWER 786 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1966:502528 CAPLUS
DN 65:102528
OREF 65:19179h,19180a-c
TI Effects of vitamin E upon lipid metabolism and experimental **atherosclerosis**
AU Fukumoto, Shinichi
CS Univ. Kumamoto, Japan
SO Kumamoto Daigaku Taishitsu Igaku Kenkyusho Hokoku (1965), 16(1), 1-45
DT Journal
LA Japanese

L20 ANSWER 787 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1966:107759 CAPLUS
DN 64:107759
OREF 64:20358c-e
TI Peroxides as a factor of **atherosclerosis**
AU Iwakami, Minoru
CS School Med., Univ. Nagoya, Japan
SO Nagoya J. Med. Sci. (1965), 28(1), 50-66
DT Journal
LA English

L20 ANSWER 788 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1966:6707 CAPLUS
DN 64:6707
OREF 64:1231b-c
TI The effect of vitamin E on the development of experimental **atherosclerosis** in rabbits
AU Vorob'eva, N. P.
CS 1st Med. Inst., Moscow
SO Vopr. Pitaniya (1965), 24(5), 42-5
DT Journal
LA Russian

L20 ANSWER 789 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1965:449010 CAPLUS
DN 63:49010
OREF 63:8928c-f
TI Effect of thixotropic gel of iodinated poly(vinyl alcohol) on **atherosclerosis** in experimental conditions
AU Bogomolova, L. G.; Ushakov, S. N.; Izmailova, E. F.; Lavrent'eva, E. M.; Dekster, B. G.; Petrova, L. I.
CS Inst. Blood Transfusion, Leningrad
SO Patol. Fiziol. i Eksperim. Terapiya (1965), 9(2), 8-12
DT Journal
LA Russian

L20 ANSWER 790 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1964:55588 CAPLUS
DN 60:55588
OREF 60:9807d-e

- TI Effect of vitamin E on the total cholesterol level and blood lipoproteins
in **atherosclerosis**
AU Rugaja, A.
SO Sb. Nauchn. Rabot, 1-ya [Pervaya] Rizhsk. Gor. Klinich. Bol'nitsa (1962),
(2), 131-3
From: Ref. Zh., Biol. Khim. 1963, Abstr. No. 19F1211.
DT Journal
LA Unavailable
- L20 ANSWER 791 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1964:26277 CAPLUS
DN 60:26277
OREF 60:4673f-g
TI The therapeutic value of vitamin E in **atherosclerosis**
AU Nikitin, Yu. P.
SO Sb. Tr. Novokuznetskogo Inst. Usoversh. Vrachei (1962), 29, 130-5
From: Ref. Zh., Biol. Khim. 1963, Abstr. No. 8F1257.
DT Journal
LA Unavailable
- L20 ANSWER 792 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1964:11568 CAPLUS
DN 60:11568
OREF 60:2096c-d
TI Preventive action of vitamins A and E on the development of
cholesterol-induced **atherosclerosis**
AU Horn, Z.; Palkovits, M.; Scher, A.
CS Univ. Budapest, Hung.
SO Z. Vitamin-, Hormon-Fermentforsch. (1963), 13(1), 8-15
DT Journal
LA English
- L20 ANSWER 793 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1963:444019 CAPLUS
DN 59:44019
OREF 59:7979c-d
TI Nutrition and **atherosclerosis**. Influence of terpenes on
atherosclerosis
AU Lieber, Iris Ilona
SO Dia Med. (Cordoba, Rep. Arg.) (1963), 35, 236
DT Journal
LA Unavailable
- L20 ANSWER 794 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1963:438148 CAPLUS
DN 59:38148
OREF 59:6880h,6881a-c
TI Various drugs acting on the serum lipid pattern of **atherosclerosis**
. Therapeutic significance of an extractive heparinoid
AU Nicrosini, F.; Piccinelli, O.
CS Univ. Pavia, Italy
SO Drugs Affecting Lipid Metab., Proc. Symp., Milan (1961), Volume Date 1960
508-11
DT Journal
LA Unavailable
- L20 ANSWER 795 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1963:76136 CAPLUS
DN 58:76136
OREF 58:13040d-e
TI New views in the therapy of **atherosclerosis**
AU Giacovazzo, M.; Dal Fabbro, G.; Borso, M. T.; Garufi, L.

CS Univ. Rome
SO Rass. Fisiopatol. Clin. Terap. (Pisa) (1960), 32, 433-57
DT Journal
LA Unavailable

L20 ANSWER 796 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1963:55091 CAPLUS
DN 58:55091
OREF 58:9457a-b
TI Influence of vitamin E on lipids and blood coagulability in patients with **atherosclerosis**
AU Nikitin, Yu. P.
CS Post-Graduate Med. Inst., Novokuznetsk
SO Vopr. Pitaniya (1962), 21(No. 6), 22-7
DT Journal
LA Unavailable

L20 ANSWER 797 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1962:486367 CAPLUS
DN 57:86367
OREF 57:17275a-c
TI Blood protein composition as an index of liver function in cardiac **atherosclerosis** and the effect of vitamin E therapy
AU Shelygina, N. M.
SO Tr. Ukr. Nauchn.-Issled. Inst. Klin. Med. (1961), 7, 267-71
DT Journal
LA Unavailable

L20 ANSWER 798 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1962:486358 CAPLUS
DN 57:86358
OREF 57:17273c
TI Cholesterol metabolism and **atherosclerosis** in the rat: effects of linoleate and the vitamins A and E
AU Beeler, Donald Allen
CS Purdue Univ., Lafayette, IN
SO (1962) 85 pp. Avail.: Univ. Microfilms (Ann Arbor, Mich.), Order No. 62-3432
From: Dissertation Abstr. 23, 415-16
DT Dissertation
LA Unavailable

L20 ANSWER 799 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1962:479153 CAPLUS
DN 57:79153
OREF 57:15752e-f
TI Parenteral application of essential phospholipids in the experimental **atherosclerosis** of the rat
AU Konecki, J.; Pietkiewicz, W.; Samochowiec, L.
CS Military Hosp., Gliwice, Pol.
SO Arzneimittel-Forsch. (1962), 12, 831-5
DT Journal
LA Unavailable

L20 ANSWER 800 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1962:451661 CAPLUS
DN 57:51661
OREF 57:10323d
TI Effects of vitamin E on the blood cholinesterase activity in **atherosclerosis** patients
AU Anisimov, V. E.
SO Klinich. Meal. (1958), 36, 147-8

- CS Peop. Rep. China
SO Tianjin Yiyao (1985), 13(10), 615-17
CODEN: TIYADG; ISSN: 0253-9896
DT Journal
LA Chinese
- L20 ANSWER 755 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1985:595290 CAPLUS
DN 103:195290
TI Dietary supplementation with vitamin E in hyperlipoproteinemias: effects on plasma lipid peroxides, antioxidant activity, prostacyclin generation and platelet aggregability
AU Szczechlik, A.; Gryglewski, R. J.; Domagala, B.; Dworski, R.; Basista, M.
CS Dep. Intern. Med., Copernicus Acad. Med., Krakow, Pol.
SO Thrombosis and Haemostasis (1985), 54(2), 425-30
CODEN: THHADQ; ISSN: 0340-6245
DT Journal
LA English
- L20 ANSWER 756 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1985:576605 CAPLUS
DN 103:176605
TI Familial apolipoprotein A-I and C-III deficiency, variant II
AU Schaefer, Ernst J.; Ordovas, Jose M.; Law, Simon W.; Ghiselli, Giancarlo; Kashyap, Moti L.; Srivastava, Laxmi S.; Heaton, William H.; Albers, John J.; Connor, William E.; et al.
CS Mol. Dis. Branch, Natl. Heart, Lung, Blood Inst., Bethesda, MD, 20205, USA
SO Journal of Lipid Research (1985), 26(9), 1089-101
CODEN: JLPRAW; ISSN: 0022-2275
DT Journal
LA English
- L20 ANSWER 757 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1985:470218 CAPLUS
DN 103:70218
TI The effect of supplemental vitamin E on serum parameters in diabetics, post coronary and normal subjects
AU Bierenbaum, Marvin L.; Noonan, Frank J.; Machlin, Lawrence J.; Machlin, Steven; Stier, Arleane; Watson, Portia B.; Naso, Ann Marie; Fleischman, Alan I.
CS Vitam. Clin. Nutr. Dep., Hoffmann-La Roche Inc., Nutley, NJ, 07110, USA
SO Nutrition Reports International (1985), 31(6), 1171-80
CODEN: NURIBL; ISSN: 0029-6635
DT Journal
LA English
- L20 ANSWER 758 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1985:184072 CAPLUS
DN 102:184072
TI Vitamin E in the split of opinions - what is guaranteed?
AU Boehles, H.
CS Universitaetskinderklin., Erlangen, D-8520, Fed. Rep. Ger.
SO Deutsche Apotheker Zeitung (1985), 125(12), 598-600
CODEN: DAZEA2; ISSN: 0011-9857
DT Journal; General Review
LA German
- L20 ANSWER 759 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1985:183321 CAPLUS
DN 102:183321
TI Prostacyclin and atherosclerosis
AU Gryglewski, Ryszard J.

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 105 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 2000:93323 CAPLUS
DN 133:52
TI The evolving role of statins in the management of **atherosclerosis**
AU Vaughan, Carl J.; Gotto, Antonio M., Jr.; Basson, Craig T.
CS Division of Cardiology, Department of Medicine, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, NY, 10021, USA
SO Journal of the American College of Cardiology (2000), 35(1), 1-10
CODEN: JACCDI; ISSN: 0735-1097
PB Elsevier Science Inc.
DT Journal; General Review
LA English
RE.CNT 88 THERE ARE 88 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 106 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 2000:15355 CAPLUS
DN 132:206346
TI Diabetes enhances the uptake of cholesterol in low shear regions
AU Liem, Timothy K.; Vouyouka, Angela; Dixon, Joseph; Shukla, Shivendra; Silver, Donald; Krause, Gary; Sturek, Michael S.
CS Department of Surgery and the Dalton Cardiovascular Research Center, School of Medicine, University of Missouri, Columbia, MO, USA
SO Surgical Forum (1999), 50, 429-432
CODEN: SUFOAX; ISSN: 0071-8041
PB American College of Surgeons
DT Journal
LA English
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 107 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 2000:4636 CAPLUS
DN 132:30628
TI Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of **atherosclerosis** in homozygous familial hypercholesterolemia
AU Raal, Frederick J.; Pilcher, Gillian J.; Veller, Martin G.; Kotze, Maritha J.; Joffe, Barry I.
CS The Carbohydrate and Lipid Metabolism Research Group, Department of Medicine, and The Vascular Unit, Department of Surgery, University of the Witwatersrand, Johannesburg, 2193, S. Afr.
SO American Journal of Cardiology (1999), 84(11), 1344-1346
CODEN: AJCDAG; ISSN: 0002-9149
PB Excerpta Medica, Inc.
DT Journal
LA English
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 108 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:812038 CAPLUS
DN 132:235449
TI Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men
AU Nickenig, Georg; Baumer, Anselm T.; Temur, Yavuz; Kebben, Daniela; Jockenhovel, Friedrich; Bohm, Michael
CS Klinik III fur Innere Medizin and Klinik II fur Innere Medizin, Universitat Koln, Koln, 50924, Germany

SO Circulation (1999), 100(21), 2131-2134

CODEN: CIRCAZ; ISSN: 0009-7322

PB Lippincott Williams & Wilkins

DT Journal

LA English

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 109 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1999:795649 CAPLUS

DN 132:35554

TI Preparation of multibinding multimeric inhibitors of HMG-CoA reductase

IN Griffin, John H.; Leadbetter, Michael R.; Schmidt, Donald E., Jr.

PA Advanced Medicine, Inc., USA

SO PCT Int. Appl., 188 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 25

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| PI WO 9963994 | A1 | 19991216 | WO 1999-US11787 | 19990604 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2319761 | AA | 19991216 | CA 1999-2319761 | 19990604 |
| AU 9945436 | A1 | 19991230 | AU 1999-45436 | 19990604 |
| EP 1083894 | A1 | 20010321 | EP 1999-928345 | 19990604 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI | | | | |
| US. 6355810 | B1 | 20020312 | US 1999-325663 | 19990604 |
| ZA 2000004559 | A | 20020402 | ZA 2000-4559 | 20000831 |
| US 2002028943 | A1 | 20020307 | US 2001-760827 | 20010117 |
| PRAI US 1998-88448P | P | 19980608 | | |
| US 1998-93072P | P | 19980716 | | |
| US 1998-114083P | P | 19981228 | | |
| US 1999-325662 | A3 | 19990604 | | |
| WO 1999-US11787 | W | 19990604 | | |

OS MARPAT 132:35554

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 110 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1999:785577 CAPLUS

DN 132:301

TI An assessment of the efficacy of atorvastatin in treating patients with dyslipidemia to target LDL-cholesterol goals: the atorvastatin matrix study

AU McVey, D.; Patel, H.; Eminton, Z.; Maton, S.

CS Parke-Davis Medical Division, Hants, SO53 3ZQ, UK

SO International Journal of Clinical Practice (1999), 53(7), 509-513
CODEN: IJCPF9; ISSN: 1368-5031

PB Medicom International

DT Journal

LA English

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 111 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:736664 CAPLUS
 DN 131:346502
 TI Combinations of protein farnesyltransferase inhibitors and HMG-CoA reductase inhibitors and their use to treat cancer and other diseases
 IN Leopold, Judith; Newton, Roger Schofield
 PA Warner-Lambert Company, USA
 SO PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 9958505 | A2 | 19991118 | WO 1999-US10188 | 19990510 |
| | WO 9958505 | A3 | 20000106 | | |
| | W: | AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2331295 | AA | 19991118 | CA 1999-2331295 | 19990510 |
| | AU 9939792 | A1 | 19991129 | AU 1999-39792 | 19990510 |
| | EP 1077949 | A2 | 20010228 | EP 1999-922898 | 19990510 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | |
| | BR 9911785 | A | 20010403 | BR 1999-11785 | 19990510 |
| | JP 2002514628 | T2 | 20020521 | JP 2000-548309 | 19990510 |
| | US 6492410 | B1 | 20021210 | US 2000-674818 | 20001106 |
| | NO 2000005680 | A | 20010110 | NO 2000-5680 | 20001110 |
| PRAI | US 1998-85202P | P | 19980512 | | |
| | US 1998-92253P | P | 19980710 | | |
| | WO 1999-US10188 | W | 19990510 | | |
| OS | MARPAT | 131:346502 | | | |

L11 ANSWER 112 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:613662 CAPLUS
 DN 131:248237
 TI Statin-matrix metalloproteinase inhibitor combinations
 IN Newton, Roger Schofield; Roth, Bruce David
 PA Warner-Lambert Company, USA
 SO PCT Int. Appl., 153 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|--|----------|-----------------|----------|
| PI | WO 9947138 | A1 | 19990923 | WO 1998-US24681 | 19981120 |
| | W: | AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2309588 | AA | 19990923 | CA 1998-2309588 | 19981120 |
| | AU 9915916 | A1 | 19991011 | AU 1999-15916 | 19981120 |

BR 9815745 A 20001114 BR 1998-15745 19981120
EP 1063991 A1 20010103 EP 1998-960279 19981120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
JP 2002506818 T2 20020305 JP 2000-536378 19981120
ZA 9902106 A 19990930 ZA 1999-2106 19990316
US 2002049237 A1 20020425 US 2001-977162 20011012
PRAI US 1998-78265P P 19980317
WO 1998-US24681 W 19981120
US 1999-297592 B1 19990503
OS MARPAT 131:248237

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 113 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:609873 CAPLUS
DN 131:223312
TI Efficacy and safety of atorvastatin and pravastatin in patients with hypercholesterolemia
AU Assmann, G.; Huwel, D.; Schussman, K.-M.; Smilde, J. G.; Kosling, M.; Withagen, A. J. A. M.; Wunderlich, J.; Stoel, I.; Van Dormaal, J. J.; Neuss, J.; Oldenbroek, C.; Cuppers, M. C.; Von Eckardstein, A.; Schulte, H.; Wagner, B.; McLain, R.; Black, D. M.
CS Institut fur Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Munster, 48149, Germany
SO European Journal of Internal Medicine (1999), 10(1), 33-39
CODEN: EJIMEJ; ISSN: 0953-6205
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 114 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:538570 CAPLUS
DN 131:295415
TI Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig. Atorvastatin versus simvastatin
AU Conde, K.; Pineda, G.; Newton, R. S.; Fernandez, M. L.
CS Department of Nutritional Sciences, Lipid Metabolism Laboratory, University of Connecticut, Storrs, CT, USA
SO Biochemical Pharmacology (1999), 58(7), 1209-1219
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 115 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:501721 CAPLUS
DN 131:153629
TI Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders
AU Murdock, David K.; Murdock, Anthony K.; Murdock, Robert W.; Olson, Karen J.; Frane, Arlyne M.; Kersten, Mary E.; Joyce, Diane M.; Gantner, Sue E.
CS The Lipid Clinic of Cardiovascular Associates of Northern Wisconsin and The CARE Foundation, Wausau, WI, USA
SO American Heart Journal (1999), 138(1, Pt. 1), 151-155
CODEN: AHJOA2; ISSN: 0002-8703
PB Mosby, Inc.

DT Journal
LA English

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 116 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:489710 CAPLUS
DN 131:331943
TI Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin
AU Alfon, Jose; Royo, Teresa; Garcia-Moll, Xavier; Badimon, Lina
CS Cardiovascular Research Center, CSIC-HSCSP-UAB, Barcelona, Spain
SO Arteriosclerosis, Thrombosis, and Vascular Biology (1999), 19(7), 1812-1817
CODEN: ATVBFA; ISSN: 1079-5642
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 117 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:464665 CAPLUS
DN 131:295408
TI Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors
AU Alfon, Jose; Guasch, Joan F.; Berrozpe, Maria; Badimon, Lina
CS CSIC-HSCSP-UAB, Cardiovascular Research Center, Barcelona, 08034, Spain
SO Atherosclerosis (Shannon, Ireland) (1999), 145(2), 325-331
CODEN: ATHSBL; ISSN: 0021-9150
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 118 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:442143 CAPLUS
DN 131:306908
TI Lipophilic statins induce apoptosis of human vascular smooth muscle cells
AU Guijarro, Carlos; Blanco-Colio, Luis Miguel; Massy, Ziad A.; O'Donnell, Michael P.; Kasiske, Bertram L.; Keane, William F.; Egido, Jesus
CS Research Laboratories, Instituto de Investigacion Medica, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain
SO Kidney International, Supplement (1999), 71, S88-S91
CODEN: KISUDF; ISSN: 0098-6577
PB Blackwell Science, Inc.
DT Journal
LA English

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 119 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:282039 CAPLUS
DN 130:306593
TI Combination therapy using a HMG-CoA reductase inhibitor and a cyclooxygenase-2 (COX-2) inhibitor for reducing the risks associated with cardio- and cerebrovascular disease
IN Winokur, Melvin
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 9920110 | A1 | 19990429 | WO 1998-US21901 | 19981016 |
| | W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE,
HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG,
MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2306646 | AA | 19990429 | CA 1998-2306646 | 19981016 |
| | AU 9913612 | A1 | 19990510 | AU 1999-13612 | 19981016 |
| | AU 753657 | B2 | 20021024 | | |
| | EP 1024696 | A1 | 20000809 | EP 1998-957328 | 19981016 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
SI, LT, LV, FI, RO | | | | |
| | JP 2001520174 | T2 | 20011030 | JP 2000-516533 | 19981016 |
| | US 6245797 | B1 | 20010612 | US 1998-179349 | 19981020 |
| PRAI | US 1997-62691P | P | 19971022 | | |
| | GB 1998-6688 | A | 19980327 | | |
| | WO 1998-US21901 | W | 19981016 | | |

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 120 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:193844 CAPLUS
DN 130:227739
TI Method for lowering serum lipid levels employing an MTP inhibitor in
combination with another cholesterol lowering drug
IN Gregg, Richard E.; Pouleur, Hubert G.; Wetterau, John R., II
PA Bristol-Myers Squibb Company, USA
SO U.S., 22 pp.
CODEN: USXXAM
DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------------|----------|-----------------|----------|
| PI | US 5883109 | A | 19990316 | US 1997-854311 | 19970512 |
| PRAI | US 1997-854311 | | 19970512 | | |
| OS | MARPAT | 130:227739 | | | |

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 121 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:184130 CAPLUS
DN 130:205139
TI Combination therapy comprising atorvastatin and an antihypertensive agent
IN Scott, Robert Andrew Donald
PA Pfizer Inc., USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|------|----------|-----------------|----------|
| PI | WO 9911260 | A1 | 19990311 | WO 1998-IB1230 | 19980811 |

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
 DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 9884589 A1 19990322 AU 1998-84589 19980811
 AU 740424 B2 20011101
 EP 1009400 A1 20000621 EP 1998-935250 19980811
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
 SI, LT, LV, FI, RO
 BR 9811556 A 20000822 BR 1998-11556 19980811
 JP 2001514223 T2 20010911 JP 2000-508363 19980811
 ZA 9807839 A 20000228 ZA 1998-7839 19980828
 NO 2000000996 A 20000427 NO 2000-996 20000228
 US 2002099046 A1 20020725 US 2001-45329 20011023
 PRAI US 1997-57276P P 19970829
 WO 1998-IB1230 W 19980811
 US 2000-513887 B1 20000225

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 122 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:184129 CAPLUS
 DN 130:205138
 TI Therapeutic combinations comprising amlodipine and atorvastatin
 IN Buch, Jan; Scott, Robert Andrew Donald
 PA Pfizer Inc., USA
 SO PCT Int. Appl., 50 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9911259 | A1 | 19990311 | WO 1998-IB1225 | 19980811 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2301732 | AA | 19990311 | CA 1998-2301732 | 19980811 |
| | AU 9885548 | A1 | 19990322 | AU 1998-85548 | 19980811 |
| | EP 1003503 | A1 | 20000531 | EP 1998-936587 | 19980811 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
SI, LT, LV, FI, RO | | | | |
| | BR 9812030 | A | 20000926 | BR 1998-12030 | 19980811 |
| | JP 2001514222 | T2 | 20010911 | JP 2000-508362 | 19980811 |
| | ZA 9807844 | A | 20000228 | ZA 1998-7844 | 19980828 |
| | US 6455574 | B1 | 20020924 | US 2000-512914 | 20000225 |
| | NO 2000000998 | A | 20000228 | NO 2000-998 | 20000228 |
| | US 2003008904 | A1 | 20030109 | US 2002-214058 | 20020807 |
| PRAI | US 1997-57275P | P | 19970829 | | |
| | WO 1998-IB1225 | W | 19980811 | | |
| | US 2000-512914 | A3 | 20000225 | | |

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 123 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:159872 CAPLUS
DN 130:246722
TI Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols
AU Cziraky, Mark
CS Health Core, Newark, DE, USA
SO PharmacoEconomics (1998), 14(Suppl. 3), 29-38
CODEN: PARMEK; ISSN: 1170-7690
PB Adis International Ltd.
DT Journal
LA English
RE.CNT 82 THERE ARE 82 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 124 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:113552 CAPLUS
DN 130:173009
TI Combinations of HMG-CoA reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia
IN Bova, David J.; Dunne, Josephine
PA Kos Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------|--|----------|-----------------|----------|
| PI WO 9906046 | A1 | 19990211 | WO 1998-US15989 | 19980731 |
| W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| US 2001006644 | A1 | 20010705 | US 1997-903871 | 19970731 |
| AU 9886800 | A1 | 19990222 | AU 1998-86800 | 19980731 |
| EP 1003515 | A1 | 20000531 | EP 1998-938227 | 19980731 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | |
| NO 2000000407 | A | 20000316 | NO 2000-407 | 20000127 |
| PRAI US 1997-903871 | A | 19970731 | | |
| WO 1998-US15989 | W | 19980731 | | |

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 125 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:113543 CAPLUS
DN 130:187186
TI Pharmaceutical composition containing combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds for treating hyperlipidemia once a day at night
IN Bova, David J.; Dunne, Josephine
PA Kos Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 9906035 | A2 | 19990211 | WO 1998-US15990 | 19980731 |
| | WO 9906035 | A3 | 19990422 | | |
| | W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 9886801 | A1 | 19990222 | AU 1998-86801 | 19980731 |
| | AU 752673 | B2 | 20020926 | | |
| | EP 1017390 | A2 | 20000712 | EP 1998-938228 | 19980731 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | |
| | BR 9815548 | A | 20001107 | BR 1998-15548 | 19980731 |
| | JP 2001511444 | T2 | 20010814 | JP 2000-504849 | 19980731 |
| | NO 2000000439 | A | 20000322 | NO 2000-439 | 20000127 |
| PRAI | US 1997-903752 | A | 19970731 | | |
| | WO 1998-US15990 | W | 19980731 | | |

L11 ANSWER 126 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1999:1203 CAPLUS

DN 130:218023

TI HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of **atherosclerosis**

AU Bustos, Carmen; Hernandez-Presa, Miguel A.; Ortego, Monica; Tunon, Jose; Ortega, Luis; Perez, Fernando; Diaz, Cristina; Hernandez, Gonzalo; Egido, Jesus

CS Fundacion Jimenez Diaz, Universidad Autonoma, Madrid, 28040, Spain

SO Journal of the American College of Cardiology (1998), 32(7), 2057-2064

CODEN: JACCDI; ISSN: 0735-1097

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 127 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1998:744939 CAPLUS

DN 130:17236

TI MTP inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

IN Gregg, Richard E.; Wetterau, John R., II

PA Bristol-Myers Squibb Co., USA

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|--|----------|-----------------|----------|
| PI | WO 9850028 | A1 | 19981112 | WO 1998-US8269 | 19980423 |
| | W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, | | | |

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, ML, MR, NE, SN, TD, TG
 AU 9871559 A1 19981127 AU 1998-71559 19980423
 AU 748608 B2 20020606
 EP 1024804 A1 20000809 EP 1998-918680 19980423
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 JP 2001527551 T2 20011225 JP 1998-548138 19980423
 PRAI US 1997-45405P P 19970501
 WO 1998-US8269 W 19980423
 OS MARPAT 130:17236
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 128 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:625982 CAPLUS
 DN 130:20459
 TI Treating patients with documented **atherosclerosis** to national
 cholesterol education program-recommended low-density-lipoprotein
 cholesterol goals with atorvastatin, fluvastatin, lovastatin and
 simvastatin
 AU Brown, Alan S.; Bakker-Arkema, Rebecca G.; Yellen, Laurence; Henley,
 Robert W., Jr.; Guthrie, Richard; Campbell, Cam F.; Koren, Michael; Woo,
 William; McLain, Richard; Black, Donald M.
 CS Midwest Heart Research Foundation, Naperville, IL, USA
 SO Journal of the American College of Cardiology (1998), 32(3), 665-672
 CODEN: JACCDI; ISSN: 0735-1097
 PB Elsevier Science Inc.
 DT Journal
 LA English
 RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 129 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:509102 CAPLUS
 DN 129:153237
 TI Method for treating **atherosclerosis** with an MPT inhibitor and
 cholesterol-lowering drugs
 IN Behounek, Bruce D.; McGovern, Mark E.; Belder, Rene
 PA Bristol-Myers Squibb Co., USA
 SO PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|--|----------|-----------------|----------|
| PI | WO 9831366 | A1 | 19980723 | WO 1998-US524 | 19980112 |
| | W: | AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,
LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG | | | |
| | AU 9862397 | A1 | 19980807 | AU 1998-62397 | 19980112 |
| | AU 727895 | B2 | 20010104 | | |
| | EP 989852 | A1 | 20000405 | EP 1998-904548 | 19980112 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI | | | | |
| | JP 2001508795 | T2 | 20010703 | JP 1998-534460 | 19980112 |

PRAI US 1997-35592P P 19970117
WO 1998-US524 W 19980112

OS MARPAT 129:153237

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 130 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1998:478194 CAPLUS
DN 129:225548
TI LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors
AU de Bont, Natasja; Netea, Mihai G.; Rovers, Chantal; Smilde, Tineke;
Demacker, Pierre N. M.; van der Meer, Jos W. M.; Stalenhoef, Anton F. H.
CS Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, 6500 HB, Neth.
SO Atherosclerosis (Shannon, Ireland) (1998), 139(1), 147-152
CODEN: ATHSBL; ISSN: 0021-9150
PB Elsevier Science Ireland Ltd.
DT Journal
LA English

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 131 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1998:478160 CAPLUS
DN 129:225547
TI HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit
AU Bocan, Thomas M. A.; Bak Mueller, Sandra; Quenby Brown, Edie; Lee, Peter;
Bocan, Michelle J.; Rea, Thomas; Pape, Michael E.
CS Parke-Davis Pharmaceutical Research, Department of Vascular and Cardiac Diseases, Division of Warner Lambert Company, Ann Arbor, MI, 48105, USA
SO Atherosclerosis (Shannon, Ireland) (1998), 139(1), 21-30
CODEN: ATHSBL; ISSN: 0021-9150
PB Elsevier Science Ireland Ltd.
DT Journal
LA English

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 132 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1998:458053 CAPLUS
DN 129:184104
TI Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
AU Aviram, Michael; Rosenblat, Mira; Bisgaier, Charles L.; Newton, Roger S.
CS Technion Faculty of Medicine, Rappaport Family Institute for Research in the Medical Sciences and Rambam Medical Center, Haifa, 31096, Israel
SO Atherosclerosis (Shannon, Ireland) (1998), 138(2), 271-280
CODEN: ATHSBL; ISSN: 0021-9150
PB Elsevier Science Ireland Ltd.
DT Journal
LA English

L11 ANSWER 133 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1998:404579 CAPLUS
DN 129:130773
TI Advances in drug treatment of dyslipidemia: focus on atorvastatin
AU Davignon, Jean
CS Hyperlipidemia and Atherosclerosis Research Group, Clinical Research

SO Institute of Montreal, Montreal, QC, H2W 1R7, Can.
 Canadian Journal of Cardiology (1998), 14(Suppl. B), 28B-38B
 CODEN: CJCAEX; ISSN: 0828-282X
 PB Pulsus Group
 DT Journal; General Review
 LA English

L11 ANSWER 134 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:400182 CAPLUS
 DN 129:131131
 TI Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
 AU Hernandez-Perera, Octavio; Perez-Sala, Dolores; Navarro-Antolin, Javier; Sanchez-Pascuala, Rafael; Hernandez, Gonzalo; Diaz, Cristina; Lamas, Santiago
 CS Centro de Investigaciones Biologicas, Instituto Reina Sofia de Investigaciones Nefrologicas, Consejo Superior de Investigaciones Cientificas, Madrid, 28006, Spain
 SO Journal of Clinical Investigation (1998), 101(12), 2711-2719
 CODEN: JCINAO; ISSN: 0021-9738
 PB Rockefeller University Press
 DT Journal
 LA English

RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 135 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:388501 CAPLUS
 DN 129:54297
 TI Apo B-secretion/MTP inhibitory 4'-(trifluoromethyl)biphenyl-2-carboxylic acid (1,2,3,4-tetrahydroisoquinolin-6-yl)amides and their preparation, pharmaceutical compositions, and use
 IN Chang, George; Quallich, George Joseph
 PA Pfizer Inc., USA; Chang, George; Quallich, George Joseph
 SO PCT Int. Appl., 105 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 9823593 | A1 | 19980604 | WO 1997-IB1368 | 19971103 |
| | W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | |
| | AU 9746347 | A1 | 19980622 | AU 1997-46347 | 19971103 |
| | AU 716151 | B2 | 20000217 | | |
| | EP 944602 | A1 | 19990929 | EP 1997-945048 | 19971103 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO | | | |
| | CN 1238764 | A | 19991215 | CN 1997-180033 | 19971103 |
| | BR 9714364 | A | 20000321 | BR 1997-14364 | 19971103 |
| | JP 2000505810 | T2 | 20000516 | JP 1998-524464 | 19971103 |
| | JP 3270764 | B2 | 20020402 | | |
| | ZA 9710641 | A | 19990526 | ZA 1997-10641 | 19971126 |
| | US 6121283 | A | 20000919 | US 1999-284466 | 19990420 |

NO 9902525 A 19990526 NO 1999-2525 19990526
 KR 2000057269 A 20000915 KR 1999-704662 19990526
 CN 1380289 A 20021120 CN 2002-105189 20020219
 PRAI US 1996-32307P P 19961127
 WO 1997-IB1368 W 19971103
 OS CASREACT 129:54297; MARPAT 129:54297
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:87580 CAPLUS
 DN 128:162883
 TI Method for lowering serum lipid levels employing a microsomal triglyceride-transfer protein (MTP) inhibitor in combination with another cholesterol-lowering drug
 IN Gregg, Richard E.; Pouleur, Hubert G.; Wetterau, John R., II
 PA Bristol-Myers Squibb Co., USA
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9803069 | A1 | 19980129 | WO 1997-US12229 | 19970714 |
| | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | ZA 9705950 | A | 19990104 | ZA 1997-5950 | 19970703 |
| | AU 9736624 | A1 | 19980210 | AU 1997-36624 | 19970714 |
| | AU 716145 | B2 | 20000217 | | |
| | EP 1014791 | A1 | 20000705 | EP 1997-933435 | 19970714 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| PRAI | JP 2000515526 | T2 | 20001121 | JP 1998-507023 | 19970714 |
| | US 1996-22866P | P | 19960724 | | |
| | WO 1997-US12229 | W | 19970714 | | |
| OS | MARPAT 128:162883 | | | | |

L11 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:778860 CAPLUS
 DN 128:70496
 TI Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells
 AU Baetta, Roberta; Donetti, Elena; Comparato, Carmen; Calore, Monica; Rossi, Alessandra; Teruzzi, Chiara; Paoletti, Rodolfo; Fumagalli, Remo; Soma, Maurizio R.
 CS Institute of Pharmacological Sciences, University of Milan, Milan, 20133, Italy
 SO Pharmacological Research (1997), 36(2), 115-121
 CODEN: PHMREP; ISSN: 1043-6618
 PB Academic Press Ltd.
 DT Journal
 LA English

L11 ANSWER 138 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:696637 CAPLUS

DN 127:351217
 TI Combination therapy containing HMG-CoA reductase inhibitors for reducing the risks associated with cardiovascular disease
 IN Tobert, Jonathan A.
 PA Merck & Co., Inc., USA; Tobert, Jonathan A.
 SO PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|--|----------|-----------------|----------|
| PI | WO 9738694 | A1 | 19971023 | WO 1997-US6127 | 19970414 |
| | W: | AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | |
| | CA 2251972 | AA | 19971023 | CA 1997-2251972 | 19970414 |
| | AU 9726665 | A1 | 19971107 | AU 1997-26665 | 19970414 |
| | AU 732465 | B2 | 20010426 | | |
| | EP 904082 | A1 | 19990331 | EP 1997-918595 | 19970414 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | |
| | JP 2000508659 | T2 | 20000711 | JP 1997-537264 | 19970414 |
| PRAI | US 1996-15689P | P | 19960417 | | |
| | GB 1996-12082 | A | 19960610 | | |
| | US 1996-20977P | P | 19960624 | | |
| | GB 1996-16804 | A | 19960809 | | |
| | WO 1997-US6127 | W | 19970414 | | |

L11 ANSWER 139 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:576602 CAPLUS
 DN 127:243263
 TI Combination of a cholesterol biosynthesis inhibitor and a .beta.-lactam cholesterol absorption inhibitor as antihypercholesterolemic
 IN Davis, Harry R.
 PA Schering Corporation, USA
 SO U.S., 7 pp., Cont.-in-part of U.S. Ser. No. 995,488, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | US 5661145 | A | 19970826 | US 1995-454348 | 19950620 |
| | WO 9414433 | A1 | 19940707 | WO 1993-US12291 | 19931221 |
| | W: | AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN | | | |
| | RW: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | |
| PRAI | US 1992-995488 | B2 | 19921223 | | |
| | WO 1993-US12291 | W | 19931221 | | |
| OS | MARPAT | 127:243263 | | | |

L11 ANSWER 140 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:356461 CAPLUS
 DN 126:330797
 TI Preparation of steroid glycosides for treatment of hypercholesterolemia and related disorders
 IN Kim, Dooseop

PA Merck and Co., Inc., USA
 SO Brit. UK Pat. Appl., 78 pp.
 CODEN: BAXXDU
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| PI | GB 2304106 | A1 | 19970312 | GB 1996-16443 | 19960805 |
| PRAI | US 1995-2039P | P | 19950808 | | |
| OS | MARPAT 126:330797 | | | | |

L11 ANSWER 141 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:280110 CAPLUS
 DN 126:325296
 TI Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
 AU Bertolini, Stefano; Bittolo Bon, Gabriele; Campbell, L. Malcolm; Farnier, Michel; Langan, John; Mahla, Gerhard; Pauciullo, Paolo; Sirtori, Cesare; Egros, Fabrice; Fayyad, Rana; Nawrocki, James W.
 CS Dipartimento di Medicina Interna, Genoa, Italy
 SO Atherosclerosis (Shannon, Ireland) (1997), 130(1,2), 191-197
 CODEN: ATHSBL; ISSN: 0021-9150
 PB Elsevier
 DT Journal
 LA English

L11 ANSWER 142 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:178769 CAPLUS
 DN 126:176899
 TI Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis
 IN Tsujita, Yoshio; Horikoshi, Hiroyoshi; Shiomi, Masashi; Ito, Takashi
 PA Sankyo Co., Ltd., Japan
 SO Eur. Pat. Appl., 24 pp.
 CODEN: EPXXDW
 DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|------------------|----------|
| PI | EP 753298 | A1 | 19970115 | EP 1996-304924 | 19960703 |
| | EP 753298 | B1 | 20011121 | | |
| | R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL,
PT, SE | | | | |
| | CA 2180296 | AA | 19970104 | CA 1996-2180296 | 19960702 |
| | NO 9602784 | A | 19970106 | NO 1996-2784 | 19960702 |
| | AU 9656261 | A1 | 19970116 | AU 1996-56261 | 19960702 |
| | AU 706628 | B2 | 19990617 | | |
| | JP 09071540 | A2 | 19970318 | JP 1996-172137 | 19960702 |
| | US 5798375 | A | 19980825 | US 1996-676090 | 19960702 |
| | IL 118778 | A1 | 19990714 | IL 1996-118778 | 19960702 |
| | RU 2158607 | C2 | 20001110 | RU 1996-112769 | 19960702 |
| | TW 474809 | B | 20020201 | TW 1996-85107984 | 19960702 |
| | ZA 9605650 | A | 19970127 | ZA 1996-5650 | 19960703 |
| | CN 1148492 | A | 19970430 | CN 1996-112170 | 19960703 |
| | CN 1089584 | B | 20020828 | | |
| | CZ 286832 | B6 | 20000712 | CZ 1996-1982 | 19960703 |
| | AT 209046 | E | 20011215 | AT 1996-304924 | 19960703 |
| | ES 2165474 | T3 | 20020316 | ES 1996-304924 | 19960703 |
| | US 6159997 | A | 20001212 | US 1998-61446 | 19980416 |
| PRAI | JP 1995-167291 | A | 19950703 | | |

US 1996-676090 A3 19960702

L11 ANSWER 143 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1996:431460 CAPLUS
DN 125:76399
TI Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor for treatment of hypercholesterolemia and atherosclerosis
IN Morehouse, Lee A.
PA Morehouse, Lee, A., USA
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|-----------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | WO 9609827 | A2 | 19960404 | WO 1995-IB447 | 19950607 |
| | WO 9609827 | A3 | 19960523 | | |
| | W: AU, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RU, SI, SK, UA, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | CA 2200436 | AA | 19960404 | CA 1995-2200436 | 19950607 |
| | AU 9524532 | A1 | 19960419 | AU 1995-24532 | 19950607 |
| | EP 782451 | A1 | 19970709 | EP 1995-918721 | 19950607 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| | JP 09511753 | T2 | 19971125 | JP 1995-511549 | 19950607 |
| | BR 9504072 | A | 19960730 | BR 1995-4072 | 19950919 |
| | ZA 9507879 | A | 19970319 | ZA 1995-7879 | 19950919 |
| | US 5807834 | A | 19980915 | US 1997-793802 | 19970318 |
| | FI 9701151 | A | 19970319 | FI 1997-1151 | 19970319 |
| PRAI | US 1994-308908 | A | 19940920 | | |
| | WO 1995-IB447 | W | 19950607 | | |
| OS | MARPAT | 125:76399 | | | |

=> d 104:147555 all

ANSWER 1 CAPLUS COPYRIGHT 2003 ACS
AN 1986:147555 CAPLUS
DN 104:147555
TI Effects of vitamin C and E, trace element selenium and brown sugar in guinea pig arteriosclerosis
AU Sun, Yuming; Lu, Tianluan; Gao, Jianzhong; Dou, Shulan; Wang, Hong; Sun, Shuqin; Li, Tianyang; Sun, Rui
CS Peop. Rep. China
SO Tianjin Yiyao (1985), 13(10), 615-17
CODEN: TIYADG; ISSN: 0253-9896
DT Journal
LA Chinese
CC 18-1 (Animal Nutrition)
AB Dietary vitamin C [50-81-7] and E [1406-18-4], Se, and brown sugar decreased the incidence of arteriosclerosis induced by cholesterol (0.1 g/day) in guinea pig. In the exptl. animal diets, the supplementary amts. were 1.5 mg vitamin C, 1.5 mg vitamin E, 35 .mu.g Na₂SeO₃, and 2 g brown sugar/day/animal. Vitamin C showed the strongest effect on inhibition of arteriosclerosis. The extents of fatty liver and peroxy fatty acids were also decreased by the inhibitory agents.
ST atherosclerosis vitamin selenium sugar diet; liver lipid atherosclerosis inhibitor diet
IT Lipids, biological studies
RL: BIOL (Biological study)
(dietary atherosclerosis inhibitors effect on, of liver)

IT Atherosclerosis
(inhibition of, dietary vitamin C and E and brown sugar in)
IT Liver, composition
(lipids and peroxy fatty acids of, dietary atherosclerosis inhibitors effect on)
IT Fatty acids, biological studies
RL: BIOL (Biological study)
(peroxy, dietary atherosclerosis inhibitors effect on, of liver)
IT 50-81-7, biological studies 1406-18-4 7782-49-2, biological studies
RL: BIOL (Biological study)
(atherosclerosis inhibition by dietary)
IT 57-50-1, biological studies
RL: BIOL (Biological study)
(brown, atherosclerosis inhibition by dietary)

=> d 79:100515 all

ANSWER 1 CAPLUS COPYRIGHT 2003 ACS
AN 1973:500515 CAPLUS
DN 79:100515
TI Antiinflammatory drugs in experimental atherosclerosis. 1. Relative potencies for inhibiting plaque formation
AU Bailey, J. Martyn; Butler, Jean
CS Sch. Med., George Washington Univ., Washington, DC, USA
SO Atherosclerosis (Shannon, Ireland) (1973), 17(3), 515-22
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English
CC 1-5 (Pharmacodynamics)
AB Orally administered 9.alpha.-fluorohydrocortisone (I) [127-31-1] (30 .mu.g/day) was effective in decreasing plaque formation in cholesterol-fed rabbits. Dexamethasone [50-02-2], methylprednisolone [83-43-2], triamcinolone [124-94-7], prednisone [53-03-2], and cortisone acetate [50-04-4] were also effective at higher dose levels. All of the steroids tested decreased plaque formation by 55 to 95%. These protective effects were partially duplicated by a number of nonsteroidal inflammation inhibitors including flufenamic acid [530-78-9], phenylbutazone [50-33-9], oxyphenylbutazone [129-20-4], and mefenamic acid [61-68-7]. Aminopyrine [58-15-1] and aspirin [50-78-2] were inactive. By means of dose-response curves, it was possible to demonstrate dissociation of the hyperlipemic effects of the steroids from their protective effects. The relative potencies of these drugs in inhibiting atherosclerosis in the rabbit, paralleled closely their effectiveness in treatment of inflammatory disorders in humans.
ST atherosclerosis inflammation inhibitor; fluorohydrocortisone
atherosclerosis dexamethasone prednisone; phenylbutazone atherosclerosis
oxyphenbutazone mefenamate
IT Inflammation inhibitors
(atherosclerosis prevention by)
IT Atherosclerosis
(inflammation inhibitors effect on)
IT 530-78-9
RL: BIOL (Biological study)
(atherosclerosis prevention by)
IT 50-02-2 50-04-4 50-33-9 53-03-2 61-68-7 83-43-2 127-31-1
129-20-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(atherosclerosis prevention by)
IT 50-78-2 58-15-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(atherosclerosis prevention in relation to)

=> d 66:9364 all

ANSWER 1 CAPLUS COPYRIGHT 2003 ACS
AN 1967:9364 CAPLUS
DN 66:9364
TI Influence of antiinflammatory agents on experimental atherosclerosis
AU Bailey, John Martyn; Butler, Jean
CS Sch. of Med., George Washington Univ., Washington, DC, USA
SO Nature (London, United Kingdom) (1966), 212(5063), 731-2
CODEN: NATUAS; ISSN: 0028-0836
DT Journal
LA English
CC 12 (Mammalian Pathological Biochemistry)
AB Daily supplements of cholesterol (1 g.) in rabbit diets increased plasma lipid concns. 10-20-fold and induced atherosclerotic plaques in the thoracic aortas within 12 weeks. The addn. of 1 or 5 mg. of cortisone acetate (I) to rabbit diets contg. cholesterol increased plasma lipids, but reduced the development of atherosclerotic plaques by about 75%. Phenylbutazone (100 mg. daily) decreased plaque formation; 44% of the animals developed no plaques at all. The phenylbutazone-induced decreased plaque formations did not alter serum lipid patterns. The severity of atherosclerosis in animals treated with 100 mg. of aminopyrine was slightly less than in the controls; plasma cholesterol was considerably lower. Vitamin C (100 mg.) produced no decrease in the no. of plaques, and acetyl salicylate increased the incidence of atherosclerosis 17.1%. Rabbits fed a diet contg. 1% cholesterol for 12 weeks produced extensive plaques which did not regress during the following 12 weeks on a cholesterol-free diet, with or without daily supplementation with 5 mg. of I, indicating that I acts in the early stages of plaque formation through its antiinflammatory properties rather than through its lipemic effects.
ST LIPIDS ATHEROSCLEROSIS; ANTIINFLAMMATORIES ATHEROSCLEROSIS; CORTISONE ATHEROSCLEROSIS; ATHEROSCLEROSIS CORTISONE; STEROIDS ATHEROSCLEROSIS; CORTISONE ATHEROSCLEROSIS; ATHEROSCLEROSIS CORTISONE; LIPIDS ATHEROSCLEROSIS; ANTIINFLAMMATORIES ATHEROSCLEROSIS; STEROIDS ATHEROSCLEROSIS
IT Lipids
RL: BIOL (Biological study)
(in blood plasma, inflammation inhibitor effect on)
IT Atherosclerosis
(inflammation inhibitor effect on)
IT 50-78-2, biological studies
RL: BIOL (Biological study)
(atherosclerosis in response to)
IT 50-04-4 50-33-9 58-15-1
RL: BIOL (Biological study)
(atherosclerosis in response to)

=> d 17 201 100 198 195 194 193 all

L7 ANSWER 201 OF 202 CAPLUS COPYRIGHT 2003 ACS
AN 1967:9364 CAPLUS
DN 66:9364
TI Influence of antiinflammatory agents on experimental atherosclerosis
AU Bailey, John Martyn; Butler, Jean
CS Sch. of Med., George Washington Univ., Washington, DC, USA
SO Nature (London, United Kingdom) (1966), 212(5063), 731-2

DT CODEN: NATUAS; ISSN: 0028-0836
LA Journal
LA English
CC 12 (Mammalian Pathological Biochemistry)
AB Daily supplements of cholesterol (1 g.) in rabbit diets increased plasma lipid concns. 10-20-fold and induced atherosclerotic plaques in the thoracic aortas within 12 weeks. The addn. of 1 or 5 mg. of cortisone acetate (I) to rabbit diets contg. cholesterol increased plasma lipids, but reduced the development of atherosclerotic plaques by about 75%. Phenylbutazone (100 mg. daily) decreased plaque formation; 44% of the animals developed no plaques at all. The phenylbutazone-induced decreased plaque formations did not alter serum lipid patterns. The severity of **atherosclerosis** in animals treated with 100 mg. of aminopyrine was slightly less than in the controls; plasma cholesterol was considerably lower. Vitamin C (100 mg.) produced no decrease in the no. of plaques, and acetyl salicylate increased the incidence of **atherosclerosis** 17.1%. Rabbits fed a diet contg. 1% cholesterol for 12 weeks produced extensive plaques which did not regress during the following 12 weeks on a cholesterol-free diet, with or without daily supplementation with 5 mg. of I, indicating that I acts in the early stages of plaque formation through its antiinflammatory properties rather than through its lipemic effects.
ST LIPIDS **ATHEROSCLEROSIS**; ANTIINFLAMMATORIES
ATHEROSCLEROSIS; CORTISONE **ATHEROSCLEROSIS**
ATHEROSCLEROSIS CORTISONE; STEROIDS **ATHEROSCLEROSIS**
CORTISONE **ATHEROSCLEROSIS**; **ATHEROSCLEROSIS** CORTISONE;
LIPIDS **ATHEROSCLEROSIS**; ANTIINFLAMMATORIES
ATHEROSCLEROSIS; STEROIDS **ATHEROSCLEROSIS**
IT Lipids
IT RL: BIOL (Biological study)
(in blood plasma, inflammation inhibitor effect on)
IT **Atherosclerosis**
(inflammation inhibitor effect on)
IT 50-78-2, biological studies
IT RL: BIOL (Biological study)
(atherosclerosis in response to)
IT 50-04-4 50-33-9 58-15-1
IT RL: BIOL (Biological study)
(**atherosclerosis** in response to)
L7 ANSWER 100 OF 202 CAPLUS COPYRIGHT 2003 ACS
AN 1999:317391 CAPLUS
DN 130:346750
TI Antithrombotic drugs in the primary medical management of intermittent claudication. A meta-analysis
AU Girolami, Bruno; Bernardi, Enrico; Prins, Martin H.; Ten Cate, Jan Wouter; Prandoni, Paolo; Hettiarachchi, Rohan; Marras, Elena; Stefani, Piero Maria; Girolami, Antonio; Buller, Harry R.
CS Institute Medical Semeiotics, University Padua, Padua, I-35100, Italy
SO Thrombosis and Haemostasis (1999), 81(5), 715-722
AB CODEN: THHADQ; ISSN: 0340-6245
PB F. K. Schattauer Verlagsgesellschaft mbH
DT Journal; General Review
LA English
CC 1-0 (Pharmacology)
AB A review with 78 refs. is given on the efficacy of antithrombotic drugs available for patients with intermittent claudication. A Medline and manual search was used to identify relevant publications. Uncontrolled or retrospective studies, double reports or trials without clin. outcomes were excluded. Included studies were graded as level 1 (randomized and double- or assessor-blind), level 2 (open randomized), or level 3 (non-randomized comparative). Mortality, cerebro- or cardiovascular events, amputations, arterial occlusions or no. of revascularization

procedures performed in the lower limbs, pain-free and total walking distance, ankle brachial index and calf blood flow, were the main outcomes considered. When feasible, end of treatment results, either continuous or binary, were combined with appropriate statistical methods. Mortality was decreased by ticlopidine compared to placebo (common odds ratio 0.68, 95% C.I., 0.49-0.95); clopidogrel decreased vascular events in comparison to aspirin (odds ratio 0.76, 95% C.I., 0.63-0.92) in level 1 studies.

Arterial occlusions and the no. of revascularization procedures performed were decreased by aspirin and ticlopidine, resp. A small improvement in pain-free walking distance was detd. by picotamide, indobufen, low mol. wt. heparins, sulodexide, and defibrotide, in small studies. Clopidogrel and ticlopidine do reduce clin. important events in patients with intermittent claudication and could be added to the primary medical treatment of these patients. The use of aspirin in these patients cannot be based on direct evidence, but only on analogy with coronary and cerebral **atherosclerosis**, where it has documented efficacy.

Other antithrombotic drugs were not properly evaluated in patients with intermittent claudication.

ST review antithrombotic intermittent claudication

IT Anticoagulants

(antithrombotic drugs in the primary medical management of intermittent claudication)

IT Artery, disease

(intermittent claudication; antithrombotic drugs in the primary medical management of intermittent claudication)

IT 50-78-2, Aspirin 32828-81-2, Picotamide 55142-85-3, Ticlopidine 57821-29-1, Sulodexide 63610-08-2, Indobufen 83712-60-1, Defibrotide 113665-84-2, Clopidogrel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antithrombotic drugs in the primary medical management of intermittent claudication)

IT 9005-49-6, Heparin, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(low mol. wt.; antithrombotic drugs in the primary medical management of intermittent claudication)

RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Adriaensen, H; Curr Med Res Opin 1976, V4, P395 MEDLINE
- (2) Allegra, C; Int J Clin Pharmacol Ther 1994, V12, P646
- (3) Andreozzi, G; Angiology 1993, V44, P307 MEDLINE
- (4) Antiplatelet Trialists' Collaboration; BMJ 1994, V308, P159
- (5) Antiplatelet Trialists' Collaboration; BMJ 1994, V308, P81
- (6) Arcan, J; Angiology 1988, V39, P802 MEDLINE
- (7) Arcan, J; Thromb Res 1986, VSuppl VI, P159
- (8) Ariyoshi, K; Am J Hematol 1997, V54, P175 MEDLINE
- (9) Aukland, A; J Clin Pathol 1982, V35, P740 MEDLINE
- (10) Auteri, A; Int J Clin Pharmacol Res 1995, V15, P57 CAPLUS
- (11) Balkau, B; J Cardiovasc Pharmacol 1994, V23(Suppl 3), PS8
- (12) Balsano, F; Circulation 1993, V87, P1563 MEDLINE
- (13) Balsano, F; J Lab Clin Med 1989, V114, P84 MEDLINE
- (14) Belcaro, G; Angiology 1991, V42, P8 MEDLINE
- (15) Belcaro, G; Curr Ther Res 1990, V48, P667
- (16) Berqvist, D; Eur J Vasc Endovasc Surg 1995, V10, P69
- (17) Blanchard, J; Nouv Rev Fr Hematol 1993, V35, P523
- (18) Bonalumi, F; Eur Rev Med Pharmacol Sci 1986, VVIII, P123
- (19) CAPRIE Steering Committee; Lancet 1996, V348, P1329
- (20) Calabro, A; Angiology 1993, V44, P188 MEDLINE
- (21) Caramelli, L; Eur Rev Med Pharmacol Sci 1988, V10, P55 MEDLINE

- (22) Castelluccio, A; Curr Med Res Opin 1991, V12, P325 MEDLINE
(23) Catania, G; Eur Rev Med Farmacol Sci 1992, V14, P149 MEDLINE
(24) Centurioni, R; Haematologica 1993, V78, P196 MEDLINE
(25) Ciocon, J; Angiology 1997, V48, P237 MEDLINE
(26) Clagett, G; Chest 1995, V108(Suppl), P431S
(27) Cloarec, M; Thromb Res 1985, VSuppl VI, P160
(28) Corsi, C; J Int Med Res 1985, V13, P40 MEDLINE
(29) Coto, V; Angiology 1989, V40, P880 MEDLINE
(30) Craveri, A; Int Angiol 1990, V9, P274 MEDLINE
(31) Crepaldi, G; Atherosclerosis 1990, V81, P233 MEDLINE
(32) de Smit, P; Acta Chir Austriaca 1992, V24, P5
(33) Dettori, A; Angiology 1989, V40, P237 MEDLINE
(34) Di Stefano, F; Curr Ther Res 1988, V44, P1
(35) Di Stefano, F; Eur Rev Med Pharmacol Sci 1984, VVI, P525
(36) Dormandy, J; J Cardiovasc Surg (Torino) 1989, V30, P50 MEDLINE
(37) Fagher, B; Angiology 1993, V44, P300 MEDLINE
(38) Fagher, B; Angiology 1994, V45, P777 MEDLINE
(39) Fontaine, V; Helv Chir Acta 1954, V5/6, P499
(40) Giansante, C; J Int Med Res 1990, V18, P400 MEDLINE
(41) Gillot, P; Curr Ther Res Clin Exp 1976, V20, P637 MEDLINE
(42) Girolami, B; Arch Intern Med 1999, V159, P337 MEDLINE
(43) Girolami, B; Thromb Haemost 1995, V6, P1386
(44) Gregorie, G; J Clin Epidemiol 1995, V48, P159
(45) Hess, H; Lancet 1985, V23, P415
(46) Holm, J; Vasa 1984, V13, P175 MEDLINE
(47) Housley, E; BMJ 1988, V296, P1483 MEDLINE
(48) Janzon, L; J Intern Med 1990, V227, P301 MEDLINE
(49) Jones, N; Br J Surg 1982, V69, P38 MEDLINE
(50) Kannel, W; Circulation 1970, V41, P875 MEDLINE
(51) Kirtstein, P; Atherosclerosis 1980, V36, P471
(52) Kovacs, M; Ann Pharmacother 1993, V27, P1060 MEDLINE
(53) Laurora, G; PanMinerva Med 1994, V36, P83 MEDLINE
(54) Libretti, A; Int J Clin Pharmacol Res 1986, V6, P59 MEDLINE
(55) Libretti, A; Monogr Atheroscl 1986, V14, P207 MEDLINE
(56) Mannarino, E; Angiology 1991, V42, P1 MEDLINE
(57) Mannarino, E; Angiology 1991, V42, P513 MEDLINE
(58) Mantel, N; J Natl Cancer Inst 1959, V22, P719 MEDLINE
(59) Marelli, C; Curr Ther Res 1990, V47, P459
(60) Moloney, B; Ticlopidine, platelets and vascular disease 1993, P99
(61) Money, S; J Vasc Surg 1998, V27, P267 MEDLINE
(62) Neirotti, M; Angiology 1994, V45, P137 MEDLINE
(63) Palmieri, G; Curr Ther Res 1987, V41, P998
(64) Palmieri, G; Int Angiol 1988, V7(Suppl 3), P41
(65) Palmieri, J; Clin Trials J 1984, V21, P411
(66) Panchenko, E; Angiology 1997, V48, P247 MEDLINE
(67) Rao, C; Linear statistical inference and its applications 1973, P389
(68) Roztocil, K; Cor Vasa 1989, V31, P128 MEDLINE
(69) Sabba, C; Int J Clin Pharmacol Ther Toxicol 1988, V26, P249 MEDLINE
(70) Schoop, W; Thromb Haemost 1983, V50, P137
(71) Shustov, S; Curr Med Res Opin 1997, V13, P573 CAPLUS
(72) Signorini, G; Angiology 1988, V39, P742 MEDLINE
(73) Strano, A; Drugs Exp Clin Res 1990, V16, P543 MEDLINE
(74) Strano, A; Semin Thromb Hemost 1991, V17, P228
(75) Tesi, M; J Drug Dev 1989, V2, P73
(76) Tonnesen, K; Int Angiol 1993, V12, P371 MEDLINE
(77) Verhaeghe, R; J Cardiovasc Pharmacol 1981, V3, P279 MEDLINE
(78) Verstraete, M; Drugs 1982, V24, P240 MEDLINE

L7 ANSWER 198 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1975:93102 CAPLUS

DN 82:93102


TI Suppression of atheromatous fibrous plaque formation by antiproliferative

AU and antiinflammatory drugs
Hollander, William; Kramsch, Dieter M.; Franzblau, Carl; Paddock, John;
Colombo, Marilyn A.
CS Med. Cent., Boston Univ., Boston, MA, USA
SO Circulation Research, Supplement (1974), 34(5, Suppl. 1), 131-41
CODEN: CIRSAF; ISSN: 0069-4185
DT Journal
LA English
CC 1-5 (Pharmacodynamics)
AB In rabbits fed an atherogenic diet plus colchicine (I) [64-86-8] or cortisone acetate [50-04-4], the aorta had fewer gross visual lesions and contained significantly less free and ester cholesterol as well as collagen and elastin than the aorta of rabbits fed the atherogenic diet alone. In contrast to I and cortisone, penicillamine [52-67-5] and aspirin [50-78-2] did not alter the extent of **atherosclerosis** or the deposition of cholesterol in the lesions, but they did inhibit the connective tissue proliferation in the lesion. On the other hand, chlorpheniramine [132-22-9] did not prevent fibrous protein deposition in the plaque but did partially prevent cellular proliferation and lipid deposition. As opposed to all the other drugs, butazolidin [50-33-9] augmented lipid infiltration into the aorta while it appeared to protect against collagen deposition. The present studies suggest that certain antiproliferative and anti-inflammatory drugs which have specific inhibitory effects on the atherosclerotic process could prove to be useful in the control of **atherosclerosis** and its sequelae.
ST colchicine atheromatous plaque formation; cortisone atheromatous plaque formation; penicillamine atheromatous plaque formation; antiinflammatory atheromatous plaque formation
IT **Atherosclerosis**
 (antiinflammatory and antiproliferative drugs in treatment of)
IT Collagens, biological studies
Elastins
RL: BIOL (Biological study)
 (of aorta, antiinflammatory and antiproliferative drugs effect on, in **atherosclerosis**)
IT 50-04-4 64-86-8
RL: BIOL (Biological study)
 (atheromatous fibrous plaque formation suppression by, in aorta)
IT 50-33-9 50-78-2 52-67-5 132-22-9
RL: BIOL (Biological study)
 (**atherosclerosis** response to, in aorta)
IT 57-88-5, biological studies
RL: BIOL (Biological study)
 (of aorta, antiinflammatory and antiproliferative drugs effect on, in **atherosclerosis**)
L7 ANSWER 195 OF 202 CAPLUS COPYRIGHT 2003 ACS
AN 1979:145804 CAPLUS
DN 90:145804
TI Anti-inflammatory drugs in experimental **atherosclerosis**. Part 4. Inhibition of **atherosclerosis** in vivo and thromboxane synthesis and platelet aggregation in vitro
AU Bailey, J. Martyn; Makheja, A. N.; Butler, Jean; Salata, K.
CS Sch. Med. Health Sci., George Washington Univ., Washington, DC, USA
SO Atherosclerosis (Shannon, Ireland) (1979), 32(2), 195-203
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English
CC 1-5 (Pharmacodynamics)
AB Groups of New Zealand white male rabbits were fed antherogenic diets
Section cross-reference(s): 14

contg. 1% cholesterol. The diets of exptl. groups were supplemented addnl. with either aspirin [50-78-2], phenylbutazone [50-33-9], mefenamic acid [61-68-7], flufenamic acid [530-78-9], oxyphenylbutazone [129-20-4] or aminopyrine [58-15-1]. Blood cholesterol and phospholipids were measured at 3-4 wk intervals. After 12 wk the animals were sacrificed and the severity of **atherosclerosis** in the thoracic aorta was measured. In sep. expts., rabbit platelets were incubated with each of the drugs individually and conversion of [¹⁴C]arachidonic acid to thromboxanes and related compds. was assayed. Inhibition of collagen and arachidonic acid-induced platelet aggregation by each drug was also measured. All drugs inhibited thromboxane synthesis and platelet aggregation in varying degrees with flufenamate and aspirin being most and aminopyrine least effective. The pattern of metabolite formation from [¹⁴C]arachidonate was consistent with a block in the cyclooxygenase reaction. Phenylbutazone, flufenamic acid, and oxyphenylbutazone produced significant redns. in atherosclerotic plaque formation without major changes in blood cholesterol levels or blood cholesterol-phospholipid ratios. Aspirin and aminopyrine were ineffective. The effectiveness of antiinflammatory drugs as inhibitors of thromboxane synthesis and platelet aggregation *in vitro* does not appear to afford a sufficient predictive index of their antiatherogenicity *in vivo*. The significance of these findings is discussed in terms of the possible involvement of cyclooxygenase derivs. in atherogenesis.

ST inflammation inhibitor **atherosclerosis** thromboxane; blood platelet antiinflammatory drug
IT Blood platelet
 (aggregation of, inflammation inhibitors inhibition of,
 antiatherogenicity in relation to)
IT Thromboxanes
 RL: FORM (Formation, nonpreparative)
 (formation of, inflammation inhibitors inhibition of,
 antiatherogenicity in relation to)
IT **Atherosclerosis**
 (inflammation inhibitors effect on, platelet aggregation and
 thromboxane formation inhibition in relation to)
IT Inflammation inhibitors
 (platelet aggregation and thromboxane formation inhibition by,
 antiatherogenicity in relation to)
IT 50-33-9, biological studies 50-78-2 58-15-1 61-68-7
129-20-4 530-78-9
 RL: BIOL (Biological study)
 (platelet aggregation and thromboxane formation inhibition by,
 antiatherogenicity in relation to)

L7 ANSWER 194 OF 202 CAPLUS COPYRIGHT 2003 ACS
AN 1979:180165 CAPLUS
DN 90:180165
TI Studies on the progression and regression of coronary and peripheral **atherosclerosis** in the cynomolgus monkey. I. Effects of dipyridamole and aspirin
AU Hollander, William; Kirkpatrick, Barbara; Paddock, John; Colombo, Marilyn; Nagraj, Siva; Prusty, Somnath
CS Med. Cent., Boston Univ., Boston, MA, USA
SO Experimental and Molecular Pathology (1979), 30(1), 55-73
CODEN: EXMPA6; ISSN: 0014-4800
DT Journal
LA English
CC 1-5 (Pharmacodynamics)
GI Section cross-reference(s): 14



AB The morphol. and biochem. changes in the arteries of the cynomolgus monkey were investigated during the induction and regression of **atherosclerosis**. During the feeding of an atherogenic diet contg. 2% cholesterol and 10% butter for 5 mo, the animals developed fibro-fatty plaques which involved the coronary and peripheral arteries and caused significant luminal narrowing of these vessels. The induced aortic lesions contained increased amts. of free and esterified cholesterol [57-88-5], collagen, elastin, and Ca. These changes were assocd. with an elevation of plasma cholesterol and an increased net influx of plasma cholesterol and low d. lipoproteins (LDL) into the aorta. Dipyridamole (I) [58-32-2] (10 mg/kg) and aspirin (II) [50-78-2] (50 mg/kg) had no effect on the arterial uptake of plasma LDL and cholesterol and did not protect against **atherosclerosis** in any of the vessels examd. During the regression period (low cholesterol diet) of 12 mo duration, the induced lesions became more fibrotic and calcified while the cellularity and lipid content of the same lesions decreased. As a result of these changes there were no significant decreases in the atherosclerotic narrowing of the coronary and peripheral vessels. The net influx of plasma LDL and cholesterol into the aorta returned to normal during the regression period. This finding together with the slow rate of aortic cholesterol equilibration suggests that the retention of cholesterol in the regressed aortic lesions is due to a defect in cholesterol transport rather than to an abnormality in intimal permeability. The addn. of I and II to the regression diet did not alter the course of the **atherosclerosis**.

ST dipyridamole aspirin **atherosclerosis**

IT Collagens, biological studies

Elastins

RL: BIOL (Biological study)

(of aorta, in **atherosclerosis**, aspirin and dipyridamole effect on)

IT **Atherosclerosis**

(progression and regression of, aspirin and dipyridamole effect)

IT Lipoproteins

RL: BIOL (Biological study)

(low-d., of blood plasma, in **atherosclerosis**, aspirin and dipyridamole effect on)

IT **50-78-2** 58-32-2

RL: BIOL (Biological study)

(**atherosclerosis** response to)

IT 7440-70-2, biological studies

RL: BIOL (Biological study)

(of aorta, in **atherosclerosis**, aspirin and dipyridamole effect on)

IT 57-88-5, biological studies

FILE 'REGISTRY' ENTERED AT 15:16:24 ON 02 DEC 2002

L1 122 S ACETAMINOPHEN
L2 0 S ASPRIN
L3 50 S ASPIRIN
L4 E STATIN
L4 1577 S E3
L5 29 S VITAMIN C
L6 77 S VITAMIN E
L7 8 S ATORVASTATIN
L7 E STANOL
L8 12 S E3
L9 3 S TIROFIBAN

FILE 'CAPLUS' ENTERED AT 15:25:14 ON 02 DEC 2002

E ATHEROSCLEROSIS 5
L10 33111 S E3
L11 10111 S L1
L12 12 S L11 AND L10.

=>

L 20, 726, 724, 754

L18 - 415

L20 ANSWER 796 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1963:55091 CAPLUS
DN 58:55091
OREF 58:9457a-b
TI Influence of vitamin E on lipids and blood coagulability in patients with **atherosclerosis**
AU Nikitin, Yu. P.
CS Post-Graduate Med. Inst., Novokuznetsk
SO Vopr. Pitaniya (1962), 21(No. 6), 22-7
DT Journal
LA Unavailable
CC 64 (Animal Nutrition)
AB Some biochem. indexes in atherosclerotic patients were examd. after administration of vitamin E (I). The serum cholesterol (II) level, lecithin (III), and ketone bodies (IV) were detd. Before administration of I the serum levels of II and III were 277 mg.%, range 193-420 and 366 mg.%, range 207-456 resp. The ratio of III/II was 1.31. After the treatment of I for 7-35 days at the rate of 50-90 mg./24 hrs., II level diminished in most cases by 10-25%, III changes varied, and the ratio III/II was 1.60. The changes in IV were not specific, nor were the changes of the recalcification time of the oxalated plasma and the changes of the tolerance of plasma to heparin II. 44 references.
IT Blood coagulation
(A, vitamin E effect on)
IT **Atherosclerosis**
(blood coagulation and lipids in blood in, vitamin E effect on)
IT Lipids
(in blood, in **atherosclerosis**, vitamin E effect on)
IT 1406-18-4, Vitamin E
(blood coagulation and lipids in blood in **atherosclerosis** in relation to)
IT 57-88-5, Cholesterol
(in blood in **atherosclerosis**, vitamin E effect on)

L20 ANSWER 794 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1963:438148 CAPLUS
DN 59:38148
OREF 59:6880h,6881a-c
TI Various drugs acting on the serum lipid pattern of **atherosclerosis**. Therapeutic significance of an extractive heparinoid
AU Nicrosini, F.; Piccinelli, O.
CS Univ. Pavia, Italy
SO Drugs Affecting Lipid Metab., Proc. Symp., Milan (1961), Volume Date 1960 508-11
DT Journal
LA Unavailable
CC 68 (Pharmacodynamics)
AB The serum lipid pattern of **atherosclerosis** shows a marked increase of total lipids, an abs. and relative increase of glycerides equal to that of total steroids, a relative decrease of phospholipids which is often abs., and an abs. and relative increase of total steroids about 67% due to the increase of steroids which do not ppt. with digitonin and which give the Lieberman-Burchard reaction (fraction A), and about 33% due to the increase of steroids which do not give this reaction and which do not ppt. with digitonin (satd. .beta.-steroids or B2 fraction, probably represented by dihydrocholesterol). Steroids pptg. with digitonin and giving at the same time the Lieberman-Burchard reaction (unsatd. .beta.-steroids or B1 fraction), i.e., cholesterol itself, appear within almost normal limits, thus presenting a relatively marked decrease. .beta.-Steroid esterification is significantly increased. At the onset of atheroma, changes in the lipids of the arterial wall show a higher concn. of total glycerides and steroids, a lower concn. of phospholipids, a

AN 1973:500515 CAPLUS
DN 79:100515
TI Antiinflammatory drugs in experimental atherosclerosis. 1. Relative potencies for inhibiting plaque formation
AU Bailey, J. Martyn; Butler, Jean
CS Sch. Med., George Washington Univ., Washington, DC, USA
SO Atherosclerosis (Shannon, Ireland) (1973), 17(3), 515-22
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English
CC 1-5 (Pharmacodynamics)
AB Orally administered 9.alpha.-fluorohydrocortisone (I) [127-31-1] (30 .mu.g/day) was effective in decreasing plaque formation in cholesterol-fed rabbits. Dexamethasone [50-02-2], methylprednisolone [83-43-2], triamcinolone [124-94-7], prednisone [53-03-2], and cortisone acetate [50-04-4] were also effective at higher dose levels. All of the steroids tested decreased plaque formation by 55 to 95%. These protective effects were partially duplicated by a number of nonsteroidal inflammation inhibitors including flufenamic acid [530-78-9], phenylbutazone [50-33-9], oxyphenylbutazone [129-20-4], and mefenamic acid [61-68-7]. Aminopyrine [58-15-1] and aspirin [50-78-2] were inactive. By means of dose-response curves, it was possible to demonstrate dissociation of the hyperlipemic effects of the steroids from their protective effects. The relative potencies of these drugs in inhibiting atherosclerosis in the rabbit, paralleled closely their effectiveness in treatment of inflammatory disorders in humans.
ST atherosclerosis inflammation inhibitor; fluorohydrocortisone
atherosclerosis dexamethasone prednisone; phenylbutazone atherosclerosis
oxyphenylbutazone mefenamate
IT Inflammation inhibitors
(atherosclerosis prevention by)
IT Atherosclerosis
(inflammation inhibitors effect on)
IT 530-78-9
RL: BIOL (Biological study)
(atherosclerosis prevention by)
IT 50-02-2 50-04-4 50-33-9 53-03-2 61-68-7 83-43-2 127-31-1
129-20-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(atherosclerosis prevention by)
IT 50-78-2 58-15-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(atherosclerosis prevention in relation to)

=>

AN 1973:500515 CAPLUS
DN 79:100515
TI Antiinflammatory drugs in experimental atherosclerosis. 1. Relative potencies for inhibiting plaque formation
AU Bailey, J. Martyn; Butler, Jean
CS Sch. Med., George Washington Univ., Washington, DC, USA
SO Atherosclerosis (Shannon, Ireland) (1973), 17(3), 515-22
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English
CC 1-5 (Pharmacodynamics)
AB Orally administered 9.alpha.-fluorohydrocortisone (I) [127-31-1] (30 .mu.g/day) was effective in decreasing plaque formation in cholesterol-fed rabbits. Dexamethasone [50-02-2], methylprednisolone [83-43-2], triamcinolone [124-94-7], prednisone [53-03-2], and cortisone acetate [50-04-4] were also effective at higher dose levels. All of the steroids tested decreased plaque formation by 55 to 95%. These protective effects were partially duplicated by a number of nonsteroidal inflammation inhibitors including flufenamic acid [530-78-9], phenylbutazone [50-33-9], oxyphenylbutazone [129-20-4], and mefenamic acid [61-68-7]. Aminopyrine [58-15-1] and aspirin [50-78-2] were inactive. By means of dose-response curves, it was possible to demonstrate dissociation of the hyperlipemic effects of the steroids from their protective effects. The relative potencies of these drugs in inhibiting atherosclerosis in the rabbit, paralleled closely their effectiveness in treatment of inflammatory disorders in humans.
ST atherosclerosis inflammation inhibitor; fluorohydrocortisone
atherosclerosis dexamethasone prednisone; phenylbutazone atherosclerosis
oxyphenylbutazone mefenamate
IT Inflammation inhibitors
 (atherosclerosis prevention by)
IT Atherosclerosis
 (inflammation inhibitors effect on)
IT 530-78-9
RL: BIOL (Biological study)
 (atherosclerosis prevention by)
IT 50-02-2 50-04-4 50-33-9 53-03-2 61-68-7 83-43-2 127-31-1
129-20-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (atherosclerosis prevention by)
IT 50-78-2 58-15-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (atherosclerosis prevention in relation to)

=>

- (6) Carr, A; Arterioscler Thromb Vasc Biol 2000, V20, P1716 CAPLUS
 ✓(7) Catapano, A; Curr Opin Cardiol 2000, V15, P355 MEDLINE
 ✓(8) Chisolm, G; J Biol Chem 1999, V274, P2959
 (9) Chong, P; Drugs 2000, V60, P55 CAPLUS
 (10) Diplock, A; Free Rad Res 2000, V33(suppl), PS21
 (11) Heinecke, J; J Lab Clin Med 1999, V133, P321 CAPLUS
 ✓(12) Hogg, N; Biochimica et Biophysica Acta 1999, V1411, P378 CAPLUS
 (13) Kapiotis, S; Arterioscler Thromb Vasc Biol 1997, V17, P2855 CAPLUS
 (14) Kinlay, S; J Cardiovasc Pharm 1998, V32(suppl 3), PS62
 ✓(15) Nenseter, M; Arterioscler Thromb Vasc Biol 1995, V15, P1338 CAPLUS
 (16) Rice-Evans, C; Free Rad Res 2000, V33(suppl), PS59
 ✓(17) Rogers, L; Free Rad Biol Med 1999, V27, PS108 - Adams
 ✓(18) Ross, R; N Engl J Med 1999, V340, P115 MEDLINE
 (19) Salonen, J; Free Rad Res 2000, V33(suppl), PS41
 (20) Slater, T; Eicosanoids, lipid peroxidation and cancer 1988, P137
 (21) Taylor, A; Circulation 1999, V100, PI
 ✓(22) Taylor, A; Naunyn Schmiedebergs Arch Pharmacol 1998, V358(suppl 2, no 1),
 PI ABony
 ✓(23) Tsujimoto, Y; Gen Pharmacol 1998, V31, P405 CAPLUS APony

L12 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:380616 CAPLUS
 DN 135:10004
 TI Compositions and methods for counteracting effects of reactive oxygen species and free radicals
 IN Shashoua, Victor E.
 PA Ceremedix, Inc., USA
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07K007-06
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1, 17

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--|----------|-----------------|----------|
| PI | WO 2001036454 | A1 | 20010525 | WO 2000-US31764 | 20001117 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | EP 1232174 | A1 | 20020821 | EP 2000-978811 | 20001117 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| PRAI | US 1999-166381P | P | 19991118 | | |
| | WO 2000-US31764 | W | 20001117 | | |
| OS | MARPAT | 135:10004 | | | |
| AB | Peptide compds. and methods for upregulating expression of a gene encoding an antioxidative enzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals are described. The peptide compds. may be used to treat or prevent diseases and conditions characterized by undesirable elevation of reactive oxygen species and other free radicals, to upregulate AP-1 gene expression, and to treat pain. The peptide compds. may be used as components of pharmaceuticals and dietary supplements. | | | | |
| ST | free radical scavenger antioxidant gene expression | | | | |

IT Transcription factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(AP-1 (activator protein 1); compns. and methods for counteracting
effects of reactive oxygen species and free radicals)

IT Nervous system
(Huntington's chorea; compns. and methods for counteracting effects of
reactive oxygen species and free radicals)

IT Nervous system
(amyotrophic lateral sclerosis; compns. and methods for counteracting
effects of reactive oxygen species and free radicals)

IT Antiarteriosclerotics
(antiatherosclerotics; compns. and methods for counteracting effects of
reactive oxygen species and free radicals)

IT Enzymes, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antioxidant, genes encoding; compns. and methods for counteracting
effects of reactive oxygen species and free radicals)

IT Gene, animal
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
use); BIOL (Biological study); PROC (Process); USES (Uses)
(antioxidant-encoding; compns. and methods for counteracting effects of
reactive oxygen species and free radicals)

IT Polycyclic compounds
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(arom. hydrocarbons; compns. and methods for counteracting effects of
reactive oxygen species and free radicals)

IT Alzheimer's disease
Anti-Alzheimer's agents
Anti-inflammatory agents
Antiarthritics
Anticonvulsants
Antidiabetic agents
Antipsychotics
Arthritis
Atherosclerosis
Burn
Cataract
Diabetes mellitus
Down's syndrome
Epilepsy
Herb
Inflammation
Leukemia
Parkinson's disease
Radical scavengers
Radiotherapy
Schizophrenia
Tea (*Camellia sinensis*)
Tranquilizers
(compns. and methods for counteracting effects of reactive oxygen
species and free radicals)

IT Quinones
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(compns. and methods for counteracting effects of reactive oxygen
species and free radicals)

IT Reactive oxygen species
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(compns. and methods for counteracting effects of reactive oxygen
species and free radicals)

IT Peptides, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Nervous system

(degeneration; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Gene

(expression; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Microorganism

Plant (Embryophyta)

(for dietary supplements; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Antioxidants

(genes encoding; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Deer

Elk

Ruminant

(green velvet antler of; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Body, anatomical

(horn, antler, green velvet; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Heart, disease

(infarction; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Reperfusion

(injury; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Brain, disease

(ischemia; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Eye, disease

(macula, degeneration; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Aromatic hydrocarbons, biological studies

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)

(polycyclic; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Newborn

(premature, oxygen toxicity in; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Aging, animal

(premature; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Kidney

(reperfusion injury; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Aging, animal

(senility; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Shock (circulatory collapse)

(septic; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Brain, disease

(stroke; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Diet

(supplements; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Nervous system
 (tardive dyskinesia; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Brain, disease
 Head
 Spinal cord
 (trauma; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Intestine, disease
 (ulcerative colitis; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Natural products, pharmaceutical
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (wuzi yanzong; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT 50-53-3, Chlorpromazine, biological studies 54-85-3, Isoniazid
 56-23-5, Carbon tetrachloride, biological studies 56-38-2, Parathion
 57-27-2, Morphine, biological studies 57-47-6, Physostigmine 58-15-1,
 Aminopyrine 59-87-0, Nitrofurazone 60-56-0, Methimazole 64-17-5,
 Ethanol, biological studies 67-20-9, Nitrofurantoin 83-34-1,
 3-Methylindole 87-17-2, Salicylanilide 92-87-5, Benzidine 100-63-0,
 Phenylhydrazine **103-90-2**, Acetaminophen 150-76-5,
 4-Hydroxyanisole 154-93-8, Bcnu 443-48-1, Metronidazole 671-16-9,
 Procarbazine 1404-00-8, Mitomycin 4685-14-7, Paraquat 5786-21-0
 7720-78-7, Ferrous sulfate 11056-06-7, Bleomycin 15663-27-1, Cisplatin
 20830-81-3, Daunomycin 23214-92-8, Doxorubicin 23288-49-5, Probucol
 33419-42-0, Etoposide 65271-80-9, Mitoxantrone
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT 7782-44-7D, Oxygen, reactive species
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT 3790-51-0 146877-90-9 236110-08-0, CMX 9236 341969-11-7
 341969-12-8 341969-13-9 341969-14-0 341969-15-1 341969-16-2
 341969-17-3 341969-18-4 341969-19-5 341969-20-8 341969-21-9
 341969-22-0 341969-23-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT 146877-89-6 236110-07-9 340813-25-4 340813-26-5 340813-27-6
 340813-28-7 340813-29-8 340813-30-1 340813-31-2 340813-32-3
 340813-34-5 340813-35-6 340813-36-7 340813-38-9 340813-39-0
 340813-40-3 340813-41-4 340813-42-5 340813-43-6 340813-44-7
 340813-45-8 340813-46-9 340974-51-8 340974-67-6
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT 197881-53-1, 3: PN: EP1136567 SEQID: 3 unclaimed DNA 243717-75-1,
 GenBank AR053203 340837-10-7 340837-11-8 340837-12-9 340837-13-0
 340837-14-1 340837-15-2
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)
(compns. and methods for counteracting effects of reactive oxygen species and free radicals)

- IT 9001-05-2, Catalase 9054-89-1, Superoxide dismutase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene encoding; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT 57-10-3, palmitic acid, biological studies 64-19-7, acetic acid,
biological studies 6217-54-5
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(peptide capping group; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Hartman; US 5455029 A 1995 CAPLUS
(2) Mao; US 5112870 A 1992 CAPLUS
(3) Reussner; US 4277464 A 1981 CAPLUS
(4) Thomas; US 5538878 A 1996 CAPLUS

L12 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 1999:783925 CAPLUS

DN 132:22753

TI Preparation of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives for the elevation of pyruvate dehydrogenase (PDH) activity

IN Butlin, Roger John; Nowak, Thorsten; Burrows, Jeremy Nicholas; Block, Michael Howard

PA Zeneca Limited, UK

SO PCT Int. Appl., 211 pp.
CODEN: PIXXD2

DT Patent

LA English



IC ICM A61K031-165

ICS C07C317-40; C07C317-44; C07C323-65; C07D213-89; C07D295-08

CC 25-12 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|-----------|----------|-----------------|----------|
| PI | WO 9962506 | A1 | 19991209 | WO 1999-GB1669 | 19990526 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2331685 | AA | 19991209 | CA 1999-2331685 | 19990526 |
| | AU 9940524 | A1 | 19991220 | AU 1999-40524 | 19990526 |
| | AU 740909 | B2 | 20011115 | | |
| | BR 9910821 | A | 20010213 | BR 1999-10821 | 19990526 |
| | EP 1082110 | A1 | 20010314 | EP 1999-923767 | 19990526 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | JP 2002516854 | T2 | 20020611 | JP 2000-551762 | 19990526 |
| | NO 2000006010 | A | 20010126 | NO 2000-6010 | 20001128 |
| PRAI | GB 1998-11427 | A | 19980529 | | |
| | WO 1999-GB1669 | W | 19990526 | | |
| OS | MARPAT | 132:22753 | | | |
| GI | | | | | |



- AB** Aryl Ph sulfone and sulfoxide derivs. (I) [where ring D = (un)substituted Ph, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, or other 6-membered N-contg. heteroaryl ring; R1 = (hetero)arylsulfonyl, (hetero)arylsulfinyl, (hetero)arylcarbonyl, (halo)alkyl, (halo)alkoxy, alkenyloxy, cyano, NO₂, halo, S-CF₃, OH, or a variety of (un)substituted functional groups; n = 1 or 2; R2 and R3 = independently (halo)alkyl or 3-5 membered (halo)cycloalkyl ring; A-B = NH-C(O), O-CH₂, S-CH₂, (trans)-vinylene, ethynylene, NH-C(S), or C(O)-CH₂; R4 = H, OH, halo, NH₂, or Me], and pharmaceutically acceptable salts or in vivo hydrolysable esters thereof, were prep'd. Pharmaceutical compns., methods, and processes for prepn. of compds. of formula I are also described. For example, (R)-(+) -2-hydroxy-2-methyl-3,3,3-trifluoropropanoic acid (prepn. given) was mixed with oxalyl chloride and added to 4-(4-acetamidophenylsulfonyl)-2-chloroaniline (prepn. given) in DCM to yield (R)-N-[4-(4-acetamidophenylsulfonyl)-2-chlorophenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (R)-(II). Title compds. elevate pyruvate dehydrogenase (PDH) activity (no data) and are useful in the treatment of diabetes mellitus, peripheral vascular disease, cardiac failure and certain cardiac myopathies, myocardial ischemia, cerebral ischemia and perfusion, muscle weakness, hyperlipidemias, Alzheimer's disease, and/or atherosclerosis.
- ST** pyruvate dehydrogenase activity elevation arylphenyl sulfone sulfoxide prepn; PDH activity elevation arylsulfonylphenyl propanamide prepn; antidiabetic arylsulfonylphenyl propanamide prepn
- IT** Antiarteriosclerotics
 (antiatherosclerotics; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)
- IT** Heart, disease
 (failure, treatment; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)
- IT** Artery, disease
 (intermittent claudication, treatment; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)
- IT** Brain, disease
 Heart, disease
 (ischemia, treatment; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)
- IT** Blood vessel, disease
 (peripheral, treatment; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate

dehydrogenase (PDH) activity)
 IT Anti-Alzheimer's agents
 Antidiabetic agents
 Hypolipemic agents
 (prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

IT Muscle, disease
 (weakness, treatment; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

IT 252019-46-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (intermediate; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

IT 615-16-7P 16353-27-8P 40644-14-2P 51834-67-4P 56073-93-9P
 76105-38-9P 76105-39-0P 83948-53-2P 84437-63-8P 242139-43-1P
 242139-49-7P 242139-58-8P 242139-61-3P 242139-62-4P 242139-67-9P
 242139-68-0P 242139-86-2P 242140-03-0P 243982-46-9P 244144-51-2P
 252019-28-6P 252019-30-0P 252019-31-1P 252019-32-2P 252019-33-3P
 252019-34-4P 252019-35-5P 252019-36-6P 252019-37-7P 252019-38-8P
 252019-39-9P 252019-40-2P 252019-41-3P 252019-42-4P 252019-43-5P
 252019-44-6P 252019-45-7P 252019-47-9P 252019-48-0P 252019-49-1P
 252019-50-4P 252019-51-5P 252019-52-6P 252019-53-7P 252019-54-8P
 252019-55-9P 252019-56-0P 252019-57-1P 252019-58-2P 252019-59-3P
 252019-60-6P 252019-61-7P 252019-62-8P 252019-63-9P 252019-64-0P
 252019-65-1P 252019-66-2P 252019-67-3P 252019-68-4P 252019-69-5P
 252019-70-8P 252019-71-9P 252019-72-0P 252019-73-1P 252019-74-2P
 252019-75-3P 252019-76-4P 252019-77-5P 252019-78-6P 252019-79-7P
 252019-80-0P 252019-81-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

IT 44864-47-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant (data on a salt from resoln.); prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

IT 62-53-3, Benzenamine, reactions 95-51-2 97-52-9, 2-Methoxy-4-nitroaniline 99-52-5 103-71-9, Phenyl isocyanate, reactions 103-90-2 106-88-7, 1,2-Epoxybutane 106-95-6, Allyl bromide, reactions 108-98-5, Thiophenol, reactions 109-90-0, Ethyl isocyanate 110-91-8, Morpholine, reactions 115-19-5, 2-Methyl-3-butyn-2-ol 121-87-9, 2-Chloro-4-nitroaniline 537-91-7 558-30-5, 1,2-Epoxy-2-methylpropane 577-19-5, 2-Bromo-1-nitrobenzene 627-18-9 1066-54-2, Trimethylsilylacetylene 1074-36-8, 4-Mercaptobenzoic acid 1122-97-0 1126-81-4, 4-Acetamidothiophenol 1193-02-8, 4-Aminothiophenol 1635-61-6, 5-Chloro-2-nitroaniline 2557-78-0, 2-Fluorothiophenol 2675-89-0 3268-49-3 4556-23-4, 4-Mercaptopyridine 4892-02-8, Methyl thiosalicylate 5003-71-4, 3-Aminopropyl bromide hydrobromide 5326-47-6, 2-Amino-5-iodobenzoic acid 7501-56-6, 3-Chloro-4-nitrobenzophenone 7661-34-9 7665-72-7, tert-Butyl glycidyl ether 7764-95-6 10198-98-8, 2-(4-Bromophenyl)pyrimidine 18162-48-6, tert-Butyldimethylsilyl chloride 29632-74-4, 2-Fluoro-4-iodoaniline 37577-28-9 40635-66-3 42016-93-3, 2-Chloro-4-iodoaniline 42753-71-9 60811-24-7, 3,4-Difluorobenzene-thiol 136434-77-0 139487-04-0 139487-06-2 147696-72-8 156275-96-6, Triisopropylsilane-thiol 157695-16-4 157695-23-3 159390-06-4 167156-16-3 252019-83-3 252019-84-4 252019-85-5

RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

| | | | | | |
|----|--------------|--------------|--------------|--------------|--------------|
| IT | 242139-87-3P | 242139-88-4P | 242140-02-9P | 242140-05-2P | 252014-87-2P |
| | 252014-89-4P | 252014-90-7P | 252014-92-9P | 252014-93-0P | 252014-94-1P |
| | 252014-95-2P | 252014-96-3P | 252014-97-4P | 252014-98-5P | 252015-68-2P |
| | 252015-75-1P | 252015-86-4P | 252015-89-7P | 252015-90-0P | 252015-98-8P |
| | 252015-99-9P | 252016-13-0P | 252016-17-4P | 252016-62-9P | 252016-66-3P |
| | 252016-67-4P | 252016-68-5P | 252016-69-6P | 252016-71-0P | 252016-72-1P |
| | 252016-81-2P | 252016-82-3P | 252016-84-5P | 252016-85-6P | 252016-86-7P |
| | 252016-87-8P | 252016-90-3P | 252016-91-4P | 252016-92-5P | 252016-93-6P |
| | 252016-95-8P | 252016-96-9P | 252016-98-1P | 252016-99-2P | 252017-00-8P |
| | 252017-21-3P | 252017-23-5P | 252017-26-8P | 252017-27-9P | 252017-28-0P |
| | 252017-29-1P | 252017-38-2P | 252017-39-3P | 252017-40-6P | 252017-41-7P |
| | 252017-42-8P | 252017-43-9P | 252017-45-1P | 252017-46-2P | 252017-49-5P |
| | 252017-50-8P | 252017-51-9P | 252017-52-0P | 252017-53-1P | 252017-54-2P |
| | 252017-56-4P | 252017-57-5P | 252017-59-7P | 252017-60-0P | 252017-61-1P |
| | 252017-62-2P | 252017-63-3P | 252017-64-4P | 252017-65-5P | 252017-66-6P |
| | 252017-67-7P | 252017-68-8P | 252017-71-3P | 252017-74-6P | 252017-75-7P |
| | 252017-77-9P | 252017-78-0P | 252017-79-1P | 252017-80-4P | 252017-87-1P |
| | 252017-88-2P | 252017-95-1P | 252017-96-2P | 252017-97-3P | 252017-98-4P |
| | 252018-01-2P | 252018-14-7P | 252018-15-8P | 252018-22-7P | 252018-23-8P |
| | 252018-24-9P | 252018-25-0P | 252018-26-1P | 252018-27-2P | 252018-28-3P |
| | 252018-29-4P | 252018-30-7P | 252018-31-8P | 252018-32-9P | 252018-33-0P |
| | 252018-34-1P | 252018-38-5P | 252018-45-4P | 252018-46-5P | 252018-47-6P |
| | 252018-48-7P | 252018-49-8P | 252018-75-0P | 252018-82-9P | 252018-84-1P |
| | 252018-85-2P | 252018-87-4P | 252018-88-5P | 252018-90-9P | 252018-91-0P |
| | 252018-93-2P | 252018-94-3P | 252018-95-4P | 252018-96-5P | 252018-98-7P |
| | 252019-00-4P | 252019-01-5P | 252019-02-6P | 252019-04-8P | 252019-05-9P |
| | 252019-06-0P | 252019-07-1P | 252019-08-2P | 252019-09-3P | 252019-10-6P |
| | 252019-11-7P | 252019-12-8P | | | |

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(target compd.; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

| | | | | | |
|----|--------------|--------------|--------------|--------------|--------------|
| IT | 242139-90-8P | 242140-06-3P | 242142-53-6P | 243982-50-5P | 252014-88-3P |
| | 252014-91-8P | 252014-99-6P | 252015-00-2P | 252015-01-3P | 252015-02-4P |
| | 252015-03-5P | 252015-04-6P | 252015-05-7P | 252015-06-8P | 252015-07-9P |
| | 252015-08-0P | 252015-09-1P | 252015-10-4P | 252015-11-5P | 252015-12-6P |
| | 252015-13-7P | 252015-14-8P | 252015-15-9P | 252015-16-0P | 252015-17-1P |
| | 252015-18-2P | 252015-19-3P | 252015-20-6P | 252015-21-7P | 252015-22-8P |
| | 252015-23-9P | 252015-24-0P | 252015-25-1P | 252015-26-2P | 252015-27-3P |
| | 252015-28-4P | 252015-29-5P | 252015-30-8P | 252015-31-9P | 252015-32-0P |
| | 252015-33-1P | 252015-34-2P | 252015-35-3P | 252015-36-4P | 252015-37-5P |
| | 252015-38-6P | 252015-39-7P | 252015-40-0P | 252015-41-1P | 252015-42-2P |
| | 252015-43-3P | 252015-44-4P | 252015-45-5P | 252015-46-6P | 252015-47-7P |
| | 252015-48-8P | 252015-50-2P | 252015-51-3P | 252015-52-4P | 252015-53-5P |
| | 252015-54-6P | 252015-55-7P | 252015-56-8P | 252015-57-9P | 252015-58-0P |
| | 252015-59-1P | 252015-60-4P | 252015-61-5P | 252015-62-6P | 252015-63-7P |
| | 252015-64-8P | 252015-65-9P | 252015-66-0P | 252015-67-1P | 252015-69-3P |
| | 252015-70-6P | 252015-71-7P | 252015-73-9P | 252015-77-3P | 252015-79-5P |
| | 252015-81-9P | 252015-83-1P | 252015-87-5P | 252015-88-6P | 252015-91-1P |
| | 252015-92-2P | 252015-93-3P | 252015-94-4P | 252015-95-5P | 252015-96-6P |
| | 252015-97-7P | 252016-00-5P | 252016-01-6P | 252016-02-7P | 252016-03-8P |
| | 252016-04-9P | 252016-05-0P | 252016-06-1P | 252016-07-2P | 252016-08-3P |
| | 252016-09-4P | 252016-10-7P | 252016-11-8P | 252016-12-9P | 252016-14-1P |
| | 252016-15-2P | 252016-16-3P | 252016-18-5P | 252016-19-6P | 252016-20-9P |
| | 252016-21-0P | 252016-22-1P | 252016-23-2P | 252016-24-3P | 252016-25-4P |

> d 112 7-12 all

L12 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2002 ACS
AN 2001:905774 CAPLUS
DN 137:72333
TI Effect of acetaminophen on **atherosclerosis**
AU Chong, Pang H.; Kezele, Bob; Pontikes, Pamala J.
CS Department of Pharmacy Practice, University of Illinois at Chicago,
Chicago, IL, 60612-3736, USA
SO Annals of Pharmacotherapy (2001), 35(11), 1476-1479
CODEN: APHRER; ISSN: 1060-0280
PB Harvey Whitney Books Co.
DT Journal; General Review
LA English
CC 1-0 (Pharmacology)
AB A review. OBJECTIVE: To evaluate the antioxidant effects of acetaminophen in **atherosclerosis**. DATA SOURCES: Exptl. literature and abstrs. accessed through MEDLINE (1966-Feb. 2001). DATA SYNTHESIS: **Atherosclerosis** is an inflammatory disorder assocd. with coronary events. The oxidative stress burden resulting from excess pro-oxidant free radical formation contributes to oxidative modification of low-d. lipoprotein (lipid peroxidn.) and is assocd. with **atherosclerosis**. Acetaminophen (phenol-like compd.) may limit these key processes that are involved. The findings of earlier exptl. lab. tests and abstrs. are evaluated. CONCLUSIONS: In vitro data suggest that acetaminophen may reduce lipid peroxidn., whereas animal data showed decreased progression of **atherosclerosis**. Further animal model and human studies are required to confirm these earlier findings.
ST review acetaminophen antioxidant **atherosclerosis**
IT Antioxidants

Atherosclerosis

Human

(acetaminophen antioxidant effect on **atherosclerosis**)IT Radicals, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(acetaminophen antioxidant effect on **atherosclerosis**)IT Antiarteriosclerotics
(antiatherosclerotics; acetaminophen antioxidant effect on
atherosclerosis)IT Peroxidation
(lipid; acetaminophen antioxidant effect on **atherosclerosis**)IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(low-d.; acetaminophen antioxidant effect on **atherosclerosis**)IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(peroxidn.; acetaminophen antioxidant effect on **atherosclerosis**)IT 103-90-2, Acetaminophen
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(acetaminophen antioxidant effect on **atherosclerosis**)

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; Physicians' desk reference. 52nd ed 1998, P2061
- (2) Aviram, M; Free Rad Res 2000, V33(suppl), PS85
- (3) Bergendi, L; Life Sci 1999, V65, P1865 CAPLUS ?
- (4) Bloodsworth, A; Arterioscler Thromb Vasc Biol 2000, V20, P1707 CAPLUS ?
- (5) Brown, A; Atherosclerosis 1999, V142, P1 CAPLUS

CS Inst. Pharmacol., N. Copernicus Acad. Med., Krakow, Pol.
SO Cardiol.: Int. Perspect., [Proc. World Congr.], 9th (1984), Meeting Date
1982, Volume 2, 1157-62. Editor(s): Chazov, E. I.; Smirnov, V. N.;
Oganov, R. G. Publisher: Plenum, New York, N. Y.
CODEN: 53HTA8

DT Conference
LA English

L20 ANSWER 760 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1985:147933 CAPLUS
DN 102:147933

TI Effect of .alpha.-tocopherol in vivo on the structure and function of
calcium-ATPase from skeletal muscle sarcoplasmic reticulum in
hypercholesterolemia

AU Timofeev, A. A.
CS USSR
SO Deposited Doc. (1984), VINITI 1728-84, 17 pp. Avail.: VINITI
DT Report
LA Russian

L20 ANSWER 761 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1985:147927 CAPLUS
DN 102:147927

TI Effect of vitamin E on **atherosclerosis** in lipid-fed rabbits

AU Lee, Min Hyuk; Koo, Kook Hwae; Lee, Yong Woo
CS Coll. Med., Hanyang Univ., Seoul, S. Korea
SO Hanyang Uidae Haksulchi (1984), 4(2), 461-76
CODEN: HIHAD3; ISSN: 0254-5942

DT Journal
LA Korean

L20 ANSWER 762 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1984:528263 CAPLUS
DN 101:128263

TI Effect of .alpha.-tocopherol and hyperbaric oxygen on the fatty acid
composition of blood plasma in rabbits with hypercholesterolemia

AU Kosukhin, A. B.
CS Inst. Physiol., Alma-Ata, USSR
SO Voprosy Meditsinskoi Khimii (1984), 30(4), 36-9
CODEN: VMDKAM; ISSN: 0042-8809

DT Journal
LA Russian

L20 ANSWER 763 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1984:488274 CAPLUS
DN 101:88274

TI Bioelectric theory of pathogenesis of **atherosclerosis**

AU Lipinski, Boguslaw
CS Found. Study Bioelectr., Boston, MA, 02135, USA
SO Journal of Bioelectricity (1984), 3(1-2), 177-91
CODEN: JOUBDX; ISSN: 0730-823X

DT Journal
LA English

L20 ANSWER 764 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1984:208221 CAPLUS
DN 100:208221

TI Tocopherol and **atherosclerosis**

AU Radak, Djordje; Djordjevic-Denic, Gordana
CS I Hir. Klin., Med. Fak., Belgrade, Yugoslavia
SO Medicinski Podmladak (1983), 35(3-4), 299-303
CODEN: MPODAC; ISSN: 0369-1527

IT 121-43-7, Trimethyl borate
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with lithiotoluene, in prepn. of phenoxyalkylamine derivs. as drugs)
IT 152719-50-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with potassium cyanate, in prepn. of phenoxyalkylamine derivs. as drugs)

=> d his

(FILE 'HOME' ENTERED AT 15:16:16 ON 02 DEC 2002)

FILE 'REGISTRY' ENTERED AT 15:16:24 ON 02 DEC 2002

L1 122 S ACETAMINOPHEN
L2 0 S ASPIRIN
L3 50 S ASPIRIN ✓
E STATIN
L4 1577 S E3
L5 29 S VITAMIN C
L6 77 S VITAMIN E
L7 8 S ATORVASTATIN —
E STANOL
L8 12 S E3
L9 3 S TIROFIBAN

FILE 'CAPLUS' ENTERED AT 15:25:14 ON 02 DEC 2002

E ATHEROSCLEROSIS

L10 33111 S E3
L11 10111 S L1
L12 12 S L11 AND L10

=> s l3

L13 15536 L3 ✓

=> s l13 and l10

L14 196 L13 AND L10

=> d l14 150-196

L14 ANSWER 150 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1991:199344 CAPLUS
DN 114:199344
TI Aspirin reduces the growth of medial and neointimal thickenings in balloon-injured rat carotid arteries
AU Voelker, Wolfgang; Faber, Verona
CS Inst. Arterioscleros. Res., Univ. Muenster, Muenster, D-4400, Germany
SO Stroke (1990), 21(12, Suppl.), IV-44-IV-45
CODEN: SJCCA7; ISSN: 0039-2499
DT Journal
LA English

L14 ANSWER 151 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1991:22375 CAPLUS
DN 114:22375
TI Interleukin-4 (IL-4) in method and compositions for degradation and prevention of fibrin deposits associated with pathological conditions
IN Hamilton, John Allan; Hart, Prudence Hamilton
PA University of Melbourne, Australia
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|--|----------|
| PI | WO 9007932 | A1 | 19900726 | WO 1990-AU13 | 19900119 |
| | W: AU, CA, JP, US | | | RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE | |
| | CA 2045574 | AA | 19900721 | CA 1990-2045574 | 19900119 |
| | AU 9049645 | A1 | 19900813 | AU 1990-49645 | 19900119 |
| | AU 639903 | B2 | 19930812 | | |
| | EP 454736 | A1 | 19911106 | EP 1990-902120 | 19900119 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE | | | | |
| | JP 04503062 | T2 | 19920604 | JP 1990-502488 | 19900119 |
| | JP 06011706 | B4 | 19940216 | | |
| | US 5236705 | A | 19930817 | US 1991-720868 | 19910918 |
| PRAI | AU 1989-2356 | | 19890120 | | |
| | WO 1990-AU13 | | 19900119 | | |

L14 ANSWER 152 OF 196 CAPLUS COPYRIGHT 2002 ACS
 AN 1990:565161 CAPLUS
 DN 113:165161
 TI Prevention of myocardial lesions in JCR:LA-corpulent rats by nifedipine
 AU Russell, James C.; Koeslag, Dorothy G.; Dolphin, Peter J.; Amy, Roger M.
 CS Dep. Surg. Pathol., Univ. Alberta, Edmonton, AB, T6G 2G3, Can.
 SO Arteriosclerosis (Dallas) (1990), 10(4), 658-64
 CODEN: ARTRDW; ISSN: 0276-5047
 DT Journal
 LA English

L14 ANSWER 153 OF 196 CAPLUS COPYRIGHT 2002 ACS
 AN 1990:549899 CAPLUS
 DN 113:149899
 TI The oxidative modification of low-density lipoproteins by macrophages
 AU Leake, David S.; Rankin, Sara M.
 CS Div. Biomed. Sci., King's Coll. London, London, WC2R 2LS, UK
 SO Biochemical Journal (1990), 270(3), 741-8
 CODEN: BIJOAK; ISSN: 0306-3275
 DT Journal
 LA English

L14 ANSWER 154 OF 196 CAPLUS COPYRIGHT 2002 ACS
 AN 1990:196102 CAPLUS
 DN 112:196102
 TI Changes of adrenoceptor density in heart and brain and the reactivity of isolated pulmonary artery ring in atherosclerotic rabbit
 AU Zeng, Guiyun; Sun, Yading; Tian, Baohong; Wang, Zhong; Hu, Yanhua; An, Yan
 CS Inst. Mater. Med., Chin. Acad. Med. Sci., Beijing, 100050, Peop. Rep. China.
 SO Zhongguo Yaoli Xuebao (1990), 11(1), 18-21
 CODEN: CYLPDN; ISSN: 0253-9756
 DT Journal
 LA Chinese

L14 ANSWER 155 OF 196 CAPLUS COPYRIGHT 2002 ACS
 AN 1989:592441 CAPLUS
 DN 111:192441
 TI Platelet-neutrophil-smooth muscle cell interactions: lipoxygenase-derived mono- and dihydroxy acids activate cholestryl ester hydrolysis by the cyclic AMP dependent protein kinase cascade
 AU Hajjar, David P.; Marcus, Aaron J.; Etingin, Orli R.
 CS Med. Coll., Cornell Univ. Med. Coll., New York, NY, 10021, USA

- SO Biochemistry (1989), 28(22), 8885-91
CODEN: BICHAW; ISSN: 0006-2960
DT Journal
LA English
- L14 ANSWER 156 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1989:437279 CAPLUS
DN 111:37279
TI Fatty acids, platelets and monocytes. Something to do with atherogenesis
AU Oesterud, B.; Hansen, J. B.
CS Inst. Med. Biol., Univ. Tromso, Tromso, Norway
SO Annals of Medicine (Stockholm, Sweden) (1989), 21(1), 47-51
CODEN: ANMDEU; ISSN: 0785-3890
DT Journal
LA English
- L14 ANSWER 157 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1989:18333 CAPLUS
DN 110:18333
TI Diminished platelet residence time on active human atherosclerotic lesions
in vivo - evidence for an optimal dose of aspirin?
AU Sinzinger, H.; Kaliman, J.; Fitscha, P.; O'Grady, J.
CS Dep. Nucl. Med., Univ. Vienna, Vienna, Austria
SO Prostaglandins, Leukotrienes and Essential Fatty Acids (1988), 34(2),
89-93
CODEN: PLEAEU; ISSN: 0952-3278
DT Journal
LA English
- L14 ANSWER 158 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1988:431853 CAPLUS
DN 109:31853
TI Effect of anticoagulant and antiplatelet drugs on in vitro smooth muscle
cell proliferation
AU Lindblad, Bengt; Burkell, William E.; Graham, Linda M.; Darvishian, David;
Harrell, Karyn; Sell, Ruth; Stanley, James C.
CS Med. Sch., Univ. Michigan, Ann Arbor, MI, USA
SO Artery (Fulton, MI, United States) (1988), 15(4), 225-33
CODEN: ARTEDR; ISSN: 0098-6127
DT Journal
LA English
- L14 ANSWER 159 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1988:431848 CAPLUS
DN 109:31848
TI Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of
platelet thrombus formation in stenosed canine coronary arteries
AU Folts, John D.; Rowe, George G.
CS Sect. Cardiol., Univ. Wisconsin Hosp., Madison, WI, 53792, USA
SO Thrombosis Research (1988), 50(4), 507-16
CODEN: THBRAA; ISSN: 0049-3848
DT Journal
LA English
- L14 ANSWER 160 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1988:431846 CAPLUS
DN 109:31846
TI Effects of low-dose aspirin on endogenous eicosanoid formation in normal
and atherosclerotic men
AU Knapp, Howard R.; Healy, Cynthia; Lawson, John; FitzGerald, Garret A.
CS Div. Clin. Pharmacol., Vanderbilt Univ., Nashville, TN, 37232, USA
SO Thrombosis Research (1988), 50(3), 377-86

- CODEN: THBRAA; ISSN: 0049-3848
DT Journal
LA English
- L14 ANSWER 161 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1988:404713 CAPLUS
DN 109:4713
TI Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin
AU Moake, Joel L.; Turner, Nancy A.; Stathopoulos, Nikos A.; Nolasco, Leticia; Hellums, J. David
CS Biomed. Eng. Lab., Rice Univ., Houston, TX, 77251, USA
SO Blood (1988), 71(5), 1366-74
CODEN: BLOOAW; ISSN: 0006-4971
DT Journal
LA English
- L14 ANSWER 162 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1988:219504 CAPLUS
DN 108:219504
TI Experimental studies on vascular contraction induced by coagulation system and platelets. With special reference to **atherosclerosis**
AU Kimura, Nobuhiko
CS Dep. Intern. Med., Hyogo Coll. Med., Nishinomiya, 663, Japan
SO Hyogo Ika Daigaku Igakkai Zasshi (1987), 12(1), 25-38
CODEN: HIDZDO; ISSN: 0385-7638
DT Journal
LA Japanese
- L14 ANSWER 163 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1988:130424 CAPLUS
DN 108:130424
TI Effect of dietary lipids on arterial thrombus formation: rationale for the support of drug therapy by diet
AU Hornstra, Gerard
CS Dep. Biochem., Limburg Univ., Maastricht, 6200 MD, Neth.
SO Seminars in Thrombosis and Hemostasis (1988), 14(1), 59-65
CODEN: STHMBV; ISSN: 0094-6176
DT Journal; General Review
LA English
- L14 ANSWER 164 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1988:16117 CAPLUS
DN 108:16117
TI The effects of acetylsalicylic acid and tolbutamide on cultured human endothelial cells with special reference to prostacyclin synthesis analyzed by platelet aggregation
AU Kawaguchi, Kenji
CS Med. Sch., Kumamoto Univ., Kumamoto, 860, Japan
SO Kumamoto Medical Journal (1987), 40(1), 37-44
CODEN: KUMJAX; ISSN: 0023-5326
DT Journal
LA English
- L14 ANSWER 165 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1987:568493 CAPLUS
DN 107:168493
TI The effect of antiplatelet drugs on graft **atherosclerosis** in rat heterotopic cardiac allografts
AU Muskett, A.; Burton, N. A.; Eichwald, E. J.; Shelby, J.; Hendrickson, M.; Sullivan, J. J.

CS Sch. Med., Univ. Utah, Salt Lake City, UT, USA
 SO Transplantation Proceedings (1987), 19(4, Suppl. 5), 74-6
 CODEN: TRPPA8; ISSN: 0041-1345
 DT Journal
 LA English

L14 ANSWER 166 OF 196 CAPLUS COPYRIGHT 2002 ACS
 AN 1987:451201 CAPLUS
 DN 107:51201
 TI The role of arachidonic acid metabolites in cardiovascular homeostasis.
 Biochemical, histological and clinical cardiovascular effects of
 non-steroidal anti-inflammatory drugs and their interactions with
 cardiovascular drugs
 AU Goodman, DeWitt S.
 CS Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA
 SO Drugs (1987), 33(Suppl. 1), 47-55
 CODEN: DRUGAY; ISSN: 0012-6667
 DT Journal; General Review
 LA English

L14 ANSWER 167 OF 196 CAPLUS COPYRIGHT 2002 ACS
 AN 1987:432862 CAPLUS
 DN 107:32862
 TI Surprising effects of the sequential administration of pentoxifylline and
 low dose acetylsalicylic acid on thrombus formation
 AU Seiffge, Dirk; Weithmann, K. Ulrich
 CS Hoechst A.-G., Wiesbaden, 6200/12, Fed. Rep. Ger.
 SO Thrombosis Research (1987), 46(2), 371-83
 CODEN: THBRAA; ISSN: 0049-3848
 DT Journal
 LA English

L14 ANSWER 168 OF 196 CAPLUS COPYRIGHT 2002 ACS
 AN 1987:18881 CAPLUS
 DN 106:18881
 TI Triterpenyl esters of organic acids and hypolipemic agents composed of
 them
 IN Kimura, Goro; Hirose, Yoshihiko; Yoshida, Kumi; Kuzuya, Fumio; Fujita,
 Katsunari
 PA Amano Pharmaceutical Co., Ltd., Japan
 SO Eur. Pat. Appl., 260 pp.
 CODEN: EPXXDW
 DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------------------------------|------|----------|-----------------|----------|
| PI | EP 166542 | A2 | 19860102 | EP 1985-303839 | 19850530 |
| | EP 166542 | A3 | 19860709 | | |
| | EP 166542 | B1 | 19900808 | | |
| | R: BE, CH, DE, FR, GB, IT, LI, NL, SE | | | | |
| | JP 60258198 | A2 | 19851220 | JP 1984-115306 | 19840604 |
| | JP 01040040 | B4 | 19890824 | | |
| | JP 60258119 | A2 | 19851220 | JP 1984-115307 | 19840604 |
| | JP 01040014 | B4 | 19890824 | | |
| | JP 61243099 | A2 | 19861029 | JP 1985-85254 | 19850419 |
| | JP 05033713 | B4 | 19930520 | | |
| | JP 61243022 | A2 | 19861029 | JP 1985-85255 | 19850419 |
| | CA 1265785 | A1 | 19900213 | CA 1985-481808 | 19850517 |
| | AU 8543130 | A1 | 19851212 | AU 1985-43130 | 19850530 |
| | AU 598724 | B2 | 19900705 | | |
| | US 4748161 | A | 19880531 | US 1985-739183 | 19850530 |

| | | | | | | |
|------|----------------|----|----------|----|---------------|----------|
| FI | 8502216 | A | 19851205 | FI | 1985-2216 | 19850603 |
| DK | 8502469 | A | 19851205 | DK | 1985-2469 | 19850603 |
| NO | 8502246 | A | 19851205 | NO | 1985-2246 | 19850603 |
| SU | 1538892 | A3 | 19900123 | SU | 1985-3913136 | 19850603 |
| ES | 544466 | A1 | 19870701 | ES | 1985-544466 | 19850604 |
| CN | 85109752 | A | 19861217 | CN | 1985-109752 | 19851220 |
| US | 4748161 | B1 | 19911015 | US | 1990-90001980 | 19900404 |
| PRAI | JP 1984-115306 | | 19840604 | | | |
| | JP 1984-115307 | | 19840604 | | | |
| | JP 1985-85254 | | 19850419 | | | |
| | JP 1985-85255 | | 19850419 | | | |
| | JP 1984-115406 | | 19840604 | | | |
| | US 1985-739183 | | 19850530 | | | |

L14 ANSWER 169 OF 196 CAPLUS COPYRIGHT 2002 ACS
 AN 1984:483760 CAPLUS
 DN 101:83760
 TI Effect of antiplatelet therapy on restenosis after experimental angioplasty
 AU Faxon, David P.; Sanborn, Timothy A.; Haudenschild, Christian C.; Ryan, Thomas J.
 CS Univ. Hosp., Boston Univ., Boston, MA, 02118, USA
 SO American Journal of Cardiology (1984), 53(12), 72-6
 CODEN: AJCDAG; ISSN: 0002-9149
 DT Journal
 LA English

L14 ANSWER 170 OF 196 CAPLUS COPYRIGHT 2002 ACS
 AN 1984:207791 CAPLUS
 DN 100:207791
 TI Cyclical abnormalities in the bactericidal function, superoxide production, and lysozyme activity of neutrophils obtained from a healthy woman during menstruation: reversal by pretreatment with aspirin
 AU Berger, Elaine M.; Harada, Ruth N.; Vatter, Albert E.; Bowman, C. Michael; Repine, John E.
 CS Health Sci. Cent., Univ. Colorado, Denver, CO, 80262, USA
 SO Journal of Infectious Diseases (1984), 149(3), 413-19
 CODEN: JIDIAQ; ISSN: 0022-1899
 DT Journal
 LA English

L14 ANSWER 171 OF 196 CAPLUS COPYRIGHT 2002 ACS
 AN 1984:96410 CAPLUS
 DN 100:96410
 TI Effect of various doses of aspirin on the development of experimental atherosclerosis
 AU Berisha, Sali; Bocari, Gezim; Santo, Arben; Hasa, Donika
 CS Univ. Tiranes, Tiranes, Albania
 SO Buletin i Universitetit te Tiranes Enver Hoxha, Seria Shkencat Mjekesore (1983), 23(2), 103-8
 CODEN: BUMJD5; ISSN: 0379-7643
 DT Journal
 LA Albanian

L14 ANSWER 172 OF 196 CAPLUS COPYRIGHT 2002 ACS
 AN 1983:520209 CAPLUS
 DN 99:120209
 TI Experimental studies on the mechanism of thrombus formation in hyperlipidemic and atherosclerotic rabbits
 AU Suehiro, Akira
 CS Dep. Intern. Med., Hyogo Coll. Med., Nishinomiya, 663, Japan
 SO Hyogo Ika Daigaku Igakkai Zasshi (1982), 7(2), 77-90

CODEN: HIDZDO; ISSN: 0385-7638
DT Journal
LA Japanese

- L14 ANSWER 173 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1983:482313 CAPLUS
DN 99:82313
TI Anti-proliferative effect of pyridinolcarbamate and of aspirin in the early stages of atherogenesis in swine
AU Kim, D. N.; Lee, K. T.; Schmee, J.; Thomas, W. A.
CS Dep. Pathol., Albany Med. Coll., Albany, NY, 12208, USA
SO Atherosclerosis (Shannon, Ireland) (1983), 48(1), 1-13
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English
- L14 ANSWER 174 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1983:416261 CAPLUS
DN 99:16261
TI Experimental evaluation of venosclerosis of aortocoronary femoral vein bypass graft in control and aspirin-persantine-treated dogs: correlation with **atherosclerosis**
AU Dewanjee, Mrinal K.
CS Radiopharm. Lab., Mayo Clin., Rochester, MN, USA
SO Radiat. Cell. Response, Rep. John Lawrence Interdiscip. Symp. Phys. Biomed. Sci., 2nd (1983), Meeting Date 1981, 61-82. Editor(s): Scott, George P.; Wahner, Heinz W. Publisher: Iowa State Univ. Press, Ames, Iowa.
CODEN: 49OAAH
DT Conference
LA English
- L14 ANSWER 175 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1982:538426 CAPLUS
DN 97:138426
TI Prevention of lipid accumulation in experimental vein bypass grafts by antiplatelet therapy
AU Bonchek, Lawrence I.; Boerboom, Lawrence E.; Olinger, Gordon N.; Pepper, John R.; Munns, James; Hutchinson, Lawrence; Kisseebah, Ahmed H.
CS Dep. Cardiothor. Surgery Med., Med. Coll. Wisconsin, Milwaukee, WI, USA
SO Circulation (1982), 66(2), 338-41
CODEN: CIRCAZ; ISSN: 0009-7322
DT Journal
LA English
- L14 ANSWER 176 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1982:210581 CAPLUS
DN 96:210581
TI Comparison of the effects of aspirin and indomethacin on aortic atherogenesis induced in rabbits
AU Jouve, Remy; Juhan-Vague, Irene; Aillaud, Marie Francoise; Serment-Jouve, Marie Pierre; Payan, Henri
CS Sch. Med., Univ. Marseille, Marseille, Fr.
SO Atherosclerosis (Shannon, Ireland) (1982), 42(2-3), 319-21
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English
- L14 ANSWER 177 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1982:155256 CAPLUS
DN 96:155256
TI Effect of aspirin on cholesterol-induced platelet activation in rabbits
AU Splawinski, J.; Corell, T.; Hasselmann, G.; Mruk, J.

- CS Dep. Pharmacol., Dumex, Copenhagen, DK-2300, Den.
SO Thrombosis Research (1982), 25(1-2), 155-61
CODEN: THBRAA; ISSN: 0049-3848
DT Journal
LA English
- L14 ANSWER 178 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1982:155205 CAPLUS
DN 96:155205
TI The effect of low-dose aspirin and dipyridamole upon atherosclerosis in the rabbit
AU Koster, J. K.; Tryka, A. F.; H'Doubler, P.; Collins, J. J., Jr.
CS Dep. Surg., Harvard Med. Sch., Boston, MA, 02115, USA
SO Artery (Fulton, MI, United States) (1981), 9(6), 405-13
CODEN: ARTEDR; ISSN: 0098-6127
DT Journal
LA English
- L14 ANSWER 179 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1982:135752 CAPLUS
DN 96:135752
TI Enhancement of experimental atherosclerosis by aspirin
AU Debons, Albert F.; Fani, Kazem; Jimenez, Fidelio A.
CS VA Med. Cent., State University New York, Brooklyn, NY, USA
SO Journal of Toxicology and Environmental Health (1981), 8(5-6), 899-906, 1 plate
CODEN: JTEHD6; ISSN: 0098-4108
DT Journal
LA English
- L14 ANSWER 180 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1982:46039 CAPLUS
DN 96:46039
TI Evaluation of the effect of acetylsalicylic acid on the thromboplastin activity of human erythrocytes
AU Ashkinazi, I. Ya.
CS USSR
SO Deposited Doc. (1980), VINITI 3752-80, 14 pp. Avail.: VINITI
DT Report
LA Russian
- L14 ANSWER 181 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1981:597384 CAPLUS
DN 95:197384
TI Endothelial damage induced by polyethylene catheter in the rat
AU Vilageliu, J.; Arano, A.; Bruseghini, L.
CS Spain
SO Methods and Findings in Experimental and Clinical Pharmacology (1981), 3(5), 279-81
CODEN: MFEPPDX; ISSN: 0379-0355
DT Journal
LA English
- L14 ANSWER 182 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1981:564988 CAPLUS
DN 95:164988
TI Studies of human platelet .alpha.-granule release in vivo
AU Files, Joe C.; Malpass, Thomas W.; Yee, Esther K.; Ritchie, James L.; Harker, Laurence A.
CS Sch. Med., Univ. Washington, Seattle, WA, USA
SO Blood (1981), 58(3), 607-18
CODEN: BLOOAW; ISSN: 0006-4971

- DT Journal
LA English
- L14 ANSWER 183 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1981:490646 CAPLUS
DN 95:90646
TI The effect of platelet regulatory drugs in experimental models of thrombosis, **atherosclerosis** and myocardial ischemia
AU White, A. M.; Butler, K. D.
CS Ciba-Geigy Pharm. Div., Horsham/West Sussex, RH12 4 AB, UK
SO Clin. Pharmacol. Ther. Proc. Plenary Lect., Symp. Ther. Sess. World Conf., 1st (1980), 213-23. Editor(s): Turner, Paul. Publisher: Macmillan, London, Engl.
CODEN: 46BIAN
DT Conference; General Review
LA English
- L14 ANSWER 184 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1981:400037 CAPLUS
DN 95:37
TI AAS and Anturan: their effects on the clinical complications of **atherosclerosis**
AU Packhama, M. A.; Mustard, J. F.
CS Dep. Biochim., Univ. Toronto, Toronto, ON, Can.
SO Medecine Moderne du Canada (1981), 36(4), 453-8
CODEN: MMCNAT; ISSN: 0025-6803
DT Journal; General Review
LA French
- L14 ANSWER 185 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1981:167566 CAPLUS
DN 94:167566
TI A new approach to the treatment of **atherosclerosis** and trapidil as an antagonist to platelet-derived growth factor
AU Ohnishi, H.; Yamaguchi, K.; Shimada, S.; Suzuki, Y.; Kumagai, A.
CS Tokyo Res. Lab., Mochida Pharm. Co., Ltd., Tokyo, 115, Japan
SO Life Sciences (1981), 28(14), 1641-6
CODEN: LIFSAK; ISSN: 0024-3205
DT Journal
LA English
- L14 ANSWER 186 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1981:96215 CAPLUS
DN 94:96215
TI Platelets, sulfinpyrazone and organ graft rejection
AU Jamieson, Stuart W.; Burton, Nelson A.; Reitz, Bruce A.
CS Dep. Cardiovasc. Surg., Stanford Univ. Hosp., Stanford, CA, USA
SO Cardiovasc. Actions Sulfinpyrazone: Basic Clin. Res., Proc. Int. Symp. (1980), Meeting Date 1979, 229-47. Editor(s): McGregor, Maurice; Mustard, J. Fraser; Oliver, Michael F. Publisher: Symp. Spec., Miami, Fla.
CODEN: 45CDA6
DT Conference
LA English
- L14 ANSWER 187 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1981:58302 CAPLUS
DN 94:58302
TI The effect of acetylsalicylic acid (ASA) on the development of atherosclerotic lesions in miniature swine
AU Clopath, P.
CS Pharm. Div., CIBA-GEIGY Ltd., Basel, CH-4002, Switz.
SO British Journal of Experimental Pathology (1980), 61(4), 440-3

- CODEN: BJEPA5; ISSN: 0007-1021
DT Journal
LA English
- L14 ANSWER 188 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1979:413847 CAPLUS
DN 91:13847
TI Aspirin inhibits development of coronary **atherosclerosis** in cynomolgus monkeys (*Macaca fascicularis*) fed an atherogenic diet
AU Pick, Ruth; Chediak, Juan; Glick, Gerald
CS Cardiovasc. Inst., Michael Reese Hosp., Chicago, IL, 60616, USA
SO J. Clin. Invest. (1979), 63(1), 158-62
CODEN: JCINAO; ISSN: 0021-9738
DT Journal
LA English
- L14 ANSWER 189 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1979:180165 CAPLUS
DN 90:180165
TI Studies on the progression and regression of coronary and peripheral **atherosclerosis** in the cynomolgus monkey. I. Effects of dipyridamole and aspirin
AU Hollander, William; Kirkpatrick, Barbara; Paddock, John; Colombo, Marilyn; Nagraj, Siva; Prusty, Somnath
CS Med. Cent., Boston Univ., Boston, Mass., USA
SO Exp. Mol. Pathol. (1979), 30(1), 55-73
CODEN: EXMPA6; ISSN: 0014-4800
DT Journal
LA English
- L14 ANSWER 190 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1979:145804 CAPLUS
DN 90:145804
TI Anti-inflammatory drugs in experimental **atherosclerosis**. Part 4. Inhibition of **atherosclerosis** in vivo and thromboxane synthesis and platelet aggregation in vitro
AU Bailey, J. Martyn; Makheja, A. N.; Butler, Jean; Salata, K.
CS Sch. Med. Health Sci., George Washington Univ., Washington, D. C., USA
SO Atherosclerosis (Shannon, Irel.) (1979), 32(2), 195-203
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English
- L14 ANSWER 191 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1977:527635 CAPLUS
DN 87:127635
TI The possible antithromboplastic effect of aspirin. Preliminary communication
AU Dincol, Koray; Ozkan, Emir; Oner, Adil; Okur, Omer; Ekmekci, Ali; Buyukozturk, Kemalettin; Ozcan, Remzi
CS Dep. Intern. Med., Istanbul Fac. Med., Istanbul, Turk.
SO Med. Bull. Istanbul Med. Fac. (Istanbul Univ.) (1976), 9(1), 11-15
CODEN: MBIFDT
DT Journal
LA English
- L14 ANSWER 192 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1977:187267 CAPLUS
DN 86:187267
TI Platelet and fibrinogen survival in coronary **atherosclerosis**. Response to medical and surgical therapy
AU Ritchie, James L.; Harker, Laurence A.

CS Sch. Med., Univ. Washington, Seattle, Wash., USA
SO Am. J. Cardiol. (1977), 39(4), 595-8
CODEN: AJCDAG
DT Journal
LA English

L14 ANSWER 193 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1975:93102 CAPLUS
DN 82:93102
TI Suppression of atheromatous fibrous plaque formation by antiproliferative and antiinflammatory drugs
AU Hollander, William; Kramsch, Dieter M.; Franzblau, Carl; Paddock, John; Colombo, Marilyn A.
CS Med. Cent., Boston Univ., Boston, Mass., USA
SO Circ. Res., Suppl. (1974), 34(5, Suppl. 1), 131-41
CODEN: CIRSAF
DT Journal
LA English

L14 ANSWER 194 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1974:534149 CAPLUS
DN 81:134149
TI Arterial and venous thromboembolism. Kinetic characterization and evaluation of therapy
AU Harker, Laurence A.; Slichter, Sherrill J.
CS Sch. Med., Univ. Washington, Seattle, Wash., USA
SO Thromb. Diath. Haemorrh. (1974), 31(2), 188-203
CODEN: TDHAAT
DT Journal
LA English

L14 ANSWER 195 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1973:500515 CAPLUS
DN 79:100515
TI Antiinflammatory drugs in experimental **atherosclerosis**. 1. Relative potencies for inhibiting plaque formation
AU Bailey, J. Martyn; Butler, Jean
CS Sch. Med., George Washington Univ., Washington, DC, USA
SO Atherosclerosis (1973), 17(3), 515-22
CODEN: ATHSBL
DT Journal
LA English

L14 ANSWER 196 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1967:9364 CAPLUS
DN 66:9364
TI Influence of antiinflammatory agents on experimental **atherosclerosis**
AU Bailey, John Martyn; Butler, Jean
CS Sch. of Med., George Washington Univ., Washington, D. C., USA
SO Nature (London) (1966), 212(5063), 731-2
CODEN: NATUAS
DT Journal
LA English

=> s 14
L15 50997 L4

=> s 115 and 110
L16 327 L15 AND L10

=> d 116 300-327

L16 ANSWER 300 OF 327 CAPIUS COPYRIGHT 2002 ACS
AN 1976:162877 CAPIUS
DN 84:162877
TI Physiologically active compounds
IN Endo, Akira; Kuroda, Masao; Tsujita, Yoshio; Terahara, Akira; Tamura, Chihiro
PA Sankyo Co., Ltd., Japan
SO Ger. Offen., 23 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | DE 2524355 | A1 | 19751218 | DE 1975-2524355 | 19750602 |
| | DE 2524355 | C2 | 19830721 | | |
| | JP 50155690 | A2 | 19751216 | JP 1974-64823 | 19740607 |
| | JP 56012114 | B4 | 19810318 | | |
| | GB 1453425 | A | 19761020 | GB 1975-23035 | 19750523 |
| | SE 7506498 | A | 19751208 | SE 1975-6498 | 19750606 |
| | SE 425253 | B | 19820913 | | |
| | SE 425253 | C | 19821230 | | |
| | DK 7502553 | A | 19751208 | DK 1975-2553 | 19750606 |
| | DK 136485 | B | 19771017 | | |
| | AT 7504304 | A | 19771015 | AT 1975-4304 | 19750606 |
| | FR 2313035 | B1 | 19781110 | FR 1975-17687 | 19750606 |
| | FR 2313035 | A1 | 19761231 | | |
| | CA 1046439 | A1 | 19790116 | CA 1975-228761 | 19750606 |
| | BE 830033 | A1 | 19751209 | BE 1975-157165 | 19750609 |
| | NL 7506848 | A | 19751209 | NL 1975-6848 | 19750609 |
| | NL 176872 | B | 19850116 | | |
| | NL 176872 | C | 19850617 | | |
| | US 4049495 | A | 19770920 | US 1975-637673 | 19751204 |
| PRAI | JP 1974-64823 | | 19740607 | | |
| | US 1975-576651 | | 19750512 | | |

L16 ANSWER 301 OF 327 CAPIUS COPYRIGHT 2002 ACS
AN 1975:512072 CAPIUS
DN 83:112072
TI Significant role of adrenaline and noradrenaline in thrombogenesis and myocardial infarction. Experimental studies in rhesus monkeys
AU Chakravarti, R. N.
CS Dep. Exp. Med., Post-Grad. Inst. Med. Educ. Res., Chandigarh, India
SO Proc. Asia Oceania Congr. Endocrinol., 5th (1974), Volume 2, 518-30.
Editor(s): Rastogi, G. K. Publisher: Endocr. Soc. India, Chandigarh, India.
CODEN: 30KMAT
DT Conference
LA English

L16 ANSWER 302 OF 327 CAPIUS COPYRIGHT 2002 ACS
AN 1975:81043 CAPIUS
DN 82:81043
TI Role of extra- and intracellular coagulation in **atherosclerosis** development
AU Kuznik, B. I.; Rusyaev, V. F.; Kuchuk, V. M.
CS Chit. Med. Inst., Chita, USSR
SO Kardiologiya (1974), 14(11), 66-72
CODEN: KARDA2
DT Journal

- LA Russian
- L16 ANSWER 303 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1974:503560 CAPLUS
DN 81:103560
TI Influence of nicotinic acid on quantitative lactate dehydrogenase and glucose-6-phosphate dehydrogenase changes in the blood and tissues of rats subjected to an experimental atherogenic diet
AU Leporda, Gh.; Haler, Constanta; Freund, S.; Zilberman, Lucia
CS Inst. Sanatate Publica si Cercet. Med., Iasi, Rom.
SO Rev. Med.-Chir. (1974), 78(1), 105-9
CODEN: RMNIBN
DT Journal
LA Romanian
- L16 ANSWER 304 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1973:533131 CAPLUS
DN 79:133131
TI Reaction of the vascular wall to biogenic amines in experimentally induced **atherosclerosis**
AU Trinus, F. P.
CS Kiev Res. Inst. Pharmacol. Toxicol., Kiev, USSR
SO Byull. Eksp. Biol. Med. (1973), 76(8), 30-2
CODEN: BEBMAE
DT Journal
LA Russian
- L16 ANSWER 305 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1973:461722 CAPLUS
DN 79:61722
TI Biochemical and morphological alterations induced by long-term administration of epinephrine, metanephrine, and thyroxine in rats
AU Trzeciak, Henryk I.
CS Dep. Pharmacol., Silesian Sch. Med., Zabrze, Pol.
SO Toxicol. Appl. Pharmacol. (1973), 25(3), 315-22
CODEN: TXAPAA9
DT Journal
LA English
- L16 ANSWER 306 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1973:119379 CAPLUS
DN 78:119379
TI Effect of pyridinol carbamate on rat adipose tissue free fatty acids
AU Grafnetter, D.; Shimamoto, T.; Numano, F.
CS Div. Cardiovasc. Dis., Inst. Clin. Exp. Med., Prague, Czech.
SO Atherosclerosis (1972), 16(2), 185-91
CODEN: ATHSBL
DT Journal
LA English
- L16 ANSWER 307 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1972:547651 CAPLUS
DN 77:147651
TI Influence of experimental **atherosclerosis** and various vasoactive drugs on cerebrospinal fluid pressure in rabbits
AU Cohen, I.; Levinger, I. M.; Herzberg, M.
CS Dep. Life Sci., Bar-Ilan Univ., Ramat Gan, Israel
SO Confin. Neurol. (1971), 33(6), 334-41
CODEN: CONEAT
DT Journal
LA English

- L16 ANSWER 308 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1972:428896 CAPLUS
DN 77:28896
TI Effect of catechol amines on coronary blood circulation during experimental renal-steroid and renal-salt hypertension, and **atherosclerosis**
AU Khomazyuk, A. I.; Neshcheret, A. P.; Yavorskii, L. A.; Zaritskii, G. V.
CS Kiev, USSR
SO Fiziol., Biokhim. Patol. Endokr. Sist. (1971), No. 1, 33-5
CODEN: FBPEAF
DT Journal
LA Russian
- L16 ANSWER 309 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1972:81105 CAPLUS
DN 76:81105
TI Antiatherosclerotic agents. 6. Effect of 1,3-propanediol bis(.alpha.-p-chlorophenoxyisobutyrate) (simfibrate) on lipolysis
AU Nakanishi, Michio; Kobayakawa, Toshihiro; Yasuda, Hiroshi; Okada, Tadao
CS Res. Lab., Yoshitomi Pharm. Ind., Ltd., Fukuoka, Japan
SO Oyo Yakuri (1970), 4(5), 761-5
CODEN: OYYAA2
DT Journal
LA Japanese
- L16 ANSWER 310 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1972:44374 CAPLUS
DN 76:44374
TI Hormones, arterial wall, and atherosclerotic involvement. I. Catecholamines
AU Velican, C.
CS "N. Gh. Lupu" Inst. Intern. Med., Bucharest, Rom.
SO Rev. Roum. Endocrinol. (1971), 8(3), 195-206
CODEN: RRENAR
DT Journal; General Review
LA English
- L16 ANSWER 311 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1971:74133 CAPLUS
DN 74:74133
TI Dynamics of changes of lipid and monoamine metabolism and the blood coagulating system during experimental **atherosclerosis** caused by restriction of movement
AU Gvishiani, G. S.; Kobakhidze, N. G.
CS USSR
SO Soobshch. Akad. Nauk Gruz. SSR (1970), 60(2), 445-7
CODEN: SAKNAH
DT Journal
LA Georgian
- L16 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1971:40530 CAPLUS
DN 74:40530
TI Cardiovascular reactions in old animals with experimental **atherosclerosis**
AU Kostyuk, L. V.; Cherkasskii, L. P.
CS Kiev, USSR
SO Starenie Fiziol. Sist. Organizma, Tr. Vses. Konf. Gerontol. Geriat., 2nd (1969), 79-85. Editor(s): Chebotarev, D. F. Publisher: Inst. Gerontol., Akad. Med. Nauk SSSR, Kiev, USSR.
CODEN: 22NSAT
DT Conference

AN 1967:9364 CAPLUS
DN 66:9364
TI Influence of antiinflammatory agents on experimental atherosclerosis
AU Bailey, John Martyn; Butler, Jean
CS Sch. of Med., George Washington Univ., Washington, DC, USA
SO Nature (London, United Kingdom) (1966), 212(5063), 731-2
CODEN: NATUAS; ISSN: 0028-0836
DT Journal
LA English
CC 12 (Mammalian Pathological Biochemistry)
AB Daily supplements of cholesterol (1 g.) in rabbit diets increased plasma lipid concns. 10-20-fold and induced atherosclerotic plaques in the thoracic aortas within 12 weeks. The addn. of 1 or 5 mg. of cortisone acetate (I) to rabbit diets contg. cholesterol increased plasma lipids, but reduced the development of atherosclerotic plaques by about 75%. Phenylbutazone (100 mg. daily) decreased plaque formation; 44% of the animals developed no plaques at all. The phenylbutazone-induced decreased plaque formations did not alter serum lipid patterns. The severity of atherosclerosis in animals treated with 100 mg. of aminopyrine was slightly less than in the controls; plasma cholesterol was considerably lower. Vitamin C (100 mg.) produced no decrease in the no. of plaques, and acetyl salicylate increased the incidence of atherosclerosis 17.1%. Rabbits fed a diet contg. 1% cholesterol for 12 weeks produced extensive plaques which did not regress during the following 12 weeks on a cholesterol-free diet, with or without daily supplementation with 5 mg. of I, indicating that I acts in the early stages of plaque formation through its antiinflammatory properties rather than through its lipemic effects.
ST LIPIDS ATHEROSCLEROSIS; ANTIINFLAMMATORIES ATHEROSCLEROSIS; CORTISONE ATHEROSCLEROSIS; ATHEROSCLEROSIS CORTISONE; STEROIDS ATHEROSCLEROSIS; CORTISONE ATHEROSCLEROSIS; ATHEROSCLEROSIS CORTISONE; LIPIDS ATHEROSCLEROSIS; ANTIINFLAMMATORIES ATHEROSCLEROSIS; STEROIDS ATHEROSCLEROSIS
IT Lipids
RL: BIOL (Biological study)
(in blood plasma, inflammation inhibitor effect on)
IT Atherosclerosis
(inflammation inhibitor effect on)
IT 50-78-2, biological studies
RL: BIOL (Biological study)
(atherosclerosis in response to)
IT 50-04-4 50-33-9 58-15-1
RL: BIOL (Biological study)
(atherosclerosis in response to)

=>

AN 1967:9364 CAPLUS
DN 66:9364
TI Influence of antiinflammatory agents on experimental atherosclerosis
AU Bailey, John Martyn; Butler, Jean
CS Sch. of Med., George Washington Univ., Washington, DC, USA
SO Nature (London, United Kingdom) (1966), 212(5063), 731-2
CODEN: NATUAS; ISSN: 0028-0836
DT Journal
LA English
CC 12 (Mammalian Pathological Biochemistry)
AB Daily supplements of cholesterol (1 g.) in rabbit diets increased plasma lipid concns. 10-20-fold and induced atherosclerotic plaques in the thoracic aortas within 12 weeks. The addn. of 1 or 5 mg. of cortisone acetate (I) to rabbit diets contg. cholesterol increased plasma lipids, but reduced the development of atherosclerotic plaques by about 75%. Phenylbutazone (100 mg. daily) decreased plaque formation; 44% of the animals developed no plaques at all. The phenylbutazone-induced decreased plaque formations did not alter serum lipid patterns. The severity of atherosclerosis in animals treated with 100 mg. of aminopyrine was slightly less than in the controls; plasma cholesterol was considerably lower. Vitamin C (100 mg.) produced no decrease in the no. of plaques, and acetyl salicylate increased the incidence of atherosclerosis 17.1%. Rabbits fed a diet contg. 1% cholesterol for 12 weeks produced extensive plaques which did not regress during the following 12 weeks on a cholesterol-free diet, with or without daily supplementation with 5 mg. of I, indicating that I acts in the early stages of plaque formation through its antiinflammatory properties rather than through its lipemic effects.
ST LIPIDS ATHEROSCLEROSIS; ANTIINFLAMMATORIES ATHEROSCLEROSIS; CORTISONE ATHEROSCLEROSIS; ATHEROSCLEROSIS CORTISONE; STEROIDS ATHEROSCLEROSIS; CORTISONE ATHEROSCLEROSIS; ATHEROSCLEROSIS CORTISONE; LIPIDS ATHEROSCLEROSIS; ANTIINFLAMMATORIES ATHEROSCLEROSIS; STEROIDS ATHEROSCLEROSIS
IT Lipids
RL: BIOL (Biological study)
(in blood plasma, inflammation inhibitor effect on)
IT Atherosclerosis
(inflammation inhibitor effect on)
IT 50-78-2, biological studies
RL: BIOL (Biological study)
(atherosclerosis in response to)
IT 50-04-4 50-33-9 58-15-1
RL: BIOL (Biological study)
(atherosclerosis in response to)

=>

AN 1979:145804 CAPLUS
DN 90:145804
TI Anti-inflammatory drugs in experimental **atherosclerosis**. Part 4. Inhibition of **atherosclerosis** in vivo and thromboxane synthesis and platelet aggregation in vitro
AU Bailey, J. Martyn; Makheja, A. N.; Butler, Jean; Salata, K.
CS Sch. Med. Health Sci., George Washington Univ., Washington, DC, USA
SO Atherosclerosis (Shannon, Ireland) (1979), 32(2), 195-203
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English
CC 1-5 (Pharmacodynamics)
Section cross-reference(s): 14
AB Groups of New Zealand white male rabbits were fed antherogenic diets contg. 1% cholesterol. The diets of exptl. groups were supplemented addnl. with either aspirin [50-78-2], phenylbutazone [50-33-9], mefenamic acid [61-68-7], flufenamic acid [530-78-9], oxyphenylbutazone [129-20-4] or aminopyrine [58-15-1]. Blood cholesterol and phospholipids were measured at 3-4 wk intervals. After 12 wk the animals were sacrificed and the severity of **atherosclerosis** in the thoracic aorta was measured. In sep. expts., rabbit platelets were incubated with each of the drugs individually and conversion of [¹⁴C]arachidonic acid to thromboxanes and related compds. was assayed. Inhibition of collagen and arachidonic acid-induced platelet aggregation by each drug was also measured. All drugs inhibited thromboxane synthesis and platelet aggregation in varying degrees with flufenamate and aspirin being most and aminopyrine least effective. The pattern of metabolite formation from [¹⁴C]arachidonate was consistent with a block in the cyclooxygenase reaction. Phenylbutazone, flufenamic acid, and oxyphenylbutazone produced significant redns. in atherosclerotic plaque formation without major changes in blood cholesterol levels or blood cholesterol-phospholipid ratios. Aspirin and aminopyrine were ineffective. The effectiveness of antiinflammatory drugs as inhibitors of thromboxane synthesis and platelet aggregation in vitro does not appear to afford a sufficient predictive index of their antiatherogenicity in vivo. The significance of these findings is discussed in terms of the possible involvement of cyclooxygenase derivs. in atherogenesis.
ST inflammation inhibitor **atherosclerosis** thromboxane; blood platelet antiinflammatory drug
IT Blood platelet
 (aggregation of, inflammation inhibitors inhibition of,
 antiatherogenicity in relation to)
IT Thromboxanes
RL: FORM (Formation, nonpreparative)
 (formation of, inflammation inhibitors inhibition of,
 antiatherogenicity in relation to)
IT **Atherosclerosis**
 (inflammation inhibitors effect on, platelet aggregation and
 thromboxane formation inhibition in relation to)
IT Inflammation inhibitors
 (platelet aggregation and thromboxane formation inhibition by,
 antiatherogenicity in relation to)
IT 50-33-9, biological studies 50-78-2 58-15-1 61-68-7
129-20-4 530-78-9
RL: BIOL (Biological study)
 (platelet aggregation and thromboxane formation inhibition by,
 antiatherogenicity in relation to)

AN 1979:145804 CAPLUS
DN 90:145804
TI Anti-inflammatory drugs in experimental **atherosclerosis**. Part
4. Inhibition of **atherosclerosis** in vivo and thromboxane
synthesis and platelet aggregation in vitro
AU Bailey, J. Martyn; Makheja, A. N.; Butler, Jean; Salata, K.
CS Sch. Med. Health Sci., George Washington Univ., Washington, DC, USA
SO Atherosclerosis (Shannon, Ireland) (1979), 32(2), 195-203
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English
CC 1-5 (Pharmacodynamics)
Section cross-reference(s): 14
AB Groups of New Zealand white male rabbits were fed antherogenic diets
contg. 1% cholesterol. The diets of exptl. groups were supplemented
addnl. with either aspirin [50-78-2], phenylbutazone
[50-33-9], mefenamic acid [61-68-7], flufenamic acid [530-78-9],
oxyphenylbutazone [129-20-4] or aminopyrine [58-15-1]. Blood
cholesterol and phospholipids were measured at 3-4 wk intervals. After 12
wk the animals were sacrificed and the severity of **atherosclerosis**
in the thoracic aorta was measured. In sep. expts., rabbit platelets were
incubated with each of the drugs individually and conversion of
[14C]arachidonic acid to thromboxanes and related compds. was assayed.
Inhibition of collagen and arachidonic acid-induced platelet aggregation
by each drug was also measured. All drugs inhibited thromboxane synthesis
and platelet aggregation in varying degrees with flufenamate and aspirin
being most and aminopyrine least effective. The pattern of metabolite
formation from [14C]arachidonate was consistent with a block in the
cyclooxygenase reaction. Phenylbutazone, flufenamic acid, and
oxyphenylbutazone produced significant redns. in atherosclerotic plaque
formation without major changes in blood cholesterol levels or blood
cholesterol-phospholipid ratios. Aspirin and aminopyrine were
ineffective. The effectiveness of antiinflammatory drugs as inhibitors of
thromboxane synthesis and platelet aggregation in vitro does not appear to
afford a sufficient predictive index of their antiatherogenicity in vivo.
The significance of these findings is discussed in terms of the possible
involvement of cyclooxygenase derivs. in atherogenesis.
ST inflammation inhibitor **atherosclerosis** thromboxane; blood
platelet antiinflammatory drug
IT Blood platelet
(aggregation of, inflammation inhibitors inhibition of,
antiatherogenicity in relation to)
IT Thromboxanes
RL: FORM (Formation, nonpreparative)
(formation of, inflammation inhibitors inhibition of,
antiatherogenicity in relation to)
IT **Atherosclerosis**
(inflammation inhibitors effect on, platelet aggregation and
thromboxane formation inhibition in relation to)
IT Inflammation inhibitors
(platelet aggregation and thromboxane formation inhibition by,
antiatherogenicity in relation to)
IT 50-33-9, biological studies 50-78-2 58-15-1 61-68-7
129-20-4 530-78-9
RL: BIOL (Biological study)
(platelet aggregation and thromboxane formation inhibition by,
antiatherogenicity in relation to)

CS The Queen's University of Belfast, Belfast, BT9 7BL, UK
SO Journal of Toxicology, Clinical Toxicology (1999), 37(4), 435-440
CODEN: JTCTDW; ISSN: 0731-3810
PB Marcel Dekker, Inc.
DT Journal
LA English
CC 18-3 (Animal Nutrition)
Section cross-reference(s): 1, 4, 63
AB Acetaminophen (paracetamol) poisoning is a major source of morbidity and mortality. It has been proposed that methionine be incorporated into acetaminophen tablets routinely as a protective mechanism. However, there has been some concern that chronic methionine supplementation may be assocd. with vascular disease. The aim of the study was to investigate if methionine supplementation causes changes in endothelial function, plasma homocysteine, or lipid peroxidn. which may be assocd. with **atherosclerosis**, using 16 healthy volunteers. Methionine supplementation did not impair endothelial-dependent vascular responses or increase lipid peroxidn. High-dose (100 mg/kg for 1 wk) supplementation caused elevation of plasma homocysteine, but doses similar to those used in combination preps. with acetaminophen did not affect plasma homocysteine concns.
ST methionine **atherosclerosis** acetaminophen toxicity
IT **Atherosclerosis**
(effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidn. in relation to acetaminophen poisoning)
IT 103-90-2, Acetaminophen
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidn. in relation to acetaminophen poisoning)
IT 6027-13-0, Homocysteine
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidn. in relation to acetaminophen poisoning)
IT 63-68-3, L-Methionine, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidn. in relation to acetaminophen poisoning)
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Araki, A; J Chromatogr 1987, V422, P43 CAPLUS
(2) Crome, P; Lancet 1976, V2, P829 MEDLINE
(3) Fau, D; J Nutr 1988, V118, P128 CAPLUS
(4) Gorog, P; J Clin Pathol 1991, V44, P765 MEDLINE
(5) Knight, J; Clin Chem 1988, V34, P2433 CAPLUS
(6) Krishnaswamy, K; Atherosclerosis 1977, V27, P253 CAPLUS
(7) McVeigh, G; Diabetologia 1992, V35, P771 MEDLINE
(8) Mrhova, O; Cor Vasa 1988, V30, P73 CAPLUS
(9) Neuvonen, P; Int J Clin Pharmacol Ther Toxicol 1985, V23, P497 CAPLUS
(10) Perry, I; Lancet 1995, V346, P1395 CAPLUS
(11) Renaud, S; Proc Soc Exp Biol Med 1966, V121, P452 CAPLUS
(12) Ross, R; N Engl J Med 1976, V295, P369 MEDLINE
(13) Stampfer, M; JAMA 1992, V268, P877 MEDLINE
(14) Toborek, M; Atherosclerosis 1995, V115, P217 CAPLUS

| | | | | |
|--------------|--------------|--------------|--------------|--------------|
| 252016-26-5P | 252016-27-6P | 252016-28-7P | 252016-29-8P | 252016-30-1P |
| 252016-31-2P | 252016-32-3P | 252016-33-4P | 252016-34-5P | 252016-35-6P |
| 252016-36-7P | 252016-37-8P | 252016-38-9P | 252016-39-0P | 252016-40-3P |
| 252016-41-4P | 252016-42-5P | 252016-43-6P | 252016-44-7P | 252016-45-8P |
| 252016-46-9P | 252016-47-0P | 252016-48-1P | 252016-49-2P | 252016-50-5P |
| 252016-51-6P | 252016-52-7P | 252016-53-8P | 252016-54-9P | 252016-55-0P |
| 252016-56-1P | 252016-57-2P | 252016-58-3P | 252016-59-4P | 252016-60-7P |
| 252016-61-8P | 252016-63-0P | 252016-64-1P | 252016-65-2P | 252016-70-9P |
| 252016-73-2P | 252016-74-3P | 252016-75-4P | 252016-76-5P | 252016-77-6P |
| 252016-78-7P | 252016-79-8P | 252016-80-1P | 252016-83-4P | 252016-88-9P |
| 252016-89-0P | 252016-94-7P | 252016-97-0P | 252017-01-9P | 252017-02-0P |
| 252017-03-1P | 252017-04-2P | 252017-05-3P | 252017-06-4P | 252017-07-5P |
| 252017-08-6P | 252017-09-7P | 252017-10-0P | 252017-11-1P | 252017-12-2P |
| 252017-13-3P | 252017-14-4P | 252017-15-5P | 252017-16-6P | 252017-17-7P |
| 252017-18-8P | 252017-19-9P | 252017-20-2P | 252017-22-4P | 252017-24-6P |
| 252017-25-7P | 252017-30-4P | 252017-31-5P | 252017-32-6P | 252017-33-7P |
| 252017-34-8P | 252017-35-9P | 252017-36-0P | 252017-37-1P | 252017-44-0P |
| 252017-47-3P | 252017-48-4P | 252017-55-3P | 252017-58-6P | 252017-69-9P |
| 252017-70-2P | 252017-72-4P | 252017-73-5P | 252017-76-8P | 252017-81-5P |
| 252017-82-6P | 252017-83-7P | 252017-84-8P | 252017-85-9P | 252017-86-0P |
| 252017-89-3P | 252017-90-6P | 252017-91-7P | 252017-92-8P | 252017-93-9P |
| 252017-94-0P | 252017-99-5P | 252018-00-1P | 252018-02-3P | 252018-03-4P |
| 252018-04-5P | 252018-05-6P | 252018-06-7P | 252018-07-8P | 252018-08-9P |
| 252018-09-0P | 252018-10-3P | 252018-11-4P | 252018-12-5P | |

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compd.; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

IT 252018-13-6P 252018-16-9P 252018-17-0P 252018-18-1P 252018-19-2P
 252018-20-5P 252018-21-6P 252018-35-2P 252018-36-3P 252018-37-4P
 252018-39-6P 252018-40-9P 252018-41-0P 252018-42-1P 252018-43-2P
 252018-44-3P 252018-50-1P 252018-51-2P 252018-52-3P 252018-53-4P
 252018-54-5P 252018-55-6P 252018-56-7P 252018-57-8P 252018-58-9P
 252018-59-0P 252018-60-3P 252018-61-4P 252018-62-5P 252018-63-6P
 252018-64-7P 252018-65-8P 252018-66-9P 252018-67-0P 252018-68-1P
 252018-69-2P 252018-70-5P 252018-71-6P 252018-72-7P 252018-73-8P
 252018-74-9P 252018-76-1P 252018-77-2P 252018-78-3P 252018-79-4P
 252018-80-7P 252018-81-8P 252018-83-0P 252018-86-3P 252018-89-6P
 252018-92-1P 252018-97-6P 252018-99-8P 252019-03-7P 252019-14-0P
 252019-18-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compd.; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Brown, F; US 5486515 A 1996 CAPLUS
- (2) Ohnmacht, C; Journal of Medicinal Chemistry 1996, V39(23), P4592 CAPLUS
- (3) Zeneca; EP 0617010 A 1994 CAPLUS
- (4) Zeneca; WO 9628151 A 1996 CAPLUS

L12 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2002 ACS
 AN 1999:593675 CAPLUS

DN 132:121896

TI Effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidation

AU McAuley, Daniel F.; Hanratty, Colm G.; McGurk, Colm; Nugent, Ailish G.; Johnston, G. Dennis

AN 1998:715148 CAPLUS
DN 130:119083
TI Effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome
AU Crocker, John F. S.; Digout, Sharon C.; Lee, Spencer H.; Rozee, Ken R.; Renton, Ken; Field, Chris A.; Acott, Philip; Murphy, Mary G.
CS Department of Pediatrics, Dalhousie University and the Izaak Walton Killam-Grace Health Centre, Halifax, NS, Can.
SO Clinical and Investigative Medicine (1998), 21(4-5), 192-202
CODEN: CNVMDL; ISSN: 0147-958X
PB Canadian Medical Association
DT Journal
LA English
CC 1-4 (Pharmacology)
AB To det. the effects of acetylsalicylic acid (ASA) and acetaminophen on mortality due to influenza B infection in neonatal and weanling mice, as well as any synergistic, antagonistic or indifferent effects of the combined antipyretic and virus on mortality in mice pre-treated with low doses of an industrial surfactant, Toximul MP8, which has been shown to reproduce many of the features of Reye's syndrome. In vitro studies were done to det. whether ASA or acetaminophen altered the normal, interferon-mediated antiviral responses of mammalian cells. The involvement of ASA or other commonly used xenobiotics in the induction of Reye's syndrome following virus illness has not been resolved; to do so, and to elucidate the underlying metabolic mechanism, requires these studies in an animal model. Prospective animal study. Newborn (945) and weanling (840) Swiss white mice, divided into 12 subgroups. Some groups received Toximul MP8 before inoculation with a dose of mouse-adapted human influenza B that produces 30% mortality (LD30); after infection, each subgroup received either placebo, ASA or acetaminophen. Mortality counts were taken daily. The in vitro effects of the antipyretics on interferon response were detd. using std. virol. techniques. Mortality, analyzed by survival curves (log rank test) or cumulative daily mortality (.chi.2 anal.). Plaque-reducing dose (PRD50) was used to det. the outcome of the in vitro analyses. In neonatal mice, only subgroups given combined treatment with acetaminophen and Toximul MP8 had a statistically significant higher mortality rate than with the mice given influenza B alone. In weanling mice, it appeared that ASA shortened the time until death; however, this difference was not statistically significant. In vitro studies demonstrated that both ASA and acetaminophen decreased the interferon-induced antiviral responses of cultured mammalian cells. Antipyretics have the potential to exacerbate the consequences of a viral infection, although the specific effects are subtle and appear to be age-related.
ST antipyretic ASA influenza B Reye's syndrome; acetaminophen toximul interaction antiviral interferon age
IT Brain, disease
Brain, disease
(Reye's syndrome; effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)
IT Aging, animal
Antipyretics
Antiviral agents
Influenza B virus
Newborn
(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)
IT Interferons
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(effects of antipyretics on mortality due to influenza B virus in a

mouse model of Reye's syndrome)

IT Anti-inflammatory agents
(nonsteroidal; effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT Drug interactions
(synergistic; effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT 50-78-2, Acetylsalicylic acid
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT 103-90-2, Acetaminophen 37341-79-0, Toximul MP8
RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)
(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD

- RE
- (1) Casteels-van Daele, M; Arch Dis Child 1997, V76, P79 MEDLINE
 - (2) Crocker, J; Exp Neurol 1991, V111, P95 MEDLINE
 - (3) Crocker, J; Lab Invest 1986, V54, P32 CAPLUS
 - (4) Davis, L; Ann Neurol 1985, V18, P556 CAPLUS
 - (5) Deshmukh, D; Proc Natl Acad Sci USA 1982, V79, P7557 CAPLUS
 - (6) Doran, T; J Pediatr 1989, V114, P1045 MEDLINE
 - (7) Fromenty, B; Pharam Ther 1995, V67, P101 CAPLUS
 - (8) Godfrey, A; N Engl J Med 1985, V313, P450
 - (9) Graham, N; J Infect Dis 1990, V162, P1277 MEDLINE
 - (10) Halpin, T; JAMA 1982, V248, P687 MEDLINE
 - (11) Hardie, R; Arch Dis Child 1996, V74, P400 MEDLINE
 - (12) Hug, G; Lab Invest 1981, V45, P89 CAPLUS
 - (13) Hurwitz, E; JAMA 1987, V257, P1905 MEDLINE
 - (14) Hurwitz, E; N Engl J Med 1985, V313, P849 MEDLINE
 - (15) Krawchuk, S; [dissertation] Dalhousie University 1989
 - (16) Lee, S; Appl Environ Microbiol 1990, V40, P787
 - (17) Levy, M; Drug Saf 1997, V16, P1 MEDLINE
 - (18) Linnemann, C; Pediatr Res 1979, V13, P44 CAPLUS
 - (19) Macdonald, M; Pediatr Res 1984, V18, P181 CAPLUS
 - (20) Malamy, J; Science 1990, V2500, P1002
 - (21) Mantel, N; Cancer Chemother Rep 1966, V50, P163 MEDLINE
 - (22) Metraux, J; Science 1990, V250, P1004 CAPLUS
 - (23) Murphy, M; Biochim Biophys Acta 1996, V1315, P208 CAPLUS
 - (24) Murphy, M; Biochim Biophys Acta 1997, V1361, P103 CAPLUS
 - (25) Oehen, S; Science 1991, V251, P195 MEDLINE
 - (26) Orlowski, J; Cleve Clin J Med 1990, V57, P323 MEDLINE
 - (27) Poss, W; Arch Pediatr Adolesc Med 1994, V148, P879 MEDLINE
 - (28) Remington, P; Pediatrics 1986, V77, P93 MEDLINE
 - (29) Reye, R; Lancet 1963, V2, P749
 - (30) Roe, C; Reye's syndrome Round Table Series, no 8 1988, P85
 - (31) Rogers, M; Pediatrics 1985, V75, P260 MEDLINE
 - (32) Rosenberg, D; South Med J 1977, V70, P660 MEDLINE
 - (33) Rozee, K; CMAJ 1982, V126, P798 MEDLINE
 - (34) Rozee, K; Canadian Pediatric Society meeting 1987
 - (35) Shindell, S; Lancet 1993, V341, P119 MEDLINE
 - (36) Smith, T; Scott Med J 1996, V41, P409
 - (37) Stanley, E; JAMA 1975, V231, P1248 MEDLINE
 - (38) Starko, K; Pediatrics 1980, V66, P859 MEDLINE
 - (39) Stumpf, D; Brain Dev 1995, V17(Suppl), P77

- (40) Trauner, D; Neurology 1988, V38, P239
- (41) Vesentini, M; Drug Metab Rev 1995, V27, P517
- (42) Waldman, R; JAMA 1982, V247, P3089 MEDLINE
- (43) Yamashita, F; Reye's syndrome IV 1985, P47

=>

AN 1998:715148 CAPLUS
DN 130:119083
TI Effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome
AU Crocker, John F. S.; Digout, Sharon C.; Lee, Spencer H.; Rozee, Ken R.; Renton, Ken; Field, Chris A.; Acott, Philip; Murphy, Mary G.
CS Department of Pediatrics, Dalhousie University and the Izaak Walton Killam-Grace Health Centre, Halifax, NS, Can.
SO Clinical and Investigative Medicine (1998), 21(4-5), 192-202
CODEN: CNVMDL; ISSN: 0147-958X
PB Canadian Medical Association
DT Journal
LA English
CC 1-4 (Pharmacology)
AB To det. the effects of acetylsalicylic acid (ASA) and acetaminophen on mortality due to influenza B infection in neonatal and weanling mice, as well as any synergistic, antagonistic or indifferent effects of the combined antipyretic and virus on mortality in mice pre-treated with low doses of an industrial surfactant, Toximul MP8, which has been shown to reproduce many of the features of Reye's syndrome. In vitro studies were done to det. whether ASA or acetaminophen altered the normal, interferon-mediated antiviral responses of mammalian cells. The involvement of ASA or other commonly used xenobiotics in the induction of Reye's syndrome following virus illness has not been resolved; to do so, and to elucidate the underlying metabolic mechanism, requires these studies in an animal model. Prospective animal study. Newborn (945) and weanling (840) Swiss white mice, divided into 12 subgroups. Some groups received Toximul MP8 before inoculation with a dose of mouse-adapted human influenza B that produces 30% mortality (LD30); after infection, each subgroup received either placebo, ASA or acetaminophen. Mortality counts were taken daily. The in vitro effects of the antipyretics on interferon response were detd. using std. virol. techniques. Mortality, analyzed by survival curves (log rank test) or cumulative daily mortality (.chi.2 anal.). Plaque-reducing dose (PRD50) was used to det. the outcome of the in vitro analyses. In neonatal mice, only subgroups given combined treatment with acetaminophen and Toximul MP8 had a statistically significant higher mortality rate than with the mice given influenza B alone. In weanling mice, it appeared that ASA shortened the time until death; however, this difference was not statistically significant. In vitro studies demonstrated that both ASA and acetaminophen decreased the interferon-induced antiviral responses of cultured mammalian cells. Antipyretics have the potential to exacerbate the consequences of a viral infection, although the specific effects are subtle and appear to be age-related.
ST antipyretic ASA influenza B Reye's syndrome; acetaminophen toximul interaction antiviral interferon age
IT Brain, disease
IT Brain, disease
IT Aging, animal
IT Antipyretics
IT Antiviral agents
IT Influenza B virus
IT Newborn
IT Interferons
IT RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

mouse model of Reye's syndrome)

IT Anti-inflammatory agents
(nonsteroidal; effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT Drug interactions
(synergistic; effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT 50-78-2, Acetylsalicylic acid
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT 103-90-2, Acetaminophen 37341-79-0, Toximul MP8
RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)
(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Casteels-van Daele, M; Arch Dis Child 1997, V76, P79 MEDLINE
- (2) Crocker, J; Exp Neurol 1991, V111, P95 MEDLINE
- (3) Crocker, J; Lab Invest 1986, V54, P32 CAPLUS
- (4) Davis, L; Ann Neurol 1985, V18, P556 CAPLUS
- (5) Deshmukh, D; Proc Natl Acad Sci USA 1982, V79, P7557 CAPLUS
- (6) Doran, T; J Pediatr 1989, V114, P1045 MEDLINE
- (7) Fromenty, B; Pharam Ther 1995, V67, P101 CAPLUS
- (8) Godfrey, A; N Engl J Med 1985, V313, P450
- (9) Graham, N; J Infect Dis 1990, V162, P1277 MEDLINE
- (10) Halpin, T; JAMA 1982, V248, P687 MEDLINE
- (11) Hardie, R; Arch Dis Child 1996, V74, P400 MEDLINE
- (12) Hug, G; Lab Invest 1981, V45, P89 CAPLUS
- (13) Hurwitz, E; JAMA 1987, V257, P1905 MEDLINE
- (14) Hurwitz, E; N Engl J Med 1985, V313, P849 MEDLINE
- (15) Krawchuk, S; [dissertation] Dalhousie University 1989
- (16) Lee, S; Appl Environ Microbiol 1990, V40, P787
- (17) Levy, M; Drug Saf 1997, V16, P1 MEDLINE
- (18) Linnemann, C; Pediatr Res 1979, V13, P44 CAPLUS
- (19) Macdonald, M; Pediatr Res 1984, V18, P181 CAPLUS
- (20) Malamy, J; Science 1990, V2500, P1002
- (21) Mantel, N; Cancer Chemother Rep 1966, V50, P163 MEDLINE
- (22) Metraux, J; Science 1990, V250, P1004 CAPLUS
- (23) Murphy, M; Biochim Biophys Acta 1996, V1315, P208 CAPLUS
- (24) Murphy, M; Biochim Biophys Acta 1997, V1361, P103 CAPLUS
- (25) Oehen, S; Science 1991, V251, P195 MEDLINE
- (26) Orlowski, J; Cleve Clin J Med 1990, V57, P323 MEDLINE
- (27) Poss, W; Arch Pediatr Adolesc Med 1994, V148, P879 MEDLINE
- (28) Remington, P; Pediatrics 1986, V77, P93 MEDLINE
- (29) Reye, R; Lancet 1963, V2, P749
- (30) Roe, C; Reye's syndrome Round Table Series, no 8 1988, P85
- (31) Rogers, M; Pediatrics 1985, V75, P260 MEDLINE
- (32) Rosenberg, D; South Med J 1977, V70, P660 MEDLINE
- (33) Rozee, K; CMAJ 1982, V126, P798 MEDLINE
- (34) Rozee, K; Canadian Pediatric Society meeting 1987
- (35) Shindell, S; Lancet 1993, V341, P119 MEDLINE
- (36) Smith, T; Scott Med J 1996, V41, P409
- (37) Stanley, E; JAMA 1975, V231, P1248 MEDLINE
- (38) Starko, K; Pediatrics 1980, V66, P859 MEDLINE
- (39) Stumpf, D; Brain Dev 1995, V17(Suppl), P77

- (40) Trauner, D; Neurology 1988, V38, P239
- (41) Vesentini, M; Drug Metab Rev 1995, V27, P517
- (42) Waldman, R; JAMA 1982, V247, P3089 MEDLINE
- (43) Yamashita, F; Reye's syndrome IV 1985, P47

=>

Welcome to STN International! Enter x:x

LOGINID:sssptau125rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Feb 24 PCTGEN now available on STN
NEWS 4 Feb 24 TEMA now available on STN
NEWS 5 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 6 Feb 26 PCTFULL now contains images
NEWS 7 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8 Mar 24 PATDPAFULL now available on STN
NEWS 9 Mar 24 Additional information for trade-named substances without structures available in REGISTRY
NEWS 10 Apr 11 Display formats in DGENE enhanced
NEWS 11 Apr 14 MEDLINE Reload
NEWS 12 Apr 17 Polymer searching in REGISTRY enhanced
NEWS 13 Jun 13 Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 14 Apr 21 New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15 Apr 28 RDISCLOSURE now available on STN
NEWS 16 May 05 Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17 May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS 18 May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19 May 19 Simultaneous left and right truncation added to WSCA
NEWS 20 May 19 RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21 Jun 06 Simultaneous left and right truncation added to CBNB
NEWS 22 Jun 06 PASCAL enhanced with additional data
NEWS 23 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 24 Jun 25 HSDB has been reloaded
NEWS 25 Jul 16 Data from 1960-1976 added to RDISCLOSURE
NEWS 26 Jul 21 Identification of STN records implemented
NEWS 27 Jul 21 Polymer class term count added to REGISTRY
NEWS 28 Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS 29 AUG 05 New pricing for EUROPATFULL and PCTFULL effective August 1, 2003

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer